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Abstract 
 
The transport capacity of the retina plays a major role in maintaining health of 
the photoreceptors cells.  In particular, age-related changes in the Bruch’s 
membrane(BrM) correspond to a decrease in the transport of nutrients and 
waste products across the Bruch’s. Matrix metalloproteinase(MMP), an 
extracellular matrix regulator was found to be sequestrated in aged BrM, with 
decreased availability for activity. Hence, it was hypothesized that a plausible 
target to rejuvenate the transportation across BrM and prevent the age-related 
processes in the macular was to increase the activity of MMP in BrM. Previous 
studies have shown an increase in MMP release secondary to RPE migration 
initiated by deliberate injury using lasers. However,conventional lasers causes 
collateral photoreceptor cell damage via primary thermal denaturation and 
secondary apoptosis. The nanosecond laser used in the present study with its 
speckled beam configuration and nanosecond pulse is designed to limit the 
primary damage profile. The main objectives of this PhD was to determine if this 
novel laser was a viable option to improve transport across BrM while 
preserving photoreceptor function, further to ascertain its efficacy and safety for 
use in human subjects to delay or prevent onset of AMD. 
Laboratory results from this thesis confirmed the importance of MMPs but 
demonstrated the inadequcy of the speckled beam configuration at higher 
energy levels. Corroborative clinical results also found beam profile inadequacy 
with the suprathreshold nature of the current energy-dose but desmonstrated 
minmal collateral damage. Clinical evaluation found a short term improvement 
of visual function. It may be concluded this novel laser has potential to be used 
as a therapeutic modality to delay AMD, but further work needs to be done to 
address the current issues of beam configuration and energy dosing for its 
optimal use in the future. 
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Chapter 1.  Introduction 
1.1 Introduction 
The concept of the effects of radiation on vision has been described since Plato, 
when Socrates advised against direct gazing at solar eclipses.  Later, 
Theophilus Bonetus described central vision loss from sun gazing in the early 
17th century.  However, it was Meyer Schwickerath who first published his 
findings of using natural sunlight to treat melanomas in 1949.(G., 1960) This 
method was of course limited by constraints of the weather, season and the 
long exposure time. In the 1950s, he then specified the development of the first 
xenon arc lamp by Carl Zeiss Laboratories, which produced radiation through 
passage of high intensity electricity through a xenon gas filled chamber. This 
method stimulated huge interest amongst ophthalmologists. He achieved 
effective treatment of melanomas, but also noticed the disappearance of 
surrounding vessels on the optic disc and other parts of peripheral retina even 
though the laser treatment site was remote. It was then that he suggested the 
use of photocoagulation using xenon arc to arrest retinal changes in 
proliferative diabetic retinopathy. (Meyer-Schwickerath, 1954) 
Although effective, the xenon arc treatment was painful, long and caused 
numerous complications such as scarring, visual field defects (scotomas) and 
damage to other structures of the eye such as the cornea and 
lens.(L'Esperance, 1966a, L'Esperance, 1966b)  
In the late 1950s, MASER (microwave amplification by stimulated emission of 
radiation) was developed by Townes at Bell Laboratories and a Russian team 
with Basov and Prokhorov who received the Nobel Prize in Physics for their 
work.(Gordon JP, 1954, Basov NG, 1954) Schawlow then proposed a similar 
effect using visible light, using ruby as laser medium.(AL., 1959) With this, in 
1960, the era of lasers began. Theodore Maiman and workers produced the first 
working laser, a solid state ruby laser which was initially designed for range-
finding for military purposes.(TH, 1960) 
During the same period, some researchers were engaged in the study of the 
pathophysiology of diabetic retinopathy, which were consequent to the design of 
treatment algorithm of laser photocoagulation in this disease. Patz and Ashton 
were the first to describe the production of a particular ‘factor x’ that was 
vasoproliferative in nature and was produced during ischemia of the retina 
	   21	  
which resulted in retinal neovascularization.(Ashton et al., 1954, Patz et al., 
1953)  
As such, early interventions of proliferative diabetic retinopathy consisted of full 
thickness laser burns which were designed to eliminate involving ischemic 
retina to prevent release of ‘factor x’. Subsequently, it was thought that an ideal 
laser system would be one that could directly close off the blood vessels and 
the argon laser met this criteria.   
In 1964, Bridges discovered the argon laser with emission in the blue (488nm) 
and green (514nm) spectrum and found these wavelengths to be strongly 
absorbed by hemoglobin and melanin with the possible potential of closing off 
blood vessels and vascular lesions.(L'Esperance, 1969) This was a 
misconception as some investigators subsequently showed that the main 
absorption site was the RPE, which was not dependent on the blue-green 
emission of the argon laser. Furthermore, 70% of emission of the argon laser 
was at 418nm which was found to be absorbed by macular pigment and caused 
unwanted side effects. (Marshall et al., 1975) 
However, it was since then that lasers became the gold standard for treatment 
of numerous retinal diseases such as proliferative diabetic retinopathy, diabetic 
macular oedema, vein occlusions etc.  
An advancement that preserved much more retina was conceived by Wolbarsht 
who postulated a model for the rationale of photocoagulation therapy for 
proliferative diabetic retinopathy. The model stated that destruction of 
photoreceptors by photocoagulation would decrease its oxygen demand and 
constrict retinal vessels, by restricting angiogenic factors.( Wolbarsht and 
Landers, 1980)  
Much later, some investigators have found that laser therapy itself causes 
release of cytokines and other factors such as MMPs, transforming growth 
factor-β (TGF-β),  pigment epithelial derived factor (PEDF) and angiostatin. 
These biochemical substances modulated the effects of laser.(Wolbarsht and 
Landers, 1980, Jennings et al., 1991, Caldwell et al., 2005, Sanchez et al., 
2007, Matsumoto et al., 1994) Given that the RPE has the highest temperature 
rise during laser, it was postulated that a basis of laser therapy could be focal to 
RPE injury with the secondary release of the various cytokines, anti-angiogenic 
and growth factors.  
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Although effective for treatment of proliferative diabetic retinopathy and limiting 
the growth of peripheral neovascularization, lasers had not met with equal 
success in the treatment of macular diseases. Results from the ETDRS 
demonstrated that macular laser was only effective at preventing visual loss at 3 
years in diffuse macular oedema, but had limited role in improving vision.(1985) 
A possible reason could be the limitation of treatment areas close to the fovea 
and the damage of the very cells (photoreceptors) the treatment was aimed to 
protect. 
Anderson and Parrish coined the term ‘selective photothermolysis’ defined by 
the ‘confinement of damage by brief laser pulses’.(Anderson and Parrish, 1983) 
Several investigators such as Birngruber et al in Germany and Marshall et al in 
London have carried out various experiments to define the optimal laser 
physical parameters that aimed to target selective RPE cells. Several laser 
parameters were examined which included wavelengths and time domain. 
With regards to wavelength of incident radiation of the laser, Mainster found that 
there was minimal impact of wavelength on RPE selectivity, except that impact 
of longer wavelengths extended further to into the choroid.(Mainster, 1986)  
In the 1980s, Sliney and Marshall suggested that pulse trains with high 
repetition rates could maximize therapeutic effect while minimizing collateral 
damage.(Sliney, 1992) 
Q-switching, a technique first proposed in 1958 by Gordon Gould, and 
subsequently demonstrated independently in the 1960s by R.W. Hellwarth and 
F.J. McClung, used electrically switched Kerr cell shutters in a ruby laser to 
produce laser of light pulses with low pulse repetition rates, higher pulse 
energies, and longer pulse durations. (Taylor, 2000, McClung, 1962) Marshall 
investigated the mechanism of action of various Q switched and non Q-
switched retinal lasers and evaluated the impact of such modalities on the 
retina. Publications in the last few decades on various animal models have 
shown that lasers in the Q-switched domain have limited collateral damage 
when compared to cw laser using various wavelengths.(Marshall et al., 1975, 
Marshall and Mellerio, 1968) 
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Earlier on, it was stated that lasers were a successful treatment modality for 
numerous retinal vascular diseases. During treatment of diabetic retinopathy, 
Gass had previously observed the disappearance of drusen post laser 
photocoagulation.  Based on this observation, several investigators carried out 
clinical investigations on the use of laser prophylaxis in non-exudative or early 
AMD.(2003, 2006, Frennesson et al., 2009, Friberg et al., 2006) The 
mechanism of disappearance of drusen observed was unknown. However, 
although the studies did show significant decrease in drusen, the outcome of 
the studies did not prove satisfactory because they also showed an increase in 
rates of neovascularization and no improvements in visual outcomes.(2003, 
2006, Frennesson et al., 2009) It was noted that the lasers used in these 
studies were in the milli to microsecond time domain and were in continuous 
wave mode. Further analysis found these neovascularization to be associated 
with higher laser intensity.(Kaiser et al., 2001) These results were not surprising 
given the knowledge of Stephen Ryan’s earlier model of laser induced 
subretinal neovascularization.(Miller et al., 1990) In this model, it was indicated 
that the impact of laser on the RPE-BrM-choroid complex and the ability of RPE 
cells to proliferate to reconstitute its monolayer determined the resultant 
formation of subretinal neovascularization. Hence, based on these knowledge, it 
was reasonable to assume that the lasers used in the prior studies was of too 
high intensity and caused adjacent damage to surrounding structures such as 
breaks in BrM and subsequent neovascularization. 
Age related macular degeneration is the leading cause of blindness amongst 
those aged 65 and above and causes 5% of total global blindness from data 
released by WHO in 2010.(Pascolini and Mariotti, 2012). In America, studies 
found that 3.8% of Americans between ages 50-59 have either intermediate or 
advanced form of the disease and this number escalates to 14% in the age 
range of 70-79. In the UK, by 2020, it was estimated that more than 650,000 
people will have advanced AMD, which is 150,000 more than the current 
number. It has been further estimated that 44,000 new cases of wet AMD a 
year in the UK will require intravitreal anti-angiogenic agent therapy.(Owen et 
al., 2012) This problem will be even more prevalent as we face a global aging 
population. The WHO has estimated that the proportion of the world’s 
population over 60 years will double to 22% by 2050, to more than 2 billion in 
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absolute numbers. (Subramanian, Ness et al 2009.; Global brief for World 
Health Day 2012 by WHO). 
Visual impairment results in both undesirable personal and socioeconomic 
consequences.  The costs of treatment, rehabilitation and hospital labor 
demands a significant economic contribution from the individual, government 
and society, both directly and indirectly.  The global cost of visual impairment 
from direct health-care costs such as treatment was estimated to cost US $255 
billion and US $89billion indirectly.(Rein et al., 2006, Alliance for Aging 
Research, 2011) In the UK, the cost of AMD already accounts for 1% of the 
annual NHS budget (which was 96billion pounds in 2013/14) 
Clinically, AMD can be classified into early, intermediate or advanced 
(neovascular or geographic atrophy) under the International 
Classification.(Ferris et al., 2013) In this classification, the five year risk of 
progression to advanced AMD ranges from 0.5% in the ageing retina (early 
AMD) to 50% amongst the intermediate group.(Ferris et al., 2013) Currently, 
there are available treatment for neovascular stage of the disease in the form of 
anti-angiogenic agents, such as Bevabizumab(avastin), Ranibizumab(Lucentis), 
aflibercept (Eylea). The therapeutic regime for wet AMD (using Ranibizumab) 
starts with 3 mandatory injections, and retreatment is dependent on evaluation 
of fluid resolution.(Brown et al., 2009, Brown et al., 2006, Subramanian et al., 
2009, Regillo et al., 2008, Ophthalmologists., 2012) Studies have shown that 
the average number of Ranibizumab injections at 12 months was 5.6. In the UK, 
the NICE approved AMD treatment (Lucentis) costs 700 pounds per injection 
and this accounts for the exorbitant direct cost AMD therapy.  
Currently, there is no treatment for dry or atrophic types of AMD and a paucity 
of prophylactic therapy for the ageing retina.  Prevention is always better than 
cure.  Understanding the etiologies of the ageing retina and its ageing transport 
systems would be key to developing a prophylactic therapy to delay or prevent 
AMD. 
The metabolic oxidative requirements of the neural retina are one of the highest 
of all tissues in the body(Cohen and Noell, 1960, Ahmed et al., 1993, Winkler et 
al., 1983) The choroid contains numerous blood vessels with a high potential 
supply of oxygen and nutrients. Thus, there is a constant chain of supply of 
nutrients and substrates to the photoreceptor cells which have the highest 
concentration of mitochondria of any cells in the inner segment layer.  This high 
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metabolic oxidative requirement increases the level of free radical releases from 
the electron transport chain in the cellular mitochondrial. (Skulachev, 1996, 
Korshunov et al., 1997) Studies previously demonstrated the daily shedding of 
lipid rich membranous disc from the distal end of the outer segments of 
photoreceptor cells, consisting of free radical damage. This allows the removal 
of damaged membranous waste products to the RPE cells, for final removal 
through the choroidal blood stream. At the proximal end, new discs are 
synthesized(Bok, 1985, Young, 1976). Henceforth, an intact transport system is 
crucial to maintain the nutritional status and waste removal for maintenance of 
the RPE. Over the last two decades, experiments conducted by Marshall and 
Hussain have demonstrated BrM as the rate limiting location of decline in the 
transport system and shown the age-related decrease in transport 
functions.(Hillenkamp et al., 2004, Hussain et al., 2002, Hussain et al., 2010c, 
Moore et al., 1995a)  In addition, the same team had demonstrated the 
involvement of the metalloproteinase pathway in the maintenance of transport 
across the BrM.(Kumar et al., 2010, Ahir et al., 2002, Hussain et al., 2011)  
Hence, clinical observations by Gass with regards to laser and decreased 
drusen load become more intriguing. One possible postulation could be the 
effect of laser on causing RPE injury with subsequent RPE proliferation which 
causes release of MMPs that cleans the BrM.  
In the following, these background knowledge on the development of retinal 
lasers in recent years as well as the transport mechanism of the outer retina 
and the physiological changes in ageing in the outer retina would be discussed. 
The background to the nanosecond laser, termed 2RT laser, would be 
elaborated. 
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1.2 Lasers for Retinal Therapy 
The early history and development of retinal lasers have been discussed. The 
following details the literature on the mechanism of laser damage and the profile 
of laser damage on the retina from lasers in different time domain. 
1.2.1 Mechanism of Retinal Lasers Damage 
Retinal photocoagulation was and is still the widely accepted clinical therapy for 
numerous ocular conditions such as proliferative diabetic retinopathy, diabetic 
macular oedema (DMO), central serous retinopathy (CSR).  
The mechanism of retinal lasers damage involves tissue destruction from forces 
generated by thermal degradation of incident energy absorbed by the target 
tissue. (Marshall, 1970) The amount of energy absorbed by the target tissue 
was thought to be dependent on the wavelength of incident radiation and 
absorption characteristics of irradiated tissue. The extent of tissue destruction is 
related to 1. degree of exposure energy; 2. area of irradiation (laser spot size); 
and 3. duration of exposure.  
The fundamental changes in the laser mechanism of action are in accordance 
with the laser time domain. The biological effects of laser are the result of one 
or a combination of several mechanisms such as photochemical, thermal, 
thermo-mechanical, which with the exception of photochemical effects are 
virtually independent of wavelength. In the millisecond domain, thermal damage 
is the predominating mechanism.  Depending on spot size, energy and pulse 
duration, damage initiated in the RPE may be conducted to adjacent tissue. By 
contrast, several authors have shown that pulse in the nano to microsecond 
domain resulted in heat absorption by melanosomes, causing microcavitation 
and mechanical disruption of the RPE. (Kelly and Lin 1997; Lin et al. 
1999;Brinkmann et al. 2000;Roegener et al. 2004; Schuele et al. 2005; Lee et 
al. 2007). Subnanoseconds and picoseconds exposures may result in optical 
breakdown and plasma formation or ionization (Cain et al. 2005; Roach et al. 
2004;(Edsall, 1997) 
Current lasers are continuous wave with pulse domains in millisecond to 0.1 
second regime. They result in thermal denaturation of adjacent retinal layers 
and distance of its internal spread is time-dependent.(Table 1.1) The 
neuroretinal impacts of conventional and current lasers in millisecond time 
domain have been widely investigated.(Bowbyes et al., 1973, Marshall et al., 
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1975, Wolbarsht et al., 1965, Zweng et al., 1967, Muqit et al., 2010a, Borland et 
al., 1978) Numerous researchers concur with the theory that RPE is the primary 
layer responsible for absorption in laser light. RPE contain melanosomes which 
absorbs up to 50% of the incident laser energy. This results in RPE cell death 
and subsequent migration and cell division with consequent release of 
cytokines, anti-angiogenic factors and matrix metalloproteinase (MMPs).(Ahir et 
al., 2002, Chidlow et al., 2013)  
In the 1980s, Birnrugber studied the effects of various wavelengths and found 
that there were minimal differential effects caused by different wavelengths, 
except that longer wavelengths was penetrated deeper. In the same study, he 
found an inverse relationship between length of damage and laser pulse 
duration.(Table 1.1) Improvements in laser technology from long to shorter time 
domains saw significant benefits in reducing the length of damage through the 
inner retina. 
With regards to area of irradiation, image spot size was found to be 
interdependent on pulse duration and functions differently at milliseconds and 
nanoseconds time domain. For example, in the millisecond time domain, 
thermal damage was found to be highly dependent on retinal image size. (Lund 
et al. 2007; Schulmeister et al. 2008a) (Figure 1.1) In the millisecond domain, 
the smaller image size would result in greater radial cooling effects and a 
smaller increase in peak energy.  In contrast, pulses in the sub nanoseconds 
domain was found to have limited therapeutic index due to the very high peak 
energy from these exposures which must be overcome by large spot sizes to 
maximize heat flow and prevent outer retinal hemorrhages.(DH., 1988)  
Multiple pulsing can reduce the overall temperature increases in the RPE and 
limit the extent of damage from thermal diffusion. For example, single pulses of 
millisecond duration will lead to high temperature increase which will cause 
neuroretinal effects and disruptive effects such as choroidal bleeding whilst 
multiple pulses which reduces peak temperatures through the theory of additive 
effects of thermal energy will therefore cause a reduction in peak temperatures 
and greater selectivity of organelles and/or anatomical layer as target.(Sliney, 
1999) The Arrhenius equation can be used to predict additivity for pulses in the 
thermal damage mechanism pulse duration. (Lukashevet al. 1996; Schulmeister 
2007). In accordance to Arrhenius model, there is a proportional rate of 
increase in thermal damage to tissue with increasing temperature. Based on 
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extensive retinal injury studies conducted to derive safe exposure limits, the 
limited additivity of thermal coagulation from pulse and inter-pulse rest periods 
allows accumulation of thermal energy without subsequent effects of thermal 
mechanical disruption of adjacent tissues such as the inner retina. This 
thermally additive exposure had been described mathematically as number of 
pulses N raised to -1/4 power (N^-1/4). This empirical formulation means that the 
threshold energy per pulse will only be 10% of single pulsed threshold when 
N=10,000 pulses. This additivity is dependent on thermal confinement and 
thermal relaxation time, which is in turn dependent on the absorption molecule 
and tissue (melanin and RPE). Brinkmann et al have determined the thermal 
confinement period of melanin and RPE to be 0.5 to 1.0µs and 20 to 25µs 
respectively.(Brinkmann, 2005) (Neumann and Brinkmann 2005)  
Another form of pulsed mode systems is the Q switched technology. Q switched 
systems are used in ophthalmology for its high peak energy to cause photo-
disruptive effects. Examples of its use include Yag capsulotomy where there is 
no biological heat absorber and the capsular damage is a function of the 
transmitting laser parameters only. At the level of the retina, the resultant 
damage is dependent upon the laser transmission and the biological absorption, 
which in this case, is mainly the melanin in the RPE. Marshall first described the 
differences in various plausible mechanisms of laser photocoagulation in 1970 
by comparing Q-switched and non Q-switched lasers in various short pulsed 
domains in Dutch rabbits. In Q switched lasers, the mean output power is much 
higher than a cw laser such that RPE cells undergo complete degeneration in 
the center of the laser lesion, whilst at RPE cells at the periphery undergo ‘blast’ 
forces from the micro-explosions generated in the center. This resulted in the 
pigment granules and cytoplasm disintegrating and breaking away from the 
cellular boundaries. The explosive nature of the center of laser lesion resulted in 
subretinal hemorrhage. (Marshall 1968 experimental eye research)(Figure 1.2) 
This effect can be reduced with increasing the diameter of the laser beam, by 
diffusing the laser energy.(Marshall, 1970)  
Hence, it can be concluded that conventional and current laser in the 
millisecond time domain results in a degree of neuroretinal damage. The shorter 
time duration in micro-nanoseconds transits from thermal to mainly mechanical 
mechanism of action with improved selective damage of the RPE layer. Flat 
mount histology compared the limited impact on RPE cells using Q switched 
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lasers as compared to non Qswitched lasers in single and multipulsed modes. 
(Marshall, 1970)  Roider and group have also demonstrated with invitro 
experiments the limitation of damage using ultrashort pulses.(Roider et al. 1993; 
Brinkmann et al. 2000; Roegener et al. 2004).  
Even until now, the lasers used in clinical scenarios are in the cw mode and in 
the millisecond or microsecond time domain. Although effective in treatment 
vascular disease, it causes thermal diffusion damage to the surrounding layer. 
2RT laser is the first doubled-frequency Nd:YAG laser in the nanosecond time 
domain using a Q switched system, with a large spot size which is postulated to 
have limited effects to within the RPE.  
 
Table 1.1 Pulse duration and thermal diffusion distance, by Birngruber, 
Roider and team 
Pulse Duration Thermal Diffusion Distance / µm 
1 second 1000 
0.5 seconds 707 
100msec 320 
50msec 225 
10msec 100 
1msec 32 
100µsec 10 
10µsec 3.2 
1µsec 1 
1nanosec 0.5 
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Figure 1.1 Laser energy distribution in spot sizes in millisecond duration 	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
Figure 1.1 is a pictorial representation explaining the effect of laser irradiation size 
(retinal laser spot) on peak energy. A, represents the peak energy effect of small 
laser spot size whilst B represents effect from large laser spot size.  
In A, the smaller spot size allows cooling effect to reach the center of laser spot 
quickly and hence, a lower peak energy.  
In B, retinal irradiance profile is too large for any consequential cooling effect to 
effectively reach the center of the irradiated spot during pulse exposure. This results 
in a high effective peak energy.  
Hence, the smaller the spot, the shorter the time to reach its center and faster 
cooling effect and lower peak energy or exposure limit. 
 
Adapted from Schulmeister, Theory of the basis of radial cooling 
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Figure 1.2a, 1.2b RPE damage using a non Q switched and Q switched 
laser 
 
 
	  
 
 
 
 
 	  	  	  	  
 
 
 
Figure 1.2a shows the zones of laser damage on the RPE using a non Q switched 
laser. Note the 3 zones of laser damage; Central zone (A) with destroyed pigment 
epithelial cells the size of incident beam; Peripheral zone B with a ring of pigments, 
from the radial streaming of pigmentation from the central zone and zone (C) 
demonstrats an area of reduced pigmentation from further outward displacement of 
pigment granules. 
 
Figure 1.2b shows zones of RPE damage from Q switched laser. The inner arrows 
show complete void of RPE cells from microexplosions of individual RPE cells from 
the high energy and a peripheral zone of ‘blast’ effects from the center of the lesion. 
 
Pictures are taken from Marshall, 1970. 
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Figure 1.3 Pictorial demonstration of mechanism of laser damage in 
different time domain 
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Figure 1.3 is a pictorial demonstration of mechanism and length of damage in 
varying time domains. The millisecond time domain shows heat absorption in 
thermal mechanism of action, with resulting vaporization and ‘micro explosion’ of 
individual RPE cells. This results in thermal diffusion distance in the range of 
100µm.  
In the microsecond time domain, there is less heat energy absorption with a 
shorter thermal diffusion distance of 3-4µm. Still, the tips of outer segment of PRL 
are affected. 
In the nanosecond time domain, energy absorption results in microbubble 
formation and damage to surrounding organelles, with micro cavitation and death 
of discrete RPE cell. This results in limitation of damage to RPE layer. 
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1.2.2 Concept of Primary and Secondary Laser Damage 
It was established earlier that the ideal retinal laser would be one that is 
between 400 to 600µm wavelength, with a short time domain, sufficiently low 
energy, multipulsed and with an adequately large spot size. The reason for this 
is to prevent primary damage which is defined by the laser-tissue interaction at 
the level of the RPE, photoreceptor cells and beyond. This happens acutely to 
within 48 hours post laser. 
Less is known of the secondary induced damage by laser. This is a much-
neglected concept, which holds importance for long term prognosis for visual 
function.  Secondary laser damage is defined by the apoptosis of photoreceptor 
outer segments from the lack of support mechanism resulting in a dysfunctional 
transport to and from the photoreceptor cells. The reason for this is because the 
time period for a physiological disc renewal and shedding is 48 hours, however, 
with the current size of laser beam used clinically (ie, 100 to 200µm), the time 
period for RPE wound healing takes approximately 7 days. Hence, the 
imbalance resulting from time taken to re-establish RPE layer and facilitating 
the metabolic needs for photoreceptor cells, in theory, will cause secondary 
damage to photoreceptor cells. In contrast to primary damage, this secondary 
effect takes days to occur. (Figure 1.4) 
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Figure 1.4 Illustration of primary and secondary laser damage in the retina 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 illustrates the concept of primary and secondary laser 
damage in the retina. Primary damage is defined by the acute phase 
of laser-tissue interaction, with consequential damage to the 
surrounding layers. 
Secondary damage is defined by death of photoreceptor cells from 
the lack of support mechanism such as the RPE and hence, 
dysfunctional transport mechanism.  
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1.2.3 Underlying Concepts of the 2RT Laser 
Fundamentally, one of the aims of modern lasers would be to allow the use of 
laser in the fovea avascular zone, without harmful effects to the neural layer. 
The edge of the fovea avascular zone was defined as a limit to current and 
conventional layers due to the extensive laser damage described earlier. (Muqit 
et al., 2010a, Bowbyes et al., 1973, Marshall et al., 1975) This limited the use of 
laser in the treatment of macular diseases.  The concepts of primary and 
secondary damage has been described. The following describes the underlying 
concepts in the design of a nanosecond, speckled beam laser, which was 
aimed at circumventing primary and secondary damage of retinal lasers.	  	  
With the speckled beam configuration, this laser was hypothesized to cause 
disparate groups of RPE cell death in a 400µm spot size. With this, there would 
islands of preservation of RPE cells and timely reconstitution of the single RPE 
layer. This would hence prevent secondary apoptosis of photoreceptor cells. In 
addition, with the larger areas available for RPE migration, there should be in 
effect a higher release of cytokines and immune-modulatory factors released 
from RPE migration. 
The 2RT laser functions in a single 3 nanosecond pulse laser. The ultrashort 
pulse duration in the nanosecond time domain would in theory limit the length of 
damage. Nanosecond lasers was shown in animal models to have a smaller 
therapeutic range than the longer time domains.(Framme et al., 2002) This 
decrease in therapeutic range have a risk of causing secondary subretinal 
bleeds. This therapeutic range may be increased by first, repetitive pulsing and 
second, increasing the laser spot size (as in the 2RT laser).  Fully knowing that 
an enlarged spot size will be subject to secondary damage as mentioned 
above, the indication of the current laser design was meant to address this 
problem. 
Figure 1.5 shows the mechanism of laser damage in the different time domain 
as compared to the 2RT laser. 
Preliminarily, this laser was used by Pelusconi et al in treatment of diffuse 
diabetic macular oedema and found to have less functional defects on the retina 
as compared to conventional laser. Guymer and team in Australia performed a 
small pilot study with the use of the 2RT to treat early AMD. Unfortunately, the 
team have mis-concocted a treatment algorithm with 12 laser lesions and 
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average laser energy of 0.3mJ, which resulted in minimal improvements using 
flicker perimetry but otherwise no visual acuity changes. (ARVO abstract 2012) 
Thus far, there is no proper assessment of this unique laser as a modality to 
prevent AMD.  
 
Figure 1.5 Schematic diagrams of the effects on the retina and Bruch’s 
membrane caused by a) a millisecond laser, b) a microsecond laser and c) 
a nanosecond laser. 	  	  
Figure 1.5a. 10msec laser 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5a  The 10msec laser.  
Mechanism of Action: Diffusion of thermal denaturation to the 
photoreceptor cells and inner retina. Secondary damage results 
from the impeded transport system across the RPE cell layer 
resulting in apoptosis of the photoreceptor cells. 	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Figure 1.5b Microsecond laser 
 
 
 
 
 
 
 
Figure 1.5c. Nano-second laser  
 
Figure 1.5b: The microsecond laser. 
Mechanism of action:  
Primary damage: photoreceptor cell damage reduced, however, the 
tips of the outer segments are still prone to secondary damage. 
Secondary damage: Impedes transport mechanism across RPE-
Bruch’s membrane complex, resulting in less nutrient availability for 
photoreceptor cells. 
Thermal diffusion distance of approximately 10µm. 
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Figure 1.5c: The nanosecond laser 
In the pictorial diagram of the nanosecond laser (1), the Gaussian beam 
type nanosecond laser shows secondary damage from a large area of 
irradiation. In (2), the 2RT laser has a ‘speckled beam configuration’ of 
which there are discontiguous areas of RPE cell death and migration that 
occur in each 400µm spot size, ensuring continuous and maximal 
improvement of transport mechanism across the retina. 
Mechanism of action: 2RT is a nanosecond pulsed laser, which uses very 
low energy levels to produce a limited effect that selectively targets 
melanosomes within the retinal pigment epithelium cells. It is the first laser 
that employs the technology of diffusion of the laser beam. This novel 
therapy means that only 25% of the laser energy reaches the RPE in a grid 
pattern within the 400µm beam. This laser energy absorption by 
melanosomes within RPE cells causes microbubbles and cavitations to 
form, damaging a percentage of RPE cells within the laser spots without 
rupture of the cell membranes.  	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1.3 Anatomy of the outer retina 
1.3.1 Retina 
As mentioned above, the balance between nutrient transport and waste removal 
is of utmost importance in maintaining the health of the photoreceptor cells. In 
the following, basic background knowledge of the transport system across the 
inner and outer retina would be reviewed. The following is a brief description of 
the anatomy of the retina, with particular focus to the outer retina. 
The retina is the innermost layer of the eye and is important for the conversion 
of information from the external environment as neural impulses to the brain for 
intricate analysis. There are two layers of the retina, the inner neurosensory 
layer and the outer retina, consisting of the RPE which is bound on its posterior 
surface by the BrM and choroid.  
The following gives a brief description of the important topographical regions of 
the anatomy of the retina (Figure 1.6) 
The posterior pole:  A 5 to 6mm diameter circular zone of retina between the 
arcades of the temporal retinal arteries which is shown in histology to have 
highest concentrations of cones and has more than single layer of ganglion cell 
bodies. 
The macula lutea: known in latin as the ‘yellow spot’. 1.5mm diameter area in 
the posterior pole, approximately 1.5 disc diameter lateral to the optic disc. 
Consists of high concentration of xanthophyll carotenoid pigments (zeaxanthin 
and lutein) which acts as a filter for protection against ultra-violet irradiation. 
The fovea: 0.35mm diameter area of depression in the macular consisting only 
of cones where the cones are concentrated at maximum density. 
The peripheral retina: remaining of the retina outside posterior pole to the ora 
serrate. Rich in rods and has only one layer of ganglion cell bodies. 
Ora serrate: Transitional zone where the neuroretina is continuous with 
nonpigmented epithelial cells of pars plana. 
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Figure 1.6 Pictorial diagram of the anatomy of the retina 	  
	  	   	  
 
 
 
 
 
 	  	  	  	  	  	  
 
 	  	  	  	  	  	  
Figure 1.6 is a pictorial representation of the anatomy of the retina, adapted 
from Forresters, The Eye, Basic science in practice, Third edition 
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1.3.1.1 Neurosensory Retina 
The neurosensory retina is a 300µm thick matrix of neural tissue. Very 
importantly, the three main layers that are involved in the transduction, 
transmission and conduction of impulses from light are the photoreceptor cells, 
bipolar cells and ganglion cells whose activity are modulated by the horizontal 
cells and amacrine cells respectively. (Figure 1.7) 
Figure 1.7 Diagram of anatomy of neural retina 
 
 
 
 
 
 
 
Figure 1.7 is a diagrammatic representation of the anatomy 
involved in the neurosensory retina in terms of transduction, 
transmission and conduction pathways of light impulses to 
electrical signals to the brain. 	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1.3.1.2 The Photoreceptor Layer 
There are 2 types of cells in the photoreceptor layer (rods and cones). There 
are approximately 115million rods and 6.5 million cones in the human eye. 
Rods are responsible for contrast, bright and motion whilst cones co-ordinate 
volor vision, spatial resolution and fine visual resolution. Rods dominate the 
peripheral retina, whilst cones are mostly concentrated in the macular, and the 
fovea is exclusively cones. 
Each rod and cone is a long and narrow cell with an inner and outer segment 
joined by a modified cilium. These inner and outer segments are connected to 
the cell body by the outer limiting membrane which then passes into the outer 
nuclear layer of the retina and axons pass into the outer plexiform layer to form 
synapses with bipolar and horizontal cells.  The inner and outer segments 
contain visual pigments which aid in the photochemical transduction of light into 
neuronal impulses. 
As mentioned, photoreceptor cells (rods and cones) of the vertebrate retina are 
highly specialized cells which responds to the stimulus of light, and relays this 
response to surrounding neurons as optical input to the brain. To facilitate its 
function, photoreceptor cells undergoes series of metabolic activities to maintain 
necessary visual components, regeneration and waste removal. 
Early autoradiographic studies demonstrated similar pathways of photoreceptor 
metabolism in rats, frogs, rhesus monkey. Light-sensitive outer segment of the 
retinal rods consists of a stack of a thousand densely packed discs, each with a 
double layer of infolded plasma membrane . Bok and Young have traced the 
pathways from protein synthesis, which includes the visual pigment rhodopsin, 
in inner segment of cell through transfer through the cilium to base of the outer 
segment where the protein are then incorporated into newly formed 
membranous disc. This addition of new membranous discs at the base of a 
photoreceptor cell outer segment requires the synchronized removal of old disc 
through phagocytosis of RPE cells.(Young and Bok, 1969) The rate of rod 
renewal varies between species and location within the retina; with rats having 
a range of 8 to 14 days for complete turnover and rhesus monkey with a range 
of 9 to 13 days.(Bok, 1970) (Figure 1.8) 
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Figure 1.8 Pictorial demonstration of rod outer segment renewal 	  
 
 
 
Ambient temperature and light variation in the microenvironment of 
photoreceptor cells also increases rate of renewal and formation of outer 
segment disc. (Bok 1967 J of sci boiology) 
Dysfunctional RPE has been hypothesized to be the cause of some retinal 
dystrophic diseases. Experiments on RCS rats have demonstrated the 
involvement of poor phagocytosis of outer segments by RPE to be causative 
factor for eventual photoreceptor demise(Herron et al., 1969). Kroll and 
Machemer first demonstrated that photoreceptor metabolic functions decline 
very rapidly from retinal detachment.(Kroll and Machemer, 1969) In vitro 
amphibian culture also showed that rod renewal becomes dysfunctional within 2 
days of retinal detachment.(Hale et al., 1991) Hence, from the knowledge 
obtained from early experiments, it may indirectly concluded that the area of 
RPE death induced by laser may induce a ‘dystrophic-like’ microenvironment 
where photoreceptor renewal rate is stagnated from the lack of nutrition from 
regenerated visual pigments and the buildup of old disc, which inhibits the 
metabolic removal of waste from the choriocapillaries.  
The work done previously provided an understanding to the impact of laser on 
secondary damage as defined earlier. In simple terms, the larger the laser spot 
size, the larger the area denuded of RPE and the longer it would take to re-
Diagram from Young and Bok 1969. 
Renewal of rod outer segments as revealed by 
radioautography after injection of radioactive amino 
acids. The location of radioactive protein is indicated by 
black dots .Os: outer segment; cc: connecting cilium; e: 
ellipsoid; m: myoid ;n: nucleus.  
A- Minutes after injection, radioactive protein is 
concentrated in the myoid portion of the inner segment, 
the major site of protein synthesis .  
B-Hours later, newly formed protein aggregates at the 
base of the outer segment, the site of membrane 
assembly.  
C- The heavily labeled membranous discs are gradually 
displaced by the repeated formation of newer discs at 
the base of the outer segment. These new discs are 
weakly labeled, due to the continued presence of low 
levels of labeled precursor in the tissue fluids .  
D-The moving band of intense radioactivity disappears 
when it reaches the apex of the cell. 	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establish complete RPE cell layer, which may hinder the reparative period for 
photoreceptors and result in secondary apoptosis and long term damage.  	  	  
1.3.1.3 Retinal Pigment Epithelium 
The RPE is a single cuboidal layer of epithelial cells lining the BrM with its 
apical microvilli interdigitating with the outer segments of the photoreceptor 
cells.  RPE vary in size and shape and is dependent on age and location. By 
and large, RPE cells closer to the center of the retina or the macular are 14µm 
in height and 10µm in lateral dimension, whilst in the periphery, the cells are 
14µm in height and up to 60µm laterally.  The total number of RPE cells per 
human eye ranges from 4.2 to 6.1 million with more cell loss in older eyes. The 
RPE has low regenerative potential and in the event of injury, reacts by 
hyperplasia of adjacent cells.  
The main functions of the RPE are as per follow: 
1. to assist in directional nutritional and waste transport between the 
choroidal and neuronal layer; 
2. to facilitate visual pigment through cis-trans formation of retinoid and to 
act as a reservoir to store retinoids.   
3. eliminating fluid from subretinal space. 
 
It is crucial to understand the repair mechanism of the RPE and photoreceptors, 
especially post injury or induced injury from laser. RPE plays a crucial role in 
the exchange of materials from the photoreceptors to choroidal capillaries. This 
one cell layer structure is strategically located between the photoreceptors and 
choroidal layers and forms one of the blood-retina barriers with its tight junction 
between cells.  Autoradiography studies from Bok and Young in the 1960s have 
demonstrated the direct participation of the RPE in outer segment disc removal 
processes in frogs.  RPE was found to be involved in the metabolic process of 
vitamin A, which is an important light-detecting pigment located in the outer 
segments of photoreceptor cells. Vitamin A from old outer segment disc 
entering the RPE was released through isomerization into its useful form back 
to photoreceptor cells. The RPE also synthesize and secrete components of the 
mucopolysaccharide materials lying between spaces of outer segments.(Young, 
1976, Bok, 1970, Young and Bok, 1970) Hence, the RPE plays a crucial role in 
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maintaining the health of photoreceptor cells. 
It is an established fact that RPE do have limited regenerative and repair 
capabilities.(Al-Hussaini et al., 2008, Wallow and Tso, 1973b) Histological 
studies have demonstrated initial necrosis of RPE, budding of individual RPE 
cells and multilayered RPE formation in laser lesion within 7 days after 
conventional continuous wave argon laser application.(Smiddy et al., 1986, 
Wallow, 1984) In vitro experiments demonstrated the capacity of RPE to 
migrate following laser therapy. Local RPE lesions were also found to induce a 
global RPE cell division, with repaired tissue having pronounced reduced 
pigmentation.(Al-Hussaini et al., 2008) Time course of repair for ARPE 19 cell 
culture with applied laser of 300mW power 200µm spot size, 0.1s duration was 
found to complete in 7 days. In the same study, the authors attributed repair of 
laser lesion to involve both cell migration and proliferation, with changes not 
limited to the lesions. Changes were found in expression of genes involved in 
regulation of cell proliferation, migration and tissue repair and induction of 
alarmin IL33 and heat shock protein HSPA6.(Tababat-Khani et al., 2013) 
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1.3.1.4 Bruch’s Membrane 
The BrM is an acellular connective tissue layer whose thickness is 2-4µm, but 
this increases with age and pathology.  The BrM is a pentalamina layer which 
consists of 5 layers: the RPE basal lamina; the inner collagenous zone; a 
middle elastic layer with perforations; an outer collagenous zone and the 
basement membrane of the endothelial cells in the choriocapillaries. 
 
Given an understanding of the anatomy of the retina and in particular the outer 
retina, the following will focus on the integration of these anatomical structures 
in relation to the transport functions of the outer retina. 
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1.3.2 Transport Mechanism of the Outer Retina 
Nutrient transport across Bruch’s membrane and RPE 
Branches of the central retinal artery supply the inner human retina whilst the 
capillaries of the choroidal circulation supply the outer retina. It was shown that 
the latter accounts for most of the metabolic needs of photoreceptor cells.(A, 
1970, Wilson et al., 1973, Alm and Bill, 1973)  
The ease of transport across the BrM and RPE is dependent upon a particular 
molecule’s size, charge, hydrophobic/hydrophilic nature.(Figure 1.9, 1.10) . The 
BrM is the first barrier down the transport system. By default, the BrM is an 
aceullar pentalaminated extracellular matrix (ECM) and can only allow passive 
transport as per Fick’s law of diffusion. However, its collagenous and fibrillar 
layout renders it a ‘sieve-like’ configuration, giving it apparent ‘pore’ size 
distributions in discrete layers of the membrane.(Marshall J, 1988) The ‘pore’ 
theory of fluid transport and diffusion was further supported by ultra structural 
studies and transport studies using various sized fluorescein 
isothicynate(FITC)labeled dextrans, which demonstrated the presence of 
different ‘pore sizes’, with the inner collagenous layer containing the smaller 
pores and hence, the rate limiting structure. A size exclusion limit was obtained 
from experimental studies by Starita et al (Starita et al., 1997), which explained 
the effect of size of molecules traversing the BrM to the neural retina. 
Having passed through the BrM, the molecule would traverse the monolayer 
RPE. The convoluted basolateral aspect of the RPE is in direct contact with 
BrM, minimizing diffusional distance for rapid transport of released metabolites 
and increasing the surface area for metabolic exchange. The RPE cells are 
joined by tight junctions known as ‘zonulae occludentes’ which were known to 
constitute the outer blood retinal barrier.(Shakib et al., 1972) To gain access 
through the RPE, metabolites either diffuse down their concentration gradients, 
or are carried via membrane carriers.(Heller and Bok, 1976, Miyamoto and Del 
Monte, 1994, Kundaiker et al., 1996) 
Having been transported through the BrM and RPE, metabolites would be 
released to the photoreceptor cells via 2 plausible pathways. First, released 
metabolites diffuse freely or carried by carrier proteins for uptake by inner 
segments, or second, by direct transport through the microvilli extensions from 
the RPE cytoplasm to the interdigitating distal part of outer segment.(A.A 
Hussain, 2004) 
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Transport of Waste across RPE and Bruch’s membrane 
The transport pathway for waste products traverse in the opposite direction to 
nutritional transport described above.  In general, waste products are small 
soluble substances that can easily diffuse down their concentration gradients 
into the choroidal capillaries for final removal. After being released from the 
outer segment, the RPE phagocytose an approximate level of 6000-8000 discs 
daily (Feeney-Burns et al., 1980, D, 1994) which then undergo biochemical 
breakdown with lysozymes within the cytoplasm of the RPE. Some basic amino 
acids, fatty acids and retinoid from the break down would be recycled to the 
photoreceptors for use. Other waste products such as urea would then diffuse 
down their concentration gradients into the vascular network. However, with a 
large amount of free radical damage, some waste material degradation by RPE 
would still be incomplete and this would result in production of residual bodies 
such as lipofuscin (Feeney-Burns et al., 1980, Dorey et al., 1989). Some of 
these smaller fragments may escape the RPE but ultimately get trapped within 
the inner layer of Bruch’s, other larger fragments will become deposited on 
surface of BrM, forming lipo-proteinases products known as drusen. 
Hydraulic conductivity is an important part of the system transport. In normal 
eyes, fluid flow had been observed to have a posterior direction, from retina to 
choroid. In a study by Marmor et al, most of the outward fluid flow across the 
RPE were found to be conducted via active transport, from apical to basal 
compartments whilst a smaller percentage was driven by passive osmotic 
gradients between the subretinal space and choroid. (Negi and Marmor, 1986), 
The inner collagenous layer of the BrM had been demonstrated to contribute 
significantly to the resistance between the RPE and BrM.(Starita et al., 1997, 
Moore et al., 1995a). Hence, the small pore radii in this region make it the rate 
limiting structure for hydraulic conductivity. An equation based on geometric 
analysis across this resistance barrier shows that a slight change in the radii of 
the pores would cause huge changes to hydraulic conductivity across the 
BrM.(Equation 1)(Renkin, 1954, Wyler et al., 1979, Lebrun and Junter, 
1993)From this equation, the radii (r) was raised to a power of 4, thus, any age 
related changes to it’s the structure of the BrM would result in deleterious 
effects.  
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Equation 1:	  	  
	  
	  
 
 
 
Figure 1.9 Transport pathways across the Bruch’s membrane 
                 
                   
 
 	  	  	  	  	  	    
Figure 1.9 is a simplified diagram of the fluid and molecular transport in and out of 
the retina across the BrM. 
 
 
 
Lp: HC 
r : radius 
I : path length of conducting pore 
n : viscosity of fluid in pore 
o: density of pore of various radii  
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Figure 1.10 Transport of metabolites in the outer retina 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Transport pathway for metabolites between choroid to 
photoreceptor cells. (a) represent small solutes, (b) represent 
macromolecules.  
(1) After release from choriocapillaries,  
(2) Metabolites passively diffuse across Bruch’s membrane  
(3) Taken up at the basal convoluted surface of RPE either by free 
diffusion or carrier mediated active or passive transport. 
(4) (a,b) Metabolites are then released into the interphotorecepter 
matrix(IPM)  
(5) Diffuses down a concentration gradient across the IPM to be taken up 
by inner segment layer. 
Figure from Hussain et al (A.A Hussain, 2004) 	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1.4 Ageing of the outer retina 
Ageing changes are seen in neural retina, RPE, BrM and choroiocapillaries. Of 
these, the most important cause of changes was in the RPE and BrM. As such, 
these structures are dealt with in further details. 
1.4.1 Ageing retina pigment epithelial  
Ageing causes a spectrum of degenerative structural and biochemical changes 
in the RPE.  With age, there is a loss of effective cellular volume from retention 
of phagocytic material in the form of residual body and lipofuscin.  Changes with 
consequences to the transport element can be seen in the loss of the 
complexity of basal convolution and microvilli. Despite this, experiments have 
shown that RPE cells can be loaded with lipofuscin and yet still function. Hence, 
it is not the rate limiting factor in terms of ageing transport and metabolic 
dysfunction. 
Further downstream, in pathology such as age related macular degeneration 
(AMD), investigators have found degenerative RPE, which included changes 
ranging from hyperplasia, hypertrophy, atrophy with associated thinning of 
choriocapillaries, thickening of BrM and photoreceptor cell death.	  (Sarks et al., 
1988)	  	  
The term ‘senescent’ RPE refers to a stage whereby normally mitosing RPE 
cells no longer divide.  This happens when the cycle of telomere-telomerase 
becomes deregulated beyond a certain point when cells no longer divide.  In 
fact, this concept had been proven both in vivo in primate eyes and in in-vitro 
experiments. (Mishima et al., 1999) Despite this, the senescent RPE cells were 
still found to be still metabolically active and release secretory enzymes and 
proteins. (Cao et al., 2013) This created a pro-inflammatory environment, which 
some authors hypothesize to be a causative factor in AMD.(Bandyopadhyay 
and Rohrer, 2012) 
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1.4.2 Ageing Bruch’s  
Structural 
Structurally, the BrM increases from 2µm in thickness in the first decade of age 
to 7µm by the 10th decade.(Ramrattan et al., 1994b) Furthermore, Pauleikhoff et 
al have previously found an increase in lipid content in the BrM, hence 
introducing a hydrophobic barrier amongst aged eyes.(Pauleikhoff et al., 1990) 
Furthermore, these changes were found to be more pronounced in the macula 
as compared to the periphery.(Holz et al., 1994)   
GE Marshall et al also found increased collagen type IV in choroidal endothelial 
cell basement membrane.(Marshall et al., 1992) They have attributed the 
increase in type IV collagen to be associated with the focal thickening between 
choriocapillaries and BrM due to ageing.(Marshall et al., 1992) Starita et al have 
also demonstrated that the highest resistance in aged BrM was between the 
inner collagenous layer and layer of elastin.(Starita et al., 1997) Hence, it may 
be assumed from various experimental data that the increase in type IV 
collagen and formation of dysfunctional collagen from AGEs play a significant 
role in causing resistance and decrease in transportation function across the 
BrM with age.  
 
Physiological 
There are dynamic changes in terms of molecular and physiological aspects of 
BrM throughout life.  With age, investigators have found notable molecular 
modification and reconfiguration in the BrM, resulting in increase in thickness 
and its reduced filtration capacity. (van der Schaft et al., 1992, Ramrattan et al., 
1994b, Moore and Clover, 2001a) The following summarizes the constellation of 
molecular changes in the BrM: 
1. Increased cross linkage of collagen, which resulted in the increase of 
strength, and density of the collagen network but decreased in elasticity, 
flexibility and filtration capabilities. (Ugarte et al., 2006) 
2. Higher turnover rate of BrM proteoglycans; proteoglycans are glue of 
extracellular matrices in BrM. As proteoglycan size increases, heparin 
sulphate fraction increases.  Heparin sulphate is known to have anti-
inflammatory properties either by interacting with complement factor H, 
an important regulator of the complement cascade and the local immune 
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response or by modulating complement activity via inhibition of the 
cleavage of complement factors B and C3, to respectively Bn and 
C3b.(Meri and Pangburn, 1994) Given the association between the 
complement system and development of AMD, the interaction between 
heparin sulphate and PGs may be one of the key molecular switches that 
turn normal RPE/BrM ageing into AMD pathology.(Scholl et al., 2008, 
Charbel Issa et al., 2011) 
3. Increased mineralisation of BrM:   
Some authors claim to have have demonstrated a link between BrM 
calcification and AMD.  It was postulated that extensive calcification of 
the BrM renders it brittle resulting in breaks, forming neovascularisation. 
(Spraul et al., 1999a) However, in empirical studies, the elasticity of 
membrane cannot be broken even when subject to pressures way 
outside its physiological limits. (Ugarte et al., 2006) 
4. Increased content of advanced AGEs in BrM were noted; AGEs are 
glycosylated or oxidised fat or proteins. AGEs accumulate on structural 
protein, like collagen in BrM where they inhibit protein function and cause 
AMD.(Glenn et al., 2009, Baynes, 2001)  
5. Accumulation of lipids in BrM. The increase of age found progressive 
accumulation of lipids such as phospholipids, triglycerides, FA and free 
cholesterol in BrM.  This was noted especially in the macular.(Baynes, 
2001, Sheraidah et al., 1993, Holz et al., 1994, Pauleikhoff et al., 1990) 
Some authors have found a 7x-increased concentration of cholesterol 
esters in the macular amongst the elderly as compared to its periphery. 
The accumulation of lipids with increasing age, reduces the capacity of 
BrM to facilitate fluid and macromolecular exchange between the choroid 
and the RPE or vice versa which is essential for retina function.(Marshall 
J, 1988)  
6. Abnormalities in the MMP system were found with increased levels of 
TIMP 3 inhibitor and AGEs and reduced active MMP2 and 9 from AMD 
donors compared to age-matched controls(Kamei and Hollyfield, 1999b, 
Hussain et al., 2011)  
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7. Additional high molecular weight MMP species (HMW 1 and 2) consisting 
of polymers of MMP 2 and 9 and much larger macromolecular weight 
complex (LMMC) with HMW1, HMW2, Pro MMP 9, Pro MMP 2 identified 
in BrM. (Kumar et al., 2010) 
 
Functional changes of Ageing Bruch’s membrane 
Hydraulic conductivity defined as a measure of water transport through a 
system, which in this case is across the BrM. With age, this basic transport 
need was found to be compromised.(Starita et al., 1996a) Foulds et al 
performed early experiments to determine the direction and rate of flow of water 
across the retina.(Moseley and Foulds, 1982) However, limited studies were 
done to specifically determine rate of fluid output by RPE in a normal eye. One 
clinical study using B scan ultrasonography to determine rate of regression of 
retinal bleb in a non-rhematogenous retinal detachment had found the rate of 
RPE transport to be approximately 0.11µl/hour/mm2.(Chihara and Nao-i, 1985) 
A presumed pressure on the RPE-Bruch’s membrane complex is 4mmHg as 
found in experiments using monkey eyes. (Emi et al., 1989) (Maurice et al., 
1971) Based on the information above, a well accepted equation for hydraulic 
conductivity calculation is HC=flow/pressure, and the calculated minimal HC for 
baseline requirements would be 0.65 x 10^-10m/s/Pa. (A.A Hussain, 2004)This 
calculated value was noted to be low because the calculation did not consider 
the drop in pressure across the BrM and had not considered the age related 
decrease in transport across the BrM. Experiments by Moore et al(1995a) had 
shown that an approximately 11% of human Bruch’s sample taken from a set of 
donors aged 50 and above did not meet this calculated basic requirement. 
(Moore et al., 1995a) 
Invitro studies by Moore et al (1995) and Starita et al(1996) previously 
demonstrated the compromise of hydraulic conductivity across the BrM with 
ageing and have found these changes to be exaggerated in the macular 
region.(Moore et al., 1995a, Starita et al., 1996a) (Figure 1.11) From the 
previous experiments, it was demonstrated that ageing causes exponential 
decrease in hydraulic conductivity across the BrM in both macular and 
peripheral region and the calculated half-life for this decrease was 16 and 23 
years respectively.  With these results of exponential decay, Moore et al 
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hypothesized that the mechanisms of decrease in fluid transport had been 
‘programmed’ from birth and calculated the ‘finite period of viable function’ to be 
101 and 131 years respectively.(Figure 1.11) (Moore et al., 1995a) However, in 
reality, individual ageing rates will also be dependent upon environmental and 
behavioral issues such as diet, light exposure, smoking etc. 
Amino acids are required for regeneration of outer segment disc and to replace 
neurotransmitter stores. Eight amino acids of varying sizes have been used to 
investigate the diffusional transport across the human Bruch’s and shown a 
linear decrease with age.(Hussain et al., 2002) Further studies with large 
molecules (Macromolecules), Hussain et al previously calculated using FITC 
dextrans as quasispherical probes that the exclusion radii for the inner 
collagenous resistance layer was 5.88nm, in the amino acid studies, the solute 
flux rates were reduced to 60% when solute radius was 10% of pore radius. 
Hence, in theory, large proteins such as albumin, transferrin and ceruloploasmin 
with radii of 3.58nm, 4.3nm and 4.68nm (61, 73, 79% pore radius) would not be 
able to pass through the conducting pore, restricting their transport. (Hussain, 
1999) 
Thus, with age, fluid and nutritional transport are certainly compromised. 
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Figure 1.11 HC plots across Bruch's membrane at (a) macular and 
(b) periphery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b 
1
Figure 1.11 a and b shows age dependent variation of HC of human 
BrM.In this experiment by Hussain et al, HC of BrM was determined in 58 
donors (1-81 years of age). Half life of macular region was calculated to 
be 16 years (a), whilst that of the periphery was 25 years (b). Graphs 
adapted from Moore et al, 1995 and Starita et al 1996.	  
2
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Table 1.2 Hydraulic conductivity in ageing physiology 
REFERENCE INVITRO 
MODEL 
RESULTS CONCLUSION 
Fisher RF Eye 
1987(Fisher, 
1987b) 
Human eyes HC decrease across 
BrM with age and 
Young’s modulus 
increase. Opposite 
results to lens 
capsule. Static 
measurement of HC. 
Implications on ageing 
macula and cataract. 
Moore et al 
1995(Moore 
et al., 1995a) 
Human BrM-
Choroid complex 
Age related 
exponential decrease 
in HC. 1. HC 
decrease is greater in 
first 4 decades of life; 
2. HC decrease more 
centrally then 
peripherally. Dynamic 
measurement of HC. 
The findings could be 
attributed to changes in 
BrM and CC with age. 
Other studies have 
found increased lipid 
deposits more centrally 
than peripherally. 
Starita et 
al(Starita et 
al., 1997) 
Human BrM-
choroid (old and 
young donors) 
Using excimer laser 
in series of 3 
pulses(0.75um) to 
ablate Bruch’s 
membrane, it was 
found that the 
greatest resistance of 
HC was in the inner 
collagenous layer. 
Dynamic 
measurement of HC. 
No corresponding 
morphological or 
histological data to 
correlate with this 
finding. 
Ahir et al(Ahir 
et al., 2002) 
Cultured RPE 
medium, HC 
across BrM 
using various 
methodologies 
with a latent and 
activated MMPs 
(MMP 2 and 9) 
Both activated MMP 
9 and 2 were 
released during cell 
proliferation. 
Activated MMP 9 and 
2 both causes 
increases of HC 
across BrM complex 
up to 3 folds. MMP9 
effect was found to 
be more pronounced 
in older eyes. 
Activation of MMP 
coincides with cell cycle 
and is a promising 
pathway to regulate the 
ECM of the BrM. 
Hillenkamp et 
al(Hillenkamp 
et al., 2004) 
Bovine 
eyes(<2years), 
human eyes(13 
to 81 years). 
Excimer laser to 
ablate BM and 
investigate the 
effect of path 
length in the 
macromolecular 
transport 
mechanism 
across BM. 
Path length and 
matrix component 
influenced the 
macromolecular 
transport mechanism 
across BrM with age. 
Choroidal thinning 
was not associated 
with restriction of 
transport. 
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Table 1.3 Changes in the BrM secondary to ageing 
Structural Physiological Functional 
Increase in vesicles and 
membranous materials 
first in the inner 
collagenous layer with 
age.(Feeney-Burns and 
Ellersieck, 1985)  
Increase in TIMP3 in 
Bruch’s membrane.(Kamei 
and Hollyfield, 1999b, 
Fariss et al., 1997a)  
Hydraulic conductivity 
across BrM decreases 
exponentially with 
age.(Starita et al., 1997, 
Moore et al., 1995a) 
Progressive increase in 
membranous lipids with 
age in BrM.(Newsome et 
al., 1987b, Bird and 
Marshall, 1986, Bird, 
1992, Sarks et al., 1999)  
Active-MMP 2 and 9 more 
prominent in peripheral than 
macular region in Bruch’s 
membrane.(Guo et al., 
1999b) 
Macromolecular 
permeability across BrM 
decreases linearly with 
age.(Hussain, 2002;Moore, 
2001) 
Increased crosslinking 
from AGEs and 
advanced lipoxidation 
products in BrM with 
age.(Karwatowski et al., 
1995b, Handa et al., 
1999) 
Presence of MMP 1, 3 , 2 
and 9 in Bruch’s membrane 
with increased inactivation 
with age.(Guo et al., 1999b)  
Macromolecular 
permeability decreases 
comparatively further in 
macular area in aged 
BrM.(Hussain et al., 2010c, 
Starita et al., 1996a, Moore 
et al., 1995a) 
Type IV collagen 
increases in BrM with 
age along RPE 
basement membrane 
and choroidal 
endothelium. 
Laminin increased in 
inner collagenous layer 
and basal linear 
deposits.(Marshall et al., 
1992, Marshall et al., 
1994) 
Increased bound MMP 2 
and 9 in ageing Bruch’s 
membrane, decreasing free 
pool for activation.(Kumar et 
al., 2010) 
 
Increase in thickness of 
BrM from 2 to 5um from 
1st to 10th decade of life. 
(Ramrattan et al., 
1994b) 
  
Increased deposition of 
material between RPE 
and BrM 
(drusen).(Sarks, 1976b, 
Green and Key, 1977) 
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1.5 Matrix Metalloproteinase  
Matrix Metalloproteinase(MMP) is an extracellular matrix regulator which was 
shown to be involved in the pathophysiological pathways leading to ageing in 
the retina. The following will review the molecular biology of MMPs, the 
involvement of MMPs in other parts of the body, and in particular reference to 
the outer retina and AMD. 
For the purpose of this thesis, pro or latent MMPs refer to the inactive or bound 
state of MMPs and active-MMPs refer to MMPs in the active or free form. 	  
1.5.1 Molecular Biology of Matrix Metalloproteinase 	  
Gross and Lapiere first discovered Metalloproteinases 50 years ago during 
tadpole tail metamorphosis.(Gross and Lapiere, 1962) Since then, it was found 
that the complex turnover process of the extracellular matrix(ECM) is regulated 
by  a family of 20 zinc-binding, calcium dependent enzymes, the matrix 
metalloproteinases (MMP). MMPs are classified to the type of ECM regulated, 
namely collagenases, gelatinases, stromelysins etc(Table 1.3). MMP activity 
are regulated by its inducers such as inflammatory marks (TNF-beta, ILF) and 
its inhibitors (TIMPs) (Table 1.4). In addition to its role to cleave proteins of the 
extracellular matrix, it also acts as a feedback to activate or inactivate other 
signaling pathways, including receptors, adhesion molecules and growth 
factors. (Table 1.5) 
MMPs have a common structure which includes a pro-peptide consisting of 80 
amino acids, a catalytic domain of 170 amino acids, a ‘hinge region’ which 
connects to the hemopexin C-terminal domain of 200 amino acids. Exceptions 
to this include MMP-7, -23 and -26.  All MMPs are released as inactive 
zymogens which consists of a ‘cysteine switch’ in the pro-peptide domain that 
binds to the zinc ion in the catalytic domain. This prevents MMP activation by 
preventing a water molecule to bind to zinc, preventing catalysis to its active 
form. The hemopexin C-terminal domain has a large surface for protein-protein 
interaction and serves as substrate recognition and  for interaction for specific 
tissue inhibitor of matrix metalloproteinase (TIMPs). 
Proenzymes of MMPs (or ProMMPs) are activated in a step-wise fashion. First, 
other tissue or plasma proteinase bind to a ‘bait’ region in the pro-peptide 
domain which then undergoes cleavage to remove part of the pro-peptide. The 
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second step involves complete removal of the pro-peptide by action of either 
MMP intermediates or other active MMPs. (Nagase et al., 1990, Peppin and 
Weiss, 1986) 
MMPs can also be activated artificially by treatment using mercurial 
compounds, or chaotropic agents. This technique is used in the laboratory to 
activate inactive MMPs. 
For the purpose of this thesis, only MMP 9 and 2 would be further elaborated. 
 
Human Matrix Metalloproteinase 9: 
Human matrix metalloproteinases are released as pro-forms, requiring 
activation for its activity. Both MMP 2 & 9 are thought to have collagenolytic 
activities, playing particularly important roles in final pathway of fibrillar 
collagens degradation, particularly collagen type I. Hence, both play a vital role 
in ECM remodeling. 
Human MMP 9 is a type IV collagenase and participates in degradation of a 
wide range of substrates, which includes gelatin; type IV, V, XIV collagens; X2-
macroglobulin; elastin; vitreonectin and proteoglycan. Activation of Pro MMP 9 
is currently still poorly understood but some data has suggested the influence of 
MMP 2 in cleaving pro-domain of MMP 9.(Toth et al., 2003)  
 
Human MMP 2 
Activation of MMP 2 is complex and mediated by MMP 14 and TIMP 2. First, 
the proMMP 2 forms a complex with TIMP 2 through its hemopexin C terminal 
domain with the non-inhibitory C terminal domain of TIMP 2.  This complex then 
binds to an active MMP 14 via the free N-terminal MMP inhibitory domain of 
TIMP 2. The propeptide of the proMMP 2 then links to another molecular of 
active MMP14. The two adjacent MMP14 molecules interact through their 
hemopexin C terminal domains. A tetrameric quaternary compound of 
proMMP2 is formed, whereby one molecular of MMP14 acts as a proMMP2-
TIMP2 receptor and the other activates the proMMP2 by cleaving the pro-
peptide.  (Alcazar et al., 2007, Smine and Plantner, 1997, Butler et al., 1998)  
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1.5.2 Systemic Involvement of Matrix Metalloproteinases 
MMP activation has widespread important biological physiological functions 
such as embryonic development wound healing and angiogenesis, but could 
overtly cause injuries and disorders involving cancer, inflammation and several 
auto-immune diseases.(Li et al., 2012, Said et al., 2014, Schveigert et al., 2013)  
The balance between the latent and stimulated forms of MMP is required under 
physiological conditions, but deregulated MMP profiles have been reported in 
several diseases such as coronary artery disease, myocardial infarction, 
coronary  aneurysm and stroke. (Nagase et al., 2006, Longo et al., 2002, Wang 
et al., 2002) (Figure 1.10) 
More recently, several protective functions of MMP have been found. These 
include the role of MMP 9 in chronic renal failure, stroke recovery by remodeling 
of neuronal extracellular matrix and Alzheimer’s disease by the regulation of the 
β−amyloid deposits by MMP9.(Aston-Mourney et al., 2013, Okada et al., 2012) 
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Table 1.4 Types of MMP 	  
 
 
Table 1.5 Inducers and inhibitors of MMP 
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Table 1.6 Biological activities mediated by MMP cleavage 
Biological effect Responsible 
MMPs 
Substrate cleaved 
Keratinocyte migration and reepithelialization MMP-1 Type I collagen 
Osteoclast activation MMP-13 Type I collagen 
Neurite outgrowth MMP-2 Chondroitinsulphate 
proteoglycan 
Adipocyte differentiation, MMP-7, Fibronectin 
cell migration MMP-1,-2, and 
-3 
Fibronectin 
cell migration MT1-MMP CD44 
Mammary epithelial cell apoptosis MMP-3 Basement 
membrane 
Mammary epithelial alveolar formation MMP-3 Basement 
membrane 
Epithelial-mesenchymal conversion 
(mammary epithelial cells) 
MMP-3 E-cadherin 
Mesenchymal cell differentiation with 
inflammatory phenotype 
MMP-2 Not identified 
Platelet aggregation MMP-1 Not identified 
Generation of angiostatin-like fragment MMP-3 Plasminogen 
MMP-7 Plasminogen  
MMP-9 Plasminogen  
MMP-12 Plasminogen  
Generation of endostatin-like fragment MMPs Type XVIII collagen 
Enhanced collagen affinity MMP-2, -3, -7, 
-9, and -13 
(but not MMP-
1) 
BM-40 
(SPARC/Osteonecti
n) 
Kidney tubulogenesis MT1-MMP Type I collagen 
Release of bFGF MMP-3, and -
13 
Perlecan 
Increased bioavailability of IGF1 and cell 
proliferation 
MMP-1, -2, -3, 
-7 , and -19 
IGFBP-3 
MMPs IGFBP-5  
MMP-11 IGFBP-1  
Activation of VEGF MMPs CTGF 
Epithelial cell migration MMP-2, MT1-
MMP, MMP-19  
Laminin 5γ2 chain 
MT1-MMP [108] Lamin 5β3  
Apoptosis (amnion epithelial cells) Collagenase Type I collagen 
Pro-inflammatory MMP-1, -3, 
and -9 
Processing IL-1β 
from the precursor 
Tumor cell resistance MMP-9 ICAM-1 
Anti-inflammatory MMP-1, -2, 
and -9 
IL-1β degradation 
Anti-inflammatory MMP-1, -2, -3, 
-13, -14 
Monocyte 
chemoatractant 
protein-3 
Increased bioavailability of TGF-β MMP-2,-3,-7 Decorin 
Disrupted cell aggregation and increased cell 
invasion 
MMP-3, MMP-
7 
E-cadherin 
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Reduced cell adhesion and spreading MT1-MMP, 
MT2-MMP, 
MT3-MMP 
Cell surface tissue 
transglutaminase 
Fas-receptor mediated apoptosis MMP-7 Fas ligand 
Pro-inflammatory MMP-7 Pro-TNFα 
Osteocleast activation MMP-7  RANK ligand 
Reduced IL-2 response MMP-9 IL-2Rα 
PAR1 activation MMP-1  Protease activated 
receptor 1 
Generation of vasoconstrictor MMP-2  Big endothelin 
Conversion of vasodilator to vasoconstrictor MMP-2  Adrenomedullin 
Vasocontriction and cell growth MMP-7  Heparin-binding 
EGF 
Neuronal apoptosis leading to 
neurodegeneration 
MMP-2  Stromal cell-derived 
factor 1α (SDF-1) 
Bioavailability of TGFβ MMP-9 precursor of TGFβ 
Thymic neovascularization MMP-9  Collagen IV 
Hypertrophic chondrocytes apoptosis and 
recruitment of osteoclast 
MMP-9  Galactin-3 
Embryo attachment to uterine epithelia MT1-MMP  MUC1, a 
transmembrane 
mucin 
Table by Visse and Nagase et al(Nagase et al., 2006) 
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Figure 1.12 Role of MMPs in systemic diseases 
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12 Pictorial diagram of detrimental and protective role of MMP in the 
human body. Because of their effect on various extracellular matrix, MMP 
serves a multiphasic role in numerous diseases.  It has long been thought that 
MMP causes disease progression (atherosclerosis, cancer, angiogenesis). 
However, it is now known that MMP (particularly MMP 2 and 9) has a critical 
role in acute diseases, but serves as a protective protease in chronic conditions, 
due to its ability to remodel extracellular matrix during recovery periods.  
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1.5.3 Involvement of Metalloproteinase in Ageing Bruch’s Membrane 
MMP profile of ageing Bruch’s membrane 
The extracellular matrix of the BrM is tightly regulated by matrix 
metalloproteinases.  These enzymes are released as pro-enzymes and 
activated by cleavage of a peptide. The activation pathways of these enzymes 
are regulated by other MMPs and tissue inhibitors of matrix 
metalloproteinase(TIMP). Previous investigations have demonstrated the 
release of MMPs by both RPE and the choroid.(Ahir et al., 2002, Guo et al., 
1999b) Til date, there is 4 known TIMPs (TIMP 1, 2, 3, 4).(Murphy, 2011) 
Abnormalities of the degradation and synthesis regulatory coupling can cause 
structural and functional changes to the BrM.  An example is Sorsby Fundus 
Dystrophy, an inherited disorder consisting of a mutational change in TIMP 3 
gene. This results in deregulation of ECM turnover. Histological studies have 
found an exaggeratedly thickened Bruch’s membrane (30um) amongst patients 
whose clinical pattern resembles that of early onset of AMD.(Weber et al., 1994)   
RPE and choroidal endothelial cells secrete MMPs 1,2,3 and 9 and TIMPs 1, 2 
3 which were also found in BrM.(Alexander et al., 1990, Della et al., 1996, 
Vranka et al., 1997, Fariss et al., 1997a, Hunt et al., 1993) Increased inactivated 
MMP 2 and 9 have been found in aged and AMD donors. Similarly, an increase 
in TIMP 3 had been noted in the BrM of aged donors.(Vranka et al., 1997, 
Fariss et al., 1997a)  This could be a cause of the structural thickening of 
Bruch’s membrane in normal aging. Thus, these evidences suggest a role of 
MMP/TIMP ratio in regulating the structural integrity of the BrM.  In a cross-
feedback fashion, it was also suggested that the integrity of the BrM is crucial in 
the RPE regulation of MMP and TIMP secretion.(Padgett et al., 1997) 
Work from our group in the past decade had demonstrated the structural and 
biological effects of MMP-2 and 9 in relation to the ageing retina. Kumar et al 
have also found an increased proportion of bound MMP in the form of 
monomeric and heterpolymeric sequestration in ageing BrM, decreasing the 
free pool available for activation. The heteropolymeric sequestration had been 
found by chromatography to consist of sequestrated Pro MMP 2 and Pro MMP 
9.(Kumar et al., 2010, Hussain et al., 2011) It was hypothesized that this 
depletes the level of MMP available for activation required for the turnover 
metabolism of the outer retina. This decrease in active MMP levels was 
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correlated to the decreased hydraulic conductivity and decreased 
macromolecular transport across the BrM.(Ahir et al., 2002)  
In essence, previous studies have shown the following with regards to MMP in 
the ageing BrM: 
• Sequestration of MMP in ageing BrM 
• Age related decreased hydraulic conductivity across BrM 
• RPE cell proliferation releases activated MMP 
• Activated MMP increases hydraulic conductivity across aged Bruch’s, 
It may be hypothesized that manipulation of the matrix metalloproteinase 
pathway, ie by increasing the quantity of activated MMP, might enhance 
regulation of the extracellular maxtrix of the aged Bruch’s, thus improving the 
transport system and delaying onset of AMD.   
 
Matrix Metalloproteinase in AMD 
Prior studies implied the contribution of MMP pathway in AMD.  Chau et al has 
found an increase in the plasma levels of pro MMP 9 in patients with early age 
related maculopathy and neovascularization in comparison to controls.(Chau et 
al., 2007)  Fiotti et al also found longer microsatellite in the region of MMP 9 to 
be associated with exudative AMD.(Fiotti et al., 2005) 
Previous in vitro studies by our team demonstrated the increased sequestration 
of MMP 2 and 9 into high molecular weight species (HMW 1 and 2) in AMD 
donors. This would deprive the levels of free pool of pro MMP for activation 
under normal regulatory circumstances.(Hussain et al., 2011) The following 
figure demonstrates the pathway for MMP sequestration in AMD. 
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Table 1.7 Gelatinase activity age-matched control versus AMD 
 
 
Figure 1.13 MMP Pathway in elderly Bruch's-choroid 	  
 
 
Pathway constructed by Hussain et al., 2011 
 
 
 
Hussain et al. IOVS 2011:4459-4466. 
Gelatinase activity Age matched Control & AMD 
Free Bound Total 
MMP  
species 
Donor 
group 
Control 
AMD 
HMW2 1435 ± 1520 12702 ± 3940 14137 ± 4725 
6685 ± 5444* 15195 ± 3018 21880 ± 8182* 
HMW1 Control 
AMD 
1335 ± 2470 5996 ± 2911 7331 ± 4040 
6327 ± 7064** 10480 ± 5616 16807 ± 11950* 
Pro-MMP-9 Control 
AMD 
9354 ± 11895 16068 ± 7692 25422 ± 16553 
33375 ± 25579*** 22572 ± 7274 55947 ± 30662* 
Pro-MMP-2 Control 
AMD 
1567 ± 1753 1393 ± 964 2960 ± 2071 
379 ± 374*  674 ± 700 1053 ± 854* 
Active MMP-9 Control 
AMD 
NDet 517 ± 376 517 ± 376 
NDet 195 ± 80* 195 ± 80* 
Active MMP-2 Control 
AMD 
357 ± 428 1978 ± 1140 2336 ± 1257 
335 ± 519 614 ± 534*** 949 ± 885* 
High Bad 
Low Good 
High Good 
Low Bad 
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1.6 Treatments of early AMD 
AMD extends from the early stages of drusen (Figure 1.14) and /or pigmentary 
changes with normal visual acuity to either exudative, wet AMD characterized 
by subfoveal choroidal neovascularisation or dry, geographic atrophy, that 
results in severe sight impairment (blindness).(Abdelsalam et al., 1999) There 
are various classifications of AMD. In the early stage of the disease, these 
classifications are based on the size of the drusen and presence of 
pigmentation.(Davis et al., 2005, Bird et al., 1995) According to the Age Related 
Eye Disease Study (AREDS) group, the rate of progression of early AMD 
defined as AREDS 3 (drusen>250µm, presence of central hyper or 
hypopigmentation) stands at 10% per annum. (Davis, Gangnon et al. 2005) 
Prior experimental model for prophylactic therapy for AMD were largely based 
on nutritional studies, on the basis of antioxidant to counteract the effects of 
inflammation. Studies have shown the link between complement factors H and 
complement pathways, classical, alternative and lectin, in particular alternative 
pathways to play a role in AMD. Epidemiological studies have also found 
association between groups with consumption of antioxidants in terms of 
vitamins and vegetables to have a lower prevalence of AMD. In detail, some of 
the nutrients that was previously investigated or currently undergoing 
investigation are highlighted below. 
(i) Fats 
The data from several large nutritional studies have been analyzed in an 
attempt to correlate the various types of fats with AMD.  These studies 
observed the quantity and quality of each type of dietary fat, including omega 3 
and 6, mono and polyunsaturated fats, saturated fats, total fats, trans fats, and 
cholesterol in relation to the risk of developing AMD.(Weikel et al., 2012). In 
general, only polyunsaturated fat and omega 3 (EPA and DHA) have been 
shown to have a beneficial effect in reducing the risk of both early AMD and 
conversion to neovascularisation. 
Studies demonstrated the positive link between long chain omega 3 fatty acids 
(such as docosahexaenoic acid, DHA and eicosapentaenoic acid, EPA) and 
decreased rates of chronic diseases, including AMD.(Pilkington et al., 2011, 
Bacova et al., 2010) The Eye Disease Case Control study (EDCC) group have 
found higher intake of omega 3 fatty acids to confer retinal protection against 
neovascular AMD (Seddon et al., 2001) Similar results were found by the US 
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Twin Study of Age Related Macular Degeneration group and the Age Related 
Eye Disease Study (AREDS) group, although the results were not statistically 
significant after adjustment for linoleic acid and arachidonic acid 
respectively.(Seddon et al., 2001, Sangiovanni et al., 2009) In particular, a 
prospective study of over 72,000 participants from the Nurses Health Study 
(NHS) and Health Professionals’ Follow up study (HPFUS) demonstrated that 
the highest intakes of DHA were associated with a reduced risk for AMD 
(Relative Risk (RR)=0.7, p<0.05 CI 0.52, 0.93) .(Cho et al., 2001)The 
Melbourne Collaborative Cohort group demonstrated that although the group 
consuming the highest amounts of omega 3 fatty acids had a slightly reduced 
risk for early AMD (Odds Ratio (OR)=0.85, 95% CI: 0.71, 1.02, p=0.03) there 
was, however, no association between the type of fatty acid and the disease. 
(Chong et al., 2009) 
There have been several studies that have produced contradictory results, 
finding deleterious effects of omega-3 fatty acid intake on AMD risk.  In the 
Carotenoids in Age Related Eye Disease Study (CAREDS)(Robman et al., 
2007), the investigators have reported an increased risk for intermediate AMD 
amongst women consuming the highest amounts of omega-3 fatty acids 
compared to women consuming the least amount of omega 3 fatty acids (OR 
2.60, CI 1.60, 4.40, p<0.01).  Also, in the NHS and HPFUS study, the group 
with the highest intake of linoleic acid had an increased risk for any stage of 
AMD (RR=1.49, 95% CI: 1.15, 1.94, p=0.0009).(Augood et al., 2008)  
Fish as a dietary source of omega-3 has also been shown to be associated with 
a decreased risk for neovascular AMD.  The AREDS group found that 
consumption of at least two servings of fish per week reduced the risk of 
neovascular AMD (OR =0.61; 95% CI:0.37, 1.00, p=0.01).(SanGiovanni, Chew 
et al 2007)  The NHS and HPFUS group also found that individuals who 
consumed more than four servings of fish per week had a reduced risk of any 
stage of AMD compared to those having less than 4 servings per week 
(RR=0.65; 95% CI: 0.46, 0.91).(Cho et al., 2001)  
In contrast, many studies, including the Beaver Dam Eye Study, CAREDS, and 
the Melbourne Collaborative Cohort did not find any association between 
consumption of mono unsaturated fatty acids such as oleic acid and any stage 
of AMD risk. (Cho et al., 2001, Delcourt et al., 2007, Robman et al., 2007) There 
were, however, reports of increasing risk of early AMD with consumption of 
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monosaturated fatty acids amongst subjects from the Blue Mountains Eye 
Study.(Smith et al., 2000)  
Increased saturated fats and cholesterol intake are associated with adverse 
health outcomes.  Similar to monosaturated fatty acids, a link was also noted 
between cholesterol and risk of early AMD in the Beaver Dam Eye Study and 
the Blue Mountains Eye Study. (Smith et al., 2000)  
In summary, other than for long chain polyunsaturated fatty acids, the evidence 
for all other fats remains relatively ambiguous. However, strong evidential data 
currently suggests that increased consumption of long chain omega 3 fatty 
acids such as EPA and DHA reduces the risk for neovascular and early AMD.  
(Roorda et al.)  
 
(Roorda et al.) Carbohydrates 
Carbohydrates have been postulated to contribute to oxidative stress and result 
in cell and tissue dysfunction Research that investigated carbohydrates intake 
and AMD utilized the glycemic index as an indicator.  The glycemic index is the 
measure of the ability of 50g of a certain glucose-rich food to raise blood 
glucose level as compared to the ability of 50g of standard food.  A high 
glycaemic index food would result in higher levels of blood glucose after two 
hours of food consumption.(Weikel et al., 2012) Almost all epidemiologic data 
have demonstrated that higher glycemic index foods were associated with 
higher risk for AMD or AMD progression.(Chiu and Taylor, 2011)   
For example, in the cross sectional analyses of the baseline data from AREDS, 
patients with higher dietary glycemic indices were at increased risk for the 
manifestation of large drusen and neovascularization.(Chiu et al., 2006) It was 
calculated that compared with those in the lowest 20% of dietary glycaemic 
index, those in the highest 20% had a 39% higher risk of advancement of 
disease.(Chiu et al., 2007). These findings corroborated results from another 
cross sectional analysis of 526 women in the NHS study.  This study found that 
women who had dietary glycemic indices in the highest one third compared to 
the lowest one third had an increased risk for AMD (OR=2.71; 95% CI: 1.24, 
5.93, p=0.01).  From these data, some authors concluded that by changing the 
dietary glycemic index by 1.0 unit (equivalent to replacing 3 pieces of white 
bread with 3 pieces of wholegrain bread as a daily consumption), approximately 
100,000 cases would be avoided in 5 years.(Chiu et al., 2007)  
	   72	  
The Blue Mountains Eye Study also noted a significant trend of decreasing risk 
for early AMD with increased intake of food with lower glycemic index, which 
included cereal fiber, breads and grains.(Kaushik et al., 2008)  
Hence, the evidence for a positive link between a high glycemic index and early 
AMD is substantial.(Roorda et al.)  
 
(Roorda et al.) Carotenoids  
Carotenoids constitute part of the macular pigments found in the retina.  Lutein 
and zeaxanthin are some of the carotenoids found in the macular 
region.(Granado et al., 2003)   
Several case control and cross sectional studies have reported high intakes of 
carotenoids such as lutein/zeaxanthin to be protective against neovascular 
AMD. (1993, Seddon et al., 1994) In the AREDS study, cross sectional analysis 
have shown that longer-term consumption of lutein/zeaxanthin provided a 20% 
reduced risk for drusen and late AMD(Chiu et al., 2009) The Carotenoids in Age 
Related Maculopathy in Italians Study (CARMIS), a randomised clinical trial in 
which patients received either a combination of 10mg lutein, 1mg zeaxanthin, 
4mg astraxanthin and an antioxidant versus no supplements, found that the 
subjects who received the combination treatment had improved and stabilised 
visual acuity.(Piermarocchi et al., 2011) The conclusions from this study were 
reinforced by the Lutein antioxidant Supplement trial (LAST) which showed 
improvements in visual acuity and contrast sensitivity in subjects who received 
the supplementation.(Trieschmann et al., 2007)  
Despite these encouraging results, there have been several cross sectional 
studies which did not demonstrate an association between serum levels of 
carotenoids and risk of any stage of AMD.  Several prospective studies, such as 
the Rotterdam prospective cohort, which has over 10,000 subjects of both 
genders living in Rotterdam, in the Netherlands, did not find an association 
between lutein/zeaxanthin intake and AMD.(van Leeuwen et al., 2005) The 
NHS and HPFUS study, and the Beaver Dam eye study had similar outcomes. 
(VandenLangenberg et al., 1998, Cho et al., 2004, Cho et al., 2008) On the 
other hand, few studies have suggested increased risk of early AMD with 
consumption of high amounts of lutein/zeaxantin. (Robman et al., 2007, Mares-
Perlman et al., 2001)  
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Beta-carotene, another carotenoid which was investigated in many studies, in 
general did not have a positive effect on risk reduction in AMD.(Smith et al., 
1997, Cardinault et al., 2005)  
Studies that evaluated other carotenoids found commonly in food-based 
products, such as lycopene, in tomato-based products, and cryptoxanthin, in 
avocados, basil and mangos, did not find a significant correlation with 
decreased AMD.(Cardinault et al., 2005, Michikawa et al., 2009)  
As carotenoids are by-products of vitamin A, which takes the form of retinol in 
the body, several analyses of vitamin A/retinol intake and plasma levels have 
been carried out to examine the role of vitamin A in promoting retinal health.  
The NHANES I study has found that increased consumption of fruits and 
vegetables rich in vitamin A results in a decreased risk for any stage of AMD 
(OR=0.59, 95%CI: 0.37, 0.99, p<0.01), whilst the Beaver Dam Eye study found 
that past or current intake of beta carotene reduced the risk for the 
manifestation of large drusen.(VandenLangenberg et al., 1998, Goldberg et al., 
1988) All other investigations of vitamin A and the risk of AMD, however, did not 
find encouraging associations.(Simonelli et al., 2002, Seddon et al., 1994)  
In summary, of all the carotenoids studied, lutein and zeaxanthin were found to 
confer most benefit to the retina and the greatest benefits lie in the most 
advanced stages of AMD. A large scale clinical trial, the AREDS 2 study is 
currently recruiting to evaluate the benefits of lutein/zeaxanthin. 
 
(iv) Vitamins 
Vitamin C is a strong antioxidant (ascorbic acid) and its affects on AMD have 
been investigated on the basis of its antioxidant properties.  However, results 
from several clinical studies concluded that there was no correlation between 
vitamin C status and retinal health.(Blumenkranz et al., 1986, 1993) This can be 
postulated to be a secondary consequence of the hydrophilic properties of 
ascorbic acid in an environment where the retina is largely lipophilic, hence 
limiting its role at this site. 
 
Vitamin D 
The general health benefits of vitamin D on chronic disease are well known. 
However, there had only been one study which investigated the role of vitamin 
D in AMD.  In the NHANES III study, non Hispanic whites with the highest 
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serum levels of vitamin D had a reduced risk of early AMD compared to those 
with low serum levels.  This effect was however not noted in non-Hispanic 
blacks or Mexican Americans. (Parekh et al., 2007) Further studies are required 
to further explore this correlation. 
 
Vitamin E 
Vitamin E is a lipophilic antioxidant (alpha-tocopherol) and was a focus of retina 
research in efforts to diminish the risk for AMD.  An earlier case control study of 
48 patients demonstrated that plasma vitamin E was significantly lower in 
patients with late AMD as compared to early AMD, or healthy age matched 
controls.(Simonelli et al., 2002) Several other analyses from the POLA study 
involving 2584 participants also found that those with high levels of plasma 
vitamin E had a reduced risk of early and late AMD, whilst the AREDS study 
which evaluated vitamin E consumption found that those consuming highest 
amounts of vitamin E had a slightly reduced risk for late AMD, compared to 
those consuming the least amounts.(Chiu et al., 2009, Delcourt et al., 1999)  
Despite these initial encouraging results, research from the Beaver Dam eye 
study, the NHS and HPFUS study, and the women’s health study (WHS) group, 
which involved a total of approximately 50,000 participants did not find any 
relationship between vitamin E levels and AMD risk. (VandenLangenberg et al., 
1998, Cho et al., 2004, Christen et al., 2010)  
Hence, taken in totality, current data from clinical trials does not support a 
significant effect of vitamin E alone on AMD. 
 
(v) Multivitamins (AREDS preparation): 
It was hypothesized that the consumption of several groups of different vitamins 
would be more effective in their mode of action compared to a single 
vitamin.(Weikel et al., 2012) Several studies have demonstrated consistently 
high levels of carotenoids, vitamin C, and vitamin E contributed to reduced risk 
of neovascular AMD when used in combination.(1993) The AREDS study 
tabulated a compound score to compare overall diet to the risk for AMD and the 
compound score included intake of vitamin E, C, zinc, lutein/zeaxanthin, DHA, 
and EPA.(Chiu et al., 2009) The subjects with the highest score had a reduced 
risk for drusen (OR=0.75; 95% CI:0.60, 0.93, p=0.048) and late AMD (OR=0.58, 
95% CI:0.40, 0.82; p=0.002).  Results from the AREDS study also 
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demonstrated that supplementation with a cocktail of beta-carotene, vitamin E, 
vitamin C, zinc and copper reduced progression from intermediate to advanced 
AMD (exudative form) by 34% over 6 years of follow up. (Chiu et al., 2009) That 
said, several authors have disputed the role of zinc in relation to its purpose to 
delay the onset of AMD.  Results from AREDS 2, with the addition of lutein and 
zeaxantin were largely equivocal. 
Despite the hint that multivitamins may delay onset of exudative AMD, there 
was no substantial evidence to conclude that multivitamins play a role in dry 
AMD. 
 
(vi) Statins 
Several epidemiologic and genetic studies have found similar risk factors for 
both AMD and atherosclerosis.  This led to the speculation that statins, long 
known for their beneficial effects on patients with atherosclerosis and 
hyperlipidemia, may have a protective role in AMD.  This hypothesis on the 
pharmacological mechanism of action of statins in preventing AMD was based 
on their serum lipid lowering effects, hence altering the structure of BrM and 
preservation of the choroidal vasculature by protection against atherosclerosis 
and the anti-inflammatory properties of statins.(Penfold et al., 2001, Friedman, 
2004) Prior work demonstrated that statins reduce plasma levels of VEGF by 
altering the transcription factors involved in VEGF production.(Dichtl et al., 
2003) VEGF is an important mediator in the development of choroidal 
neovascularisation. There were only two other trials which have evaluated the 
effect of statins on stages of AMD, and they did not demonstrate that statins 
have a beneficial role.(Guymer et al., 2005)  
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Figure 1.14 Progression of AMD 
 
   	  
Dry/Early AMD à              Intermediate AMD     à                     Advanced AMD 
(multiple small or              (extensive drusen)                             (Geographic Atrophy involving the  
intermediate drusen)                                 fovea or Sub-fovea Choroidal  
                                                                                                                    Neovascularisation) 
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1.7 Problems and Aims at Commencement of this Thesis 
1.7.1 Problems 
AMD is and will become increasing prevalent with increasing life span of the 
population, especially in developed nations. This effect of this will be the 
surmounting indirect and direct costs both because of treatment (antiVEGF in 
exudative AMD) and the social costs attributed to blindness. As mentioned 
earlier, there is no proven prophylactic therapy to delay the onset of AMD. The 
AREDS1 study have shown minimal advantage of multivitamins (vitamin C, E, 
Zinc) to delay onset of wet AMD, although several investigators have disputed 
the role of Zinc. Studies targeting carotenoids with zeaxantin, lutein etc have 
equivocal results. 
The biggest risk factor in AMD is ageing, therefore, theoretically if the ageing 
processes in the outer retina were delayed or reversed, the onset of AMD would 
be significantly delayed. Ageing in the outer retina results in debris in the retinal 
pigment epithelium and the BrM. It appears that this deposition of debris affects 
transport of metabolites into and water and waste out of the retina respectively. 
There is limited evidence that migration of the RPE cells induces release of 
enzymes which allow the cells to release their hemidemisomal complexes with 
BrM and such enzymes also initiate removal of debris. MMPs have been 
identified as the major class of agent responsible for maintaining healthy 
acellular membrane systems throughout the body. The cell death associated 
with laser irradiation of the RPE is known to initiate cell migration within 4 to 7 
days of irradiation and in turn this is associated with enzymatic release.  
Currently, laser parameters used clinically result in collateral damage to 
photoreceptor cells. To minimize such damage, the pulse duration of lasers 
have been reduced to microseconds. Whilst this minimizes primary damage, 
secondary damage may occur as a result of contiguous areas of RPE cells 
being damaged, thereby resulting in overlying areas where the photoreceptor 
cells is deprived of nutrients. 
The unique configuration of this laser aims to first limit the secondary damage 
and second, to increase the efficiency of MMP release by increasing the 
effective circumference available for RPE migration. Although in reality the RPE 
migration really may involve 4 to 5 layers of RPE cells, for simplicity purposes, 
the following effective circumference calculations will be based on a single layer 
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of the peripheral circumference of RPE cells. For example with a Gaussian 
beam of 400µm spot size laser beam, a calculated estimate of effective 
circumference for RPE migration from laser injury would be 1200µm. This would 
be equivalent to 30 RPE cells (using a lateral dimension of approximately 
40µm). With an estimated 10 to 15% discrete RPE injury in a discontinuous 
laser beam, it was expected that there would be a discontiguous areas of RPE 
injury within the 400µm spot size, hence increasing the effective circumference 
available for RPE migration and biochemical releases of enzymes.(Figure 1.15) 
This effective circumference of RPE cell migration is a crucial factor in 
determining the level of MMP release for clearing up of the debris and 
improving transportation across the BrM. There is minimal evidence that first, 
laser injury to the RPE results in MMP release, and second the effect of MMP 
on transport across the BrM. It is postulated that the number of laser spots and 
laser energy play a role in defining the volume of RPE injury. It is proposed that 
the number of laser spots have greater effect than laser energy given that a 
higher energy will result in a higher zone area of RPE damage and less 
circumferential region for RPE migration and release of enzymes, in addition to 
the secondary laser damage.(figure 1.15) 
Guymer and team in Australia, at the time of commencement of this thesis, was 
in the initial stages of a pilot study whereby 12 clock hour laser lesions were 
proposed as the treatment algorithm and flicker perimetry was used as the 
primary treatment outcome. It is in question whether this minimal number of 
lesions would have any effect on the macular and the sensitivity of the flicker 
perimetry to monitor response given the paucity of published data.   
When the design of this PhD was initiated, there were no other published 
clinical assessments of the 2RT laser used in human subjects. With the 12 
clock hour lesions, the initial pilot study in Australia had been deemed 
inappropriate due to the misconception of the treatment algorithm and the use 
of changes in flicker perimetry to define their outcome. In reality, in early AMD, 
there are few clinical tests that are sensitive enough to determine subtle 
changes expected in this select group of patients. This becomes a problem in 
the design of clinical trials to monitor treatment response.  Most clinical trials is 
almost exclusively dependent on VA changes, however, the problem arises 
when subjects enter the trial with 6/6 vision and otherwise asymptomatic. 
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In essence, there are several problems concerning the laser configuration of the 
2RT laser and its use in early AMD that have been identified in this thesis.  
The following lists the problems at time of commencement of this thesis: 
 
Problem 1: Laser is an ideal modality to cause RPE injury and initiate the 
migratory processes with secondary release of factors such as MMPs and 
cytokines etc. However, as mentioned, laser in the current form (milliseconds) 
was found to result in collateral primary damage to the adjacent layers. It was 
discussed that the nanosecond time domain would be effective in causing 
limited damage, however, with the large area of irradiation, it would be subject 
to secondary damage. The 2RT laser with its speckled beam configuration was 
designed to allow discontiguous injury to the RPE cells in a 400µm spot size, 
with the aim to circumvent this problem. No previous studies have been 
attempted to qualify this laser beam profile and its effect on the RPE. 
 
Problem 2: Although it was known that that RPE migration results in MMP 
release which in turn clears up the debris, there is still uncertainty about the 
minimum volume of RPE migration required for MMP release for BrM ‘clean up’. 
Limited in vitro experiments have shown that MMP is released from RPE 
migration post laser, but this needs to be ascertained. 
 
Problem 3: Although preliminary studies of measurements have been made on 
MMP release, the directionality (ie, apical or basal) and time sequence has not 
been fully studied.  
 
Problem 4: From the experiment by Ahir et al, it was shown that exogenously 
applied MMP result in increased hydraulic conductivity across the BrM. 
However, the effect of varying levels of MMP on the BrM with age has not been 
studied. It is critical to understand the therapeutic impact of MMP especially in 
the elderly, which will have implications on defining possible treatment algorithm 
for using the 2RT laser in delaying onset of AMD. 
 
Problem 5: There had been minimal data on the use of this novel laser in 
human subjects with AMD and the only pilot study by Guymer et al was 
inappropriate in terms of the their treatment algorithm with 12 laser lesions. 
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Hence, there is a lack of information with regards to the use of this laser in 
human subject and its effect in AMD patients to prevent or retard onset of AMD. 
Also, the treatment algorithm for this laser as a treatment modality is poorly 
defined. 
 
Problem 6: In terms of clinical assessment, there is currently no easily available 
tool to evaluate the functional deficit in very early AMD patients, which will make 
interpretation of structural or functional evaluation of pre and post treatment 
difficult.  
Given these problems, several aims of the thesis were set out in the chapter 
following. 	  
Figure 1.15 Concept of quantitative MMP release 
 
 
 
 
 
 
 
 
 
400um%
area%
a% b% c%
 
 
 
Figure 1.15 is a pictorial representation of the concept of increased efficiency 
of MMP release per unit circumfirence of RPE injury. In figure a., a 400µm 
spot size has a limited available circumference of MMP release from RPE cell 
migration. In figure b, the discrete RPE damage allows multiple simultaneous 
areas of RPE migration for MMP release.  
Figure 1.15c represents a theoretical model of increasing laser energy. With 
higher, the zone of RPE damage will cause coalescence of laser lesions, 
thereby forming a larger area of laser damage, again, with the compromise of 
available circumference for RPE migration, with the added risk of secondary 
laser damage.  
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1.7.2 Aims and Objectives 
In addressing the above problems, this thesis has been structured into 2 main 
parts; Part 1 involves laboratory investigations, which aimed to determine the 
following: 
a. the laser beam configuration of the 2RT laser; 
b. the impact of the nanosecond laser on release of MMPs;  
c. the type, direction and time sequence of release of MMPs; 
d. the effect of varying levels of MMPs on hydraulic conductivity across the 
ageing BrM 
e. defining a treatment algorithm for clinical use 
 
Part 2 of the thesis would be the clinical evaluation of the use of this laser in 
delaying the progression of AMD. Ideally, this should have been done in 
patients without the signs of early AMD, ie druse, hence, targeting to delay the 
ageing physiology. However, due to constraints of ethics, the clinical evaluation 
was done in early AMD patients. The clinical assessment of the use of the novel 
laser in early AMD undertaken was involved in determining the following: 
a. the efficacy of this laser to delay progression of AMD; and 
b. the damage and/or limitation of damage of this nanosecond laser in AMD 
patients, ie, ‘safety’. 
 
During the conceptual stage of design of individual experiments to determine 
the above objectives, the following detailed main, secondary, tertiary and 
quaternary aims were defined in accordance to the problems identified. 
 
The first main aim concerning Part 1 of this thesis involved assessing the laser 
beam design and its impact on RPE. 
Main aim: To evaluate the viability of the design of the discontinuous 
nanosecond to prevent secondary laser damage. 
Secondary aims:  
1. To assess the beam energy distribution of the 2RT laser on homogenous 
targets. 
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2. To evaluate the morphology of laser damage on heterogenous targets 
such as biological tissues and/or the RPE. 
 
Tertiary aims:  
1. To determine the diameter of laser damage as a function of laser energy. 
2. To evaluate the effect on energy levels on the effective circumference for 
RPE migration.  
3. To determine the ED50 plot of this laser on damage thresholds. 
 
Quaternary aim: 
1. To assess the effectiveness of various methodologies to determine visual 
damage of the RPE cell. 
 
Before problem 2 may be addressed, it would be important to understand the 
baseline characteristics of the release profiles of MMP. Hence, an experiment 
was designed with the following aims:  
 
Main aim: To determine the baseline characteristics of MMP release 
Secondary aims:  
1. to determine the baseline profile of MMP in an in vitro model using RPE-BrM 
choroid explant culture 
Tertiary aims:  
1. To determine the types of MMP release; 
2. To determine the time course of MMP release; 
3. To determine the direction of MMP release; 
Quaternary aim: 
1. To assess if there may be differences in MMP release characteristics 
profile between different species. 
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After the determination of a baseline MMP profile, problem 2 and 3 may be 
addressed. 
Main aim: To assess the impact of the nanosecond laser on MMP release 
Secondary aims: 
1. To determine if MMPs are released post laser application in an in vitro 
model of a RPE-BrM choroid explant culture model; 
Tertiary aims: 
1. To determine the type of MMP release; 
2. To determine the temporal sequence of MMP release; 
3. To determine the direction of MMP release; 
Quaternary aims: 
1. To determine the effect of varying laser parameters on MMP release in 
the in vitro model 
 
To address problem 4; 
Main aim: To evaluate the effect of varying levels of MMP on transport 
across the BrM 
Secondary aim:  
1. To evaluate the effect of activated MMP on transport across BrM. 
Tertiary aims: 
1. To assess the impact of varying quantity of MMP on transport across the 
BrM. 
2. To determine the impact of activated MMP on transport across the BrM 
as a function of age. 
Quaternary aims: 
1. To correlate the minimal level of activated MMP required for increasing 
transport across the BrM in the elderly age group; if any. 
2. To correlate the minimum RPE injury required for increase in transport 
across the BrM in the elderly age group; if any.  
3. To determine the laser parameters for clinical use. 
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The second part of this thesis clinically evaluates the use of this laser in early 
AMD patients. The main objectives were to evaluate the efficacy and safety (ie, 
limitation of damage as compared to conventional lasers) of the 2RT laser for 
clinical use, in patients with early AMD. To address the identified problems, a 
clinical trial (RETILASE) was designed. However, for the purposes of this 
thesis, the data obtained was analyzed differently from as set out in the trial 
protocol, to allow more in depth and scientific evaluation of the information 
gathered. 
 
The following aims were intended to evaluate the effect of the 2RT laser on 
human subjects with AMD 
Main aim: To clinically evaluate the use of the current laser system to 
delay progression of AMD. 
Secondary aims:  
1. To determine changes in visual function tests (visual acuity, contrast 
sensitivity, microperimetry, flicker perimetry) at 6 and 12 months 
2. To determine the proportion of cases treated which converted to 
advanced AMD. 
Tertiary aims: 
1. To evaluate the changes in druse morphology post laser at 6 and 12 
months. 
 
As mentioned earlier, there is minimal information with regards impact of the 
2RT (and/or limitation of damage) on human subjects. The word ‘safety’ may be 
used synonymously for the purpose of this thesis. 
Qualitative and quantitative analysis of data obtained from clinical imaging in 
the trial were performed with the following aims.  
Main aim: To evaluate the impact of the 2RT laser on human subjects. 
Secondary aims: 
1. To investigate the limitation of collateral damage (axial damage) of this 
laser system in human subjects; 
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2. To investigate the 2RT laser damage on RPE layer in human subjects. 
(in view of a possible speckled laser beam configuration) 
Tertiary aim: 
1. To investigate the functional changes over laser lesions in the macular of 
human subjects. 
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Part 1 
Chapter 2.  Assessment of the Discontinous Beam Energy 
distribution/ “Speckled Laser Beam” of the 2RT Laser 
2.1 Introduction 
The 2RT laser was theoretically designed to limit the primary and secondary 
laser damage by using a nanosecond time domain and a speckled profile 
across the laser beam. 
The fact that axial laser damage decreases with decreasing time domain is well 
accepted.  
As mentioned earlier in the Introduction chapter (chapter 1), the laser design 
with its discontinuous beam configuration would minimize the risk of having 
secondary damage by preserving some cells throughout the irradiated area. 
This beam energy distribution profile of the 2RT laser has not been evaluated. 
In this chapter, the main aim would be to assess the viability of the 2RT laser 
beam to prevent secondary laser damage. It is known that retina laser therapy 
is a linear process that is dependent on the transmission properties of the laser 
and the absorption by the biological tissue. To facilitate the evaluation of the 
laser beam at transmission and absorption, experiments will be performed to 
analyze the laser beam profile on homogenous and heterogenous targets. This 
will be further discussed under methods and materials sub-chapter. 
Lasers with ultrashort pulse time domain (ie, nanosecond) were found to have 
high peak energy which can cause secondary break in BrM and subretinal 
bleed. This may be avoided by increasing the area of laser irradiation to allow a 
spread of laser energy. The 2RT laser has a large spot size of 400µm. The 
effect of laser damage as a function of laser energy has never been 
determined. A secondary intention of this chapter would be to evaluate the 
diameter of laser damage with different laser energies and to determine the 
ED50 for this laser. 
 	  	  	  	  
	   87	  
2.2 Methods and materials 
2.2.1 Physical modelling of beam energy distribution of the 2RT laser 	  
Physical modeling of the beam energy distribution of the 2RT laser was 
performed in 3 ways (Figure 2.1):  
1. By directly assessing the laser beam,  
2. By applying the laser on a homogenous target. The homogenous target 
used in these experiments was neutral density filter (NDF).  
3. By assessing the laser beam after it has passed through a NDF. 
2.2.1.1 Assessment of laser beam profile 	  
To preliminarily assess the laser beam profile, laser shots were recorded using 
a video recording system (HD(720p) up to 30 frames  per second and 5 mega pixel 
camera, Iphone 4). The laser shots were aimed at the camera pinhole in a dark 
room. The 2RT laser prototype, which has a larger range of energies in the 
range of 0.3mJ to 1.2mJ, was used. Only few laser shots were taken at 0.5mJ 
to protect the camera (for subsequent use) from over-exposure to laser beam 
which would damage the camera. 
Post recording, video editing on imovie (MacIntosh system) was done to obtain 
photograph of individual laser shots of varying energy levels. The images were 
saved as TIFF files.  Individual images of laser shots were imported into the 
National Institute of Health (NIH) Image J(vers 1.44o) program. After importing 
the image, the black and white colors were inverted to allow a greater contrast 
of the images. The edge of the laser lesion was identified and a line was drawn 
across the middle of the laser beam from end to end using a ‘straight line’ 
option in the tool box. This program measures distance in terms of pixels. As 
such, the unit length was set to 400µm, under ‘scale’,  given this was the 
presumed laser spot size. A plot profile could be obtained using the ‘plot profile’ 
sub-category under ‘Analyze’ on the Image J software. The plot profile obtained 
would have a ‘relative transmission value’ in the y-axis. 
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2.2.1.2 Laser application on Neutral Density Filter 	  
Neutral density filter (Kodak) was used as a homogenous target to determine 
the transmission of the laser beam.  In this experiment, a ND 0.6 was used.  
The filter was mounted on the headrest of the 2RT system and attached with a 
cellophane tape.  Laser application of varying energy levels 0.6mJ to 0.1mJ,  
were applied vertically in a row, in ascending-descending order. (Figure 2.2) 
Each laser lesion was applied 1 spot size apart. Images were taken on Leica 
microscope (DMC2900) camera at 40x magnification. 
2.2.1.3 Assessment of laser beam profile through a neutral density 
filter 	  
To obtain a full range of energy profile of the laser beam, video recording 
described in 2.2.1.1 was repeated after the laser beam has been attenuated by 
NDF. NDF 0.3 was used. The reason why a different NDF stop was used was 
simply because of its availability during time of experiment. Laser was applied in 
the range of 0.3mJ to 2.0mJ. 
Individual images of laser in varying energy levels were extracted from imovie 
(as per 2.2.1.1) and imported into image J. In this series, both the images on 
corresponding NDF and from laser beam were analyzed. Further analysis was 
undertaken for the laser beam. After obtaining the plot profile for both NDF and 
laser beam, in image J, under ‘image’, choose ‘color’ and click on ‘ RGB’. This 
will change the image to red, green and blue colors in accordance to pixel 
intensity of the image. This was initially done as a ‘trial and error’ to determine if 
there might be a difference in intensity of the laser beam with different energies. 
However, after analyzing multiple images of increasing range of energies 
(approximately 2-3 images per energy, from 0.3mJ to 2.0mJ), it was noted that  
the color differentiation may correspond to a presumed differential laser energy 
intensity, ie, with higher laser energies, there is larger area of red, followed by 
green and blue depicts least intense areas of laser energy. 
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Figure 2.1 Pictorial demonstration of physical modeling of energy beam 
distribution of the 2RT laser 
 
 
Figure 2.2 Pictorial demonstration of laser application in varying laser 
energy levels in porcine flat mount 
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2.2.2 Assessment of Biological Effects across the Lesions Produced by 
2RT laser on Porcine RPE 
2.2.2.1 Dissection porcine eyes 
 
Fresh porcine eyes were obtained from a local abattoir before steaming and 
experiments were initiated within 12 hours of death.  Whole globes were first 
briefly rinsed in antiseptic solution before dissection.  A circumferential incision 
at the pars plana was made to remove the anterior segment, lens and vitreous.  
The retina was gently peeled away thereafter. The leaves the remaining 
posterior pole with an intact RPE-BM-choroid-sclera which was held in an ‘eye’ 
cup (quail egg cup) and affixed using pins to a hard cardboard which was 
attached to the head rest of laser machine by multiple cellophane tapes. The 
height of the explant to the laser beam exposure was adjusted by moving the 
cardboard. The surface exposing the RPE surface was facing the direction of 
laser beam 
 
2.2.2.2 Laser application 	  
The laser treatment was performed using the clinical slit-lamp delivery system 
of the 2RT system (Ellex Medical, Australia).  
In the samples, laser energy was delivered in a vertical manner towards the 
optic disc from high energy (0.45mJ per exposure) and reduced sequentially by 
0.05mJ per exposure. This was repeated in the opposite direction, forming 2 
rows of 8 laser spots each. (Please refer figure 2.3)  Spot size of the laser was 
400µm in diameter. Each application of the laser was 2 spot size apart. Based 
on the investigator’s brochure for the 2RT laser from Ellex Medical, the visual 
threshold for the 2RT laser was above 0.30mJ. As such, visibility of the sub-
threshold lesions at lower energy levels can be identified as lesion between 
adjacent ‘markers’ of higher energy. (Please refer to figure 2.3) 
A separate application of millisecond laser, 100um, 5.57J/cm^2 (Valon) was 
applied on a separate flat mount. 
Post laser, the tissue samples were immediately fixed in 2.5% glutaraldehyde 
solution.  
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Figure 2.3 Pictorial demonstration of laser application in varying laser 
energy levels in porcine flat mount 
	  	  
 
 
 
 	  	  
 	  	  	  	  	  	  	  	  	  	  	  	  
 
Figure 2.3 demonstrates the method of laser application for the flat mount histology. 
Laser is applied from high (0.45mJ ) to low (0.10mJ) and in the opposite direction in 
the adjacent row. This allows easy identification of the subthreshold low energy 
lesions between 2 higher energy lesions which can be taken as ‘marker lesions’. 
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2.2.2.3 Flat mount histology 
Post laser, the tissue was fixed in 2.5% Gluteraldehyde buffered in 0.1M 
Sodium Cacodylate Hcl buffer pH 7.4 with Calcium Chloride 1mg/ml for one 
hour. It was then rinsed in 0.25M Cacodylate-sucrose buffer with Caclium 
Chloride 1mg/ml before further dissection of the tissue under dissecting 
microscopy.   The RPE layer was peeled off and dehydrated through ascending 
series of ethanol concentrations in water - 20%, 50%, 70%, 90% and 100%. 
The tissue was then cleared in xylene and mounted with XAM on a microscope 
slide. 
Images were then taken using an upright Leica microscope with camera (DMC 
2900) at 20x magnification.  
2.2.2.4 Measurement of diameter of laser damage 
The largest diameter of laser damage was measured the built-in scale (reticule) 
within an eye piece of the microscope. The measurements were made with 
direct observation of the scale under the microscope at magnification of 20x. 
Size of sample is calculated by size noted on reticule, divided by ‘Magnification 
of Microscope’. For example, if the measurement of diameter of laser damage 
on the reticule measures 4mm, using a microscope magnification of 20x, the 
‘real size’ of sample will be calculated to be 200µm. 
2.2.2.5 RPE viability 
Calcein AM is a cell-permeant dye that can be used to determine cell viability in 
most eukaryotic cells. In live cells the nonfluorescent calcein AM is converted to 
a green-fluorescent calcein after acetoxymethyl ester hydrolysis by intracellular 
esterases.  Calcein AM dye test was performed on 0.1mJ and 0.30mJ laser 
lesions on porcine eyes to determine if there was a discrete pattern of RPE cell 
death as hypothesized with this laser design. The areas that appeared black 
signified RPE cell death. 
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2.2.2.6 Determination of ED50 of 2RT laser 
To determine ED 50 of 2RT laser on porcine RPE invitro, laser shots were 
applied as per figure 2.3 from 0.6mJ to 0.1mJ in a vertical direction. 10 rows of 
laser were applied, adjacent rows in ascending and descending order of laser 
energies. Clinically visible laser spots were observed under the slit lamp system 
of the 2RT laser.  
A dose response curve is frequently used in studies determining laser impact on 
biological tissue. Examination of the slope of the dose response curve may be 
expressed in terms of a probit plot of a collation of experimental data. By 
definition, a probit analysis is a type of regression used to analyze binomial 
response and is used to analyze dose-response experiments.(Finney, 1952) 
The ED 50 is a value refered to as the “threshold” which is a reference point on 
the probit plot, representing a 50% probability of biological injury. 
To determine the ED50 of the 2RT laser, the percentage of clinically visible 
laser spots were tabulated and a probit curve was plotted to determine in vitro 
ED 50 of the 2RT laser in terms of visibility threshold.  
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2.3 Results 
2.3.1 Physical Modelling of Energy Distribution of 2RT Laser 
2.3.1.1 Assessment of laser beam profile 
The laser beam profile was assessed at 0.5mJ. The center of the laser beam 
was noticeably homogenous with increasing scatter towards the periphery. The 
plotted profile of the laser beam shows a Gaussian-type laser beam with noise. 
 
Figure 2.4 Analysis of laser beam profile at 0.5mJ 
  
                 
2.3.1.2 Results from Neutral Density Filter analysis of 2RT laser 
beam 
The images below show the laser uptake on ND 0.6 gelatin filter. NDF 
microscopic images (figure 2.5) allowed the visualization of damage and 
showed correlation with beam energy distribution.  
It was noted that the size of laser lesion was approximately the same through 
the differential energy levels. 
At high energy levels, from 0.35 to 0.60mJ, the laser beam appeared to have a 
homogenous center. From 0.35mJ to 0.10mJ, there seemed to be an 
increasingly ‘speckled’ appearance. (Figure 2.5) However, the spatial distance 
between each speckle, even at the lowest energy (0.1mJ) was insufficient for 
differential damage to the RPE cells. (Figure 2.6) 
 
Figure 2.4 shows the imaged laser beam and the beam profile at 0.5mJ. Note that 
the center of laser beam appears homogenous and the beam profile analyzed 
appears Gaussian-type with noise. 
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Figure 2.5 Impact of varying 2RT laser energy on gelatin Neutral Density 
Filter 
 
 
Figure 2.6 Enlarged image to demonstrate speckle profile of laser beam 
on NDF at 0.1mJ. 
 
                                       
 
 
 
 
 
 
 
 
 
 
  
Figure 2.5 shows the NDF microscopy of laser beam in differential energy 
levels. At lower energies, there appeared to be increasing ‘speckle’ on NDF 
uptake.  
Figure 2.6 is an enlarged image of laser uptake on NDF at 0.1mJ. Note that 
although there was ‘speckle’, the difference in distance between individual 
‘speckle’ was insufficient for differential damage on RPE.  
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2.3.1.3 Laser beam analysis after passing through a NDF 
Laser beam was profile was analyzed after passing through a homogenous 
absorber (NDF 0.3). A range of laser beam energies between 0.3mJ to 2.0mJ 
was analyzed. Image obtained from NDF was compared with image obtained 
from laser beam profile. Plot profiles for different energies were plotted using 
image J(NIH). Plots have been done for every 0.1mJ unit of energy, but only 
several of the samples analyzed are illustrated below.  
3 main zones of laser lesion, shown by the colours red, green, blue were 
distinctly noted. This could respond to highest area of damage, followed by less 
lethal damage and sub-lethal damage. Shades of yellow and light blue, may 
represent ‘transition zones.’ Red is seen increasingly on the high energy, 
starting from 0.6mJ (ND 0.3, equivalent to 0.3mJ) in increasing size with smaller 
areas of green and blue.  
At lower energies, between 0.3mJ to 0.6mJ (after correction for ND 0.3, is 
equivalent to 0.1mJ and 0.3mJ), corresponding plot profiles of the laser beam 
show an almost ‘top-hat’ curve with multiple peaks or ‘noise’. This simulates a 
‘speckled’ beam profile, but the inter-peak distance in the plots were too close 
(<40µm). This finding concurred with the previous NDF findings that the spatial 
differentiation of the current last beam was insufficient for differential damage 
on RPE cells. 
At higher energies, 0.7mJ to 2.0mJ (after correction for ND 0.3 is equivalent to 
0.35mJ to 1.0mJ), curves simulating Gaussian-type distribution were noted. 
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Figure 2.7 Laser beam analysis 
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2.3.2 Results from Biological Assessment of 2RT Energy Beam 
Distribution 
2.3.2.1 Diameter of laser damage with varying energy levels on 
porcine flat mount histology 
In this flat mount histology, mean diameter of laser damage across varying 
energy levels of the 2RT laser were determined. Laser damage was noted to be 
smaller than the incident laser beam dimension of 400µm across the range of 
energy levels studied (0.10 to 0.40mJ). At 0.40mJ, the mean diameter of laser 
damage is 269.78 (+/-7.59) µm. 
The mean of diameter of 2RT laser damage increases with increasing energy, 
with a range of applied laser energy between 0.10mJ to 0.40mJ. The change in 
diameter becomes narrower with the lower energy levels. Between 0.1 to 
0.2mJ, the change in diameter of laser damage was found to be < 25µm, which 
is less than the lateral dimension of a single RPE cell. 
In this analysis, it was noted that the diameter of damage could not be 
accurately measured for laser damage<0.15mJ as the edge of laser damage is 
poorly demarcated due to the sub-threshold nature of the laser lesion.  
Valon laser applied at 5.57mJ/cm^2 and 100µm spot size had a mean diameter 
approximately equal to size of laser beam (99.70µm). 
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Table 2.1 Energy levels versus mean diameter of RPE damage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Energy level N Mean Largest 
diameter/ µm 
0.40mJ 4 269.78 (+/-7.59) 
0.35mJ 4 243.18 (+/-19.31) 
0.3mJ 4 215.4 (+/-3.30) 
0.25mJ 3 220.33 (+/-5.51) 
0.2mJ 3 197.33 (+/-5.03) 
0.15mJ 4 181.25 (+/-11.09) 
0.1mJ 6 173.30 (+/-7.76) 
Valon (100µm) 3 99.70 (+/-1.13) 
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2.3.2.2 Morphology of RPE Damage from the 2RT laser  
The morphology of acute RPE damage on flat mount histology corresponded to 
images obtained from NDF microscopy with the respective energy levels. 
At 0.4mJ, NDF shows a laser beam with a relatively homogenous center. 
Histology on porcine flat mount shows a discrete laser burn with loss of 
individual RPE cell structure. This was surrounded by a ring of highly pigmented 
RPE cells separated by a ring of empty space between adjacent cells. The 
morphology of the laser burn is similar to that seen in Gaussian-type lasers. 
(Marshall, 1970) 
With decrease in laser energy, several changes were noted. First, there was 
obvious decrease in laser burn size. Also, there was increase in pigmented cells 
in the laser burn and a smaller proportion of completely damaged RPE cells, 
with loss of cell structure and pigmentation. At the lowest energies (0.15mJ and 
0.1mJ), the edge of laser damage could not be definitely demarcated. There 
seems to be clusters of sublethal cell death admist completely destroyed RPE 
cells on flat mounts without staining.  
On calcein AM staining, there seemed to be complete cell death at 0.3mJ. It 
was noted that there were bright green areas in the lasered areas (Figure 2.8), 
however, these were likely artefacts as these discrete areas were smaller than 
an individual RPE cell. At 0.1mJ, there were small clusters of surviving cells, 
although the small clusters on calcein AM did not match completely with the flat 
mount. This suggests that most of the cells, although retaining pigmentation and 
cell structure perhaps have sublethal damage, which was not visible under light 
microscopy. 
Comparatively, the millisecond laser showed an almost completely blown out 
laser damage, leaving a ring of pigmentation. This indicated complete cell 
death. Size of laser damage was found to be approximately the same as laser 
spot size. 
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Figure 2.8 Morphology of RPE damage in terms of energy range 
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Valon laser 
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Pictures in Figure 2.8 above illustrate laser impact on both neutral density filter and 
porcine RPE in varying energy levels. All except 0.15mJ has accompanying neutral 
density filter image. Note the increase in intensity of laser damage with increasing 
laser energy and the increase in diameter of laser damage. 
In the calcein-am (live-dead cell assay) pictures, note that in 0.3mJ, there was 
complete cell death (bright green areas were likely artefacts); and in 0.1mJ, there 
appeared to be nonconfluent areas of laser RPE cell damage. 
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Table 2.2 Table describing laser damage morphology on RPE flat mount 
Energy Description 
0.4mJ Discrete laser burn with loss of individual RPE cell structure. This 
was surrounded by a ring of highly pigmented RPE cells 
separated by a ring of empty space between adjacent cells. 
0.3mJ A smaller laser burn was noted. 
There were few pigmented RPE cells in the laser burn which may 
signify surviving cells.  A similar ring of highly pigmented RPE 
cells noted along edge of laser burn. 
0.25mJ Morphology of laser damage similar to 0.3mJ, but with more 
pigmented RPE cell in the laser burn. 
0.2mJ Smaller laser burn. Damaged RPE cells with possible sublethally 
damaged cells seen as pigmented RPE, with intact hexagonal 
shape. There was a ring of laser damage, but not surrounded by 
empty cell space between adjacent cells at edge. 
0.15mJ Demarcation of laser damage less obvious. Majority of cells retain 
hexagonal shape and pigmentation with clusters of RPE cell 
death. Could signify a mixture of sublethal cell death admist 
complete cell death. 
0.1mJ Similar change to 0.15mJ 
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2.3.2.3 Probit analysis of laser damage 
Probit analysis was undertaken to determine the ophthalmoscopically visible 
laser lesion in varying energy levels in porcine ex vivo RPE-BrM explant culture.   
The 50% cell death based on threshold visibility probit curve was 0.22mJ in this 
experimental subset for the 2RT laser.	  
 
Figure 2.9 Probit curve of exvivo porcine energy levels vs 
ophthalmoscopically visible threshold 
 
 
 
        
Figure 2.9 shows a probit plot of laser visibility versus laser energy. ED 50 for this set of in 
vitro experiment on porcine eyes was 0.22mJ for ophthalmoscopically visible lesions. 
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2.4 Discussion 
In this chapter, the profile of the laser beam of the 2RT laser was analyzed 
using both physical and biological models. The unique design of the 2RT laser 
aimed to prevent both primary and secondary damage by using a nanosecond 
laser time domain and a discontinuous laser beam that was designed to 
preserve RPE cells within an area of laser irradiation. 
Results from physical modeling of the laser beam demonstrated increasing 
Gaussian-like beam profile with higher energy ranges. At energies less than 
0.35mJ, there appears to be ‘speckling’ of the laser beam profile which 
appeared ‘Top Hat’ in nature, although the degree of ‘speckling’ was considered 
to be inadequate in terms of differential RPE damage. (Figure 2.10) 
 
Figure 2.10 RPE damage from low energy 2RT laser 
 
 
The current analysis from the porcine RPE flat mount demonstrated acute 
impact of the 2RT laser, which concurred with findings from the physical 
modeling. At high laser energies (eg, 0.4mJ), morphology of laser damage 
showed an almost complete center area of cell death with a periphery row of 
pigmentation. This was similar to laser burns induced by Gaussian-type beam 
lasers. With decreasing laser energies, the acute impact of the laser  
Figure 2.10 demonstrates the possible morphology of RPE damage post 2RT 
laser at 0.15mJ. The laser energy ‘cut off’ was set at an insufficiently low level, 
hence, causing multiple peaks, which were insufficiently separated to cause 
differential RPE injury.  
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demonstrated increasing proportion of RPE cell preservation. However, it must 
be noted that this damage was analyzed at an acute stage and cannot be used 
to define subsequent changes with time. Hence, it is unknown if these cells 
were subject to sublethal damage even though they have maintained their cell 
structure.  
Results from the live/dead cell assay (calcein AM) further supported the above 
results, which show incomplete cell death at low energy levels within irradiated 
area. Although cell death was incomplete, there appears to be larger 
proportions of RPE cell death than preservation within the irradiated area which 
will almost definitely result in secondary laser damage. There is a need to 
investigate the 24 and 48 hours damage profile of the laser both invitro and in 
vivo. This is especially so in view of the current findings. It is crucial to 
determine if the structurally intact cells at low energy on flat mount histology will 
undergo full death in 24 hours.  
Although Wood et al have found similar results in their physical experimental 
model, they have mistakenly assumed this to be appearance of speckled 
distribution of the 2RT laser beam when in fact, their own illustrations 
demonstrate clumping in the center, akin to a gaussian-like laser 
damage.(Wood et al., 2011) Hence, although similar, the current findings were 
attributed to a different conclusion 
It was noteworthy that in contrast to the millisecond Valon laser (Valon), the 
laser damage of the 2RT was smaller than the laser beam diameter of 400µm, 
even at threshold and suprathreshold laser energies. There was decrease in 
size of laser damage with decreasing energy down from 0.40mJ to 0.15mJ. 
Between 0.10 to 0.20mJ, the difference in diameter of laser damage was found 
to be smaller than the lateral dimension of a single RPE cell. Hence, it can be 
argued that within this energy, the effective circumference available for RPE 
migration for a single laser lesion will be approximately the same.  
In this experimental subset, it was found that the ED50 for the 2RT laser on 
porcine RPE was 0.22mJ.  The porcine RPE is a highly pigmented pigmented 
as compared to human subjects. Furthermore, the experiment was performed 
after the removal of other energy absorbing structures such as lens, vitreous 
etc. It is a well-accepted theory that the extent of retinal laser damage is 
proportionate to degree of retinal pigmentation. (Marshall, Doctor of philosophy 
thesis) In human, especially in the Caucasian population, the clinical visible 
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laser lesion could be higher than 0.22mJ. At this level, the approximate 
diameter of laser damage was 200µm. Given that the current results show that 
the ‘speckling’ of the laser beam is inadequate, the large diameter of laser 
damage would imply that secondary laser damage would be unlikely prevented. 
The question then would be the appropriate level of energy for use. Professor 
Guymer and the team in Australia, Melbourne had taken an arbitrary value of 
70% of the threshold energy level. Threshold in this case would refer to barely 
visible lesions in human subjects. Calculations based on the ED50 plot obtained 
in the current in vitro study would obtain a laser energy value of 0.15mJ.  
There have been suggestions on the use of visible effect threshold(VET) , the 
setting at which the laser operator first observe an actual effect. This is based 
on the fact that bubbles were observed at laser treated sites in micro and 
nanosecond laser energies and produced when intracellular microbubbles 
coalesce with production of shockwaves. At levels above VET, bubbles often 
disappeared immediately, while at higher fluence levels, bubbles only 
disappeared when next laser pulse was applied. VET allows useful titration of 
laser energy in the clinical setting for individual patients.(Framme et al., 2002, 
Framme et al., 2004) 
Hence, results from different modalities to investigate the topography of the 2RT 
laser beam did not find an adequately discontinuous or ‘speckled’ beam profile. 
An element of Gaussian-type beam with noise was found with increasing laser 
energy. This suggests that the laser in the current prototype may induce 
secondary laser damage. 
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2.5 Conclusions 
Combing the analysis of the physical modeling of the laser beam and the 
biological impact on RPE damage morphology, it may be concluded that the 
‘speckled’ theory in the 2RT laser is held at low energy levels, however, the 
distance between the speckle is too close for differential RPE injury as 
intended. Also, increasing laser energy will deviate from ‘Top Hat’ to Guassian 
like beams, which will increase noise and become incoherent because of the far 
greater gradient from center to periphery in the beam. 
Although the laser beam configuration did not behave as expected, there is still 
a need to establish if this current laser in the nanosecond time domain cause 
any release of MMP by RPE cells and if so, the impact of RPE injury volume on 
MMP release. 
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Chapter 3. The Release of Matrix Metalloproteinases (MMPs) 
from Porcine and human RPE-BrM explant cultures. 
3.1.1 Introduction 
Even though there were inadequacies to the laser beam, it is still important to 
evaluate the short pulse (nanosecond) impact on MMP release. Previous work 
has demonstrated the presence of MMPs in BrM and the expression of 
ProMMP2 and 9 in RPE cell culture(Guo et al., 1999b, Alexander et al., 1991). 
Furthermore, experiments have demonstrated the sequestration of latent forms 
of MMPs 2 and 9 into high molecular weight species in the aged human BrM 
(Hussain et al., 2011).  
Guo et al previously noted the age and topographical differences in the level of 
latent gelatinases in BrM-choroid explants and the scarcity of active forms in the 
macular as compared to the periphery. The group have suggested a possible 
correlation between the reduced level of active MMPs and the age-related 
thickening, increased presence of denatured collagen, and deposition of debris 
within BrM, changes that may contribute to the pathophysiology of AMD(Guo et 
al., 1999b). The recent finding of decreased levels of active MMPs 2&9 in 
Bruch’s from donors supports this hypothesis with AMD compared to age-
matched controls (Hussain et al., 2011). More recently, the same group 
demonstrated that percentage of bound elements increase such an extent that 
the MMPs are not cleaning the BrM. 
Preliminary data from porcine and human studies have demonstrated the 
release of MMPs post laser. Ahir et al have also shown that RPE cell migration 
alters the quantity and ratio of pro/active MMPs released(Ahir et al., 2002). 
In this thesis, it is essential to predetermine the baseline characteristics of the 
types of MMP release in time and direction (apical vs. basal) in both porcine 
and human RPE-Bruch’s membrane explant culture so as to allow accurate 
interpretation of data (following experimental laser manipulation) in subsequent 
chapters.  The main objective of this chapter was to quantify the changes in 
MMP release and/or activation with time with both porcine and human species 
and to determine if there might be species related differences.  
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3.1.2 Principles of Gelatin Zymography 
 
Zymography is an electrophoretic technique adapted from sodium dodecyl 
sulfate (SDS) polyacrylamide gel electrophoresis (SDS-PAGE) containing a 
substrate, in this case, gelatin, copolymerized in the polyacrylamide, for the 
detection of gelatinolytic activity in samples.  This is a sensitive method to 
detect gelatinases (MMP2 and 9) and both the pro and active forms. 
After electrophoresis, SDS is soaked out from the zymography gel by incubation 
in a nonbuffered detergent such as Triton X-100 and renatured in an calcium 
containing activation buffer for a specific length of time and temperature which 
is dependent upon the enzyme assayed. The partially renatured enzyme then 
digest the gelatin, leaving a distinguishable zone of digestion that is noted after 
staining the gel with commassie blue.   
The presence of SDS causes denaturation of the enzymes, exposing their 
active domain which allows both pro and active forms of the enzyme to exhibit 
activity after partial renaturation. Since the enzyme migrate according to their 
molecular weight, with the pro form migrating less than active form, both pro 
and active forms of the enzyme can be detected at the zymogram.  (Murphy 
and Crabbe, 1995, Toth et al., 2012) 
 
 	    
	   116	  
3.2 Methods and materials 
3.2.1 Porcine RPE-BrM-Choroid Explant culture 	  
Fresh porcine eyes were obtained from a local abattoir and experiments were 
started within 12 hours of death.  Whole globes were first briefly rinsed in 
antiseptic solution before dissection.  An incision was made circumferentially at 
the pars plana to remove the anterior segment and vitreous.  The retina was 
gently peeled away thereafter. The remaining posterior pole was cut into 
quadrants and following transfer to phosphate buffered saline, the RPE-BM-
choroid layer was gently separated from the sclera using gentle manipulation 
with forceps and a cutting blade.   A suitably intact RPE-choroid preparation 
was then mounted between the 2 halves of the modified ussing chamber, with 
exposed tissue diameter of 6mm.  The ussing chamber was clamped with 
screws and both chambers were filled with tissue culture medium. (Figure 3.1) 
The culture medium used consisted of a mixture of Dulbecco’s modified Eagle’s 
medium (with glucose 4.5g/l) (DMEM; sigma) and supplemented with 
penicllin/streptomycin(1%), L-glutamine, sodium pyruvate(110mg/ml), taurine 
(100uM), calcium (2mM), and fetal calf serum (FCS 10%). Culture medium was 
replaced every day and medium that was removed was stored at -40 degrees 
Celsius until analysis for zymography. 
A total of 4 explants were examined.  
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3.2.2 Human RPE-BrM-Choroid Explant culture 	  
Human donor eyes age range, 56–89 years, and postmortem time of 24–48 
hours were obtained from the Moorfields Lion Eye Bank. The corneas had been 
removed at the Eye Bank for use in transplantation surgery, and the remaining 
globes were transported to the laboratory on saline moistened pads in an 
icebox. The donor eyes were managed according to the guidelines in the 
Declaration of Helsinki for research involving human tissue. After a preliminary 
fundus examination with a dissecting microscope to ensure that the eyes were 
free of disease and gross handling artifacts, a circumferential incision was made 
5 mm posterior to the scleral sulcus, and the remaining anterior segment, lens, 
and vitreous were discarded. The macular region was located and an 8-mm full 
thickness trephined section was removed and transferred to PBS. The neural 
retina was easily detached and discarded, exposing the monolayer of RPE 
cells. The tissue was examined under high power microscope to ensure 
coverage of the RPE layer. Tissue without intact RPE layer was discarded. 
Finally, under low-power magnification, the RPE Bruch’s– choroid complex was 
carefully removed from the underlying sclera by blunt dissection. This technique 
has been shown to preserve the structural integrity of the explant (Moore et al., 
1995a). The explant tissue was then clamped in the modified using chamber as 
described above. 
The culture medium used a mixture of Dulbecco’s modified Eagle’s medium 
(with glucose 4.5g/l) and F12-Ham (DMEM-F12; sigma) and supplemented with 
penicllin/streptomycin(1%), L-glutamine, calcium (2mM), and fetal calf serum 
(FCS 10%).  
 
A total of 5 explants were examined. 
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Figure 3.1 Modified Ussing chamber 	  	  
 
 
Figure 3.2a Dissection of Porcine Eyes          Figure 3.2b Ussing chamber   
                                                                              with  explant    
  
                      
Porcine eye dissected                                                                                               Ussing chamber with explant 
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3.2.3 Gelatin Zymography 
Sodium dodecyl sulfate (SDS) gel electrophoresis was performed (X Cell 
SureLock Mini-Cell System; Invitrogen, Paisley, UK). The 10% zymogram gels 
(1-mm thick) contained a 4% stacking layer and 0.1% gelatin in the separating 
layer (Novex Gels; Invitrogen). 
Aliquots of the eluant were diluted (1:2 vol/vol) in Laemmli nonreducing sample 
buffer (2.5% SDS, 4% sucrose, 0.25 M Tris-HCl, and0.1% bromophenol blue). 
Tissue samples were placed in 20 µL PBS and 40 µL nonreducing buffer and 
vortexed for 5 minutes. Twenty microliters of the mixture was loaded onto the 
gel. Prestained protein molecular weight standards of pro MMP2 and 
9(Invitrogen) and 10% fetal calf serum (FCS;Sigma-Aldrich) were also run on 
each zymogram.  After electrophoresis (150 V, 1 hour), the gels were removed, 
rinsed in distilled water, and incubated for two half-hour periods in 2.5% Triton 
X-100, to remove SDS and renature the proteins. They were then transferred to 
reaction buffer (50 mM Tris-HCl, 10 mM CaCl2, 75 mM NaCl, and 0.02% NaN3 
[pH 7.4]) and incubated at 37°C for 20 hours to allow proteolytic digestion of 
gelatin. The gels were rinsed again in distilled water and stained (SimplyBlue 
SafeStain; Invitrogen) containing Coomassie G-250 blue for a period of 3 hours. 
Destaining was performed with distilled water for 1.5 hours. MMP activity was 
observed as clear bands on a blue background. These gels were scanned at a 
resolution of 2400 dpi (3490 scanner; Epson, Nagano, Japan) and stored in 
JPEG format. The color images were uploaded into the software (Quantiscan, 
ver. 3.0; Biosoft, Cambridge, UK) in grayscale format, the colors were inverted 
so that the MMPs were visualized as dark bands against a whitish background, 
and the area under individual gelatinase bands was quantified. 
The band intensity values for each protein were corrected for background 
staining for each gel. Pixel analysis determined a graph of intensity and allowed 
the area under the curve to be calculated. By incorporating the standard in the 
gel together with the FCS sample and by normalizing staining intensity, MMP 
bands obtained from different experiments and different gels could be 
compared.	  	  
To determine the accuracy of the bands identified, an initial investigation was 
performed using porcine and human RPE-BrM choroid explant samples at day 
3 of incubation. Ratio of each of the clear bands against the length of the 
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zymogram were determined and compared against the known molecular weight 
samples from previous publications by Hussain et al. An example is shown in 
figure 3.3a. The ratio for pro MMP2 in this case is determined as A / B and 
compared with samples with known molecular weight standards (as provided by 
Hussain et al). This method was employed because of the large number of 
zymography performed in this series of experiments and whilst the using of 
molecular weight standards was ideal, it was not economically viable. 
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Figure 3.3a Example of method to determine gelatinase molecular weight 
                             
Figure 3.3b Comparison of porcine and human RPE-BrM choroid samples 
with molecular weight standards. 
                            
 
 
 	    
Figure 3.3a. Example of method to determine molecular weight of 
individual gelatinase. Figure shows a gelatinase zymography. To 
determine the exact gelatinase species, a ratio was obtained by dividing 
the length of the clear bands against the length of zymogram. This is 
then compared against samples with known molecular weight standards. 
 
Figure 3.3b. Molecular weight standards and MMP profile of porcine and 
53 year old male in RPE-BrM choroid samples.  Hussain et al provided 
molecular weight and sample of 53 year male. 
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3.3 Results 
3.3.1 MMP release characteristics of porcine RPE-BrM explant 
culture as a function of time 	  
A zymogram to show the release of MMPs from the RPE-BrM explant into the 
apical compartment is shown in Fig 3.4. Both Pro-MMPs 2&9 were present as 
double bands representing isomers of the enzymes and for quantitative 
analyses, the areas under the doublet was combined. Both active-MMP9 and 
active-MMP2 were not present in the four explants examined (shown in Fig 3.4).  
A quantitative analysis of the time-dependent variation in the levels of the 
various MMP species in both the apical and basal compartments are shown in 
figure 3.5 The secretion of Pro-MMP9 was high at the start of explant incubation 
but declined rapidly to reach a steady low baseline in both apical and basal 
compartments. This decline was rapid in the basal compartment reaching a 
plateau by day 4 compared to day 6 in the apical compartment. ProMMP2 
levels showed a stable level throughout the days of incubation in both apical 
and basal ends. The levels of MMPs depicted in the graphs of figure 3.5 
represent the amount per unit volume of medium retrieved from each 
compartment and show that these levels in the apical compartment were 
roughly equal in both compartments. 
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Figure 3.4 Zymogram of Porcine RPE-BrM choroid explants 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 shows a zymogram of baseline characteristics of apical MMP release by 
RPE-BrM explant culture over 9 days. This graph was converted to black and white 
to highlight the contrast between different bands. Note the presence of dual bands 
of Pro MMP9 and 2 which represent different isoforms of the MMP species. Note 
the decrease in intensity of ProMMP9 secretion over time.  
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Figure 3.5 Time course of MMP release in porcine RPE-BrM choroid 
explant culture 
 
ProMMP9 
  
 
Pro MMP2 
 
 
 
 
 
  
Figure 3.5 Time-course of release of MMPs from porcine RPE-BrM explants in 
culture. Only profiles for ProMMPs 2&9 are shown since there was no release 
of activated MMPs 2 & 9 in this experimental series. Level of Pro-MMP9 in 
both apical and basal compartments showed a decrease over time whilst Pro-
MMP2 showed a constant trend. Data is presented as Mean ± SEM with n=4. 
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3.3.2 MMP release characteristics of Human RPE-BrM explant 
culture as a function of time 	  
In the human RPE-BrM choroid explant culture, the explants were maintained 
for 7 days. Release of Pro-MMPs 2& 9 and Active-MMP2 were noted in both 
apical and basal compartments in this experimental series. There was no 
active-MMP9 secreted (Figure 3.7).  
Similar to porcine samples, there was a dual band representing pro MMP9, 
which suggests the presence of isoforms or different levels of glycosylation of 
the protein. The level of the higher molecular weight pro-MMP9 isoform was 
observed to decrease rapidly during the course of the explant culture (Figure 
3.6).  
A quantitative assessment of the time-dependent release of various MMP 
species obtained from five human explant cultures is depicted in Figure 3.7. 
Unlike the situation in porcine samples, the secretory levels of Pro-MMP9 
remained fairly stable up to about 4 days in culture followed by a slight 
decrease.  Levels of Pro MMP 2 remained constant throughout the incubation 
period in both apical and basal compartments.  
In the human RPE-BrM-choroid explant cultures, active-MMP2 was always 
present and remained relatively constant throughout the culture period.  
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Figure 3.6 Zymogram of Human RPE-BrM choroid explant culture 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
 
Figure 3.6 shows a zymogram of Human RPE-BrM choroid explant culture with an 
incubation period of 7 days. There is a noticeable dual band of Pro MMP9 representing 
different isoforms and a single band of ProMMP2. Active MMP2 was secreted in both apical 
and basal compartments.  
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Figure 3.7 MMP release profiles of Human RPE-BrM explant culture 
culture      
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Active-MMP2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 MMP release profiles from Human RPE explants over a culture period of 7 
days.  Levels of pro-MMP9 remained stable over the first four days of culture followed 
by a slow decline. Pro MMP 2 secretion was constant throughout the incubation 
period in both compartments. The release of active-MMP2 remained stable 
throughout the culture period. Data is shown as mean ± SEM with n=5.  
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3.3.3 Histology of Porcine and Human RPE-Bruch’s membrane 
choroid Complex Subsequent to Incubation in Culture Medium 
Histological assessment was undertaken to determine the integrity of the RPE 
monolayer following the incubation periods for human (7 days) and porcine (10 
days) samples. Although much care was taken in dissecting out an intact RPE 
preparation, the subsequent mounting of the specimen into the Ussing 
chamber, edge damage during the clamping process, and the daily replacement 
of culture medium all pose increasing risk of RPE cell detachment and loss. The 
post-mortem delays with human tissue also increase the risk of RPE loss. The 
rapid loss of Pro-MMP9 during the early incubation phase in porcine tissue and 
the slower loss in human RPE cultures could theoretically reflect loss of RPE 
cells from the explant. However, the stability of pro-MMP2 levels argues against 
such a loss in the experimental set-up. The histology of the preparations (Figure 
3.8) shows the clear presence and integrity of the RPE monolayer following the 
long incubation periods such that the time-courses obtained for the various 
MMPs must reflect secretory changes by the RPE rather than loss of cells into 
the medium. 
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Figure 3.8 Histology of porcine vs human RPE-BrM explants 
	  
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 3.8a shows the histology of a porcine RPE-BrM-choroid explant at day 10 post 
incubation. There is a continuous layer of RPE.  
Figure 3.8b shows the human RPE-BrM-choroid explant at day 7 of incubation, donor aged 
72. Note that the RPE layer is beginning to lift away from the BrM. Thickened BrM was noted 
in this sample. 
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3.4 Discussion 
Previous work has demonstrated the release of latent MMP species in human 
RPE culture and the presence of equilibrium between bound and free forms of 
MMPs in BrM.(Hussain et al., 2011, Ahir et al., 2002, Kumar et al., 2010) 
However, little is known about the time, species-dependency, and vectorial 
release of MMPs under conditions of explant culture. The understanding of 
baseline characteristics in the release of MMPs in a given species is essential 
to help interpret and understand the results of subsequent experimental 
manipulation. Another reason for undertaking baseline studies is to determine 
the period of stabilization. In the case of porcine tissue for example, levels of 
Pro-MMP9 secretion fell rapidly after initiation of the culture stabilizing within 3-4 
days. Human explants on the other hand showed stable Pro-MMP9 levels from 
day 1. These differences may be intrinsic to the species or may be a result of 
age and post-mortem deterioration of the sample.   
In general, porcine eyes were removed from young pigs with minimal post-
mortem times and this may have resulted in a more robust response in the 
stabilization of Pro-MMP9 levels.  Porcine samples may also serve as ‘young’ 
RPE against the aged human controls utilized in the present study (age 53 to 89 
years). As mentioned earlier, with age, RPE undergoes a host of changes 
ranging from a decrease in melanin content, increase in residual bodies and/or 
increase in lipofuscin and melanolipofuscin to atrophy/hypertrophy in varying 
stages of AMD. Morphologically, the crucial alteration that affects transport 
processes directly is the age-dependent decrease in RPE number and size, 
hence decreasing available surface area for fluid, nutrient and waste 
exchange(Mishima et al., 1999, Hjelmeland et al., 1999, Hageman et al., 2001, 
Kinnunen et al., 2012, MJ, 1971, Feeney-Burns et al., 1980, Feeney-Burns et 
al., 1984). Furthermore, some investigators have found a decrease in migratory 
or growth rate with older RPE passage in cell culture, a concept of senescent 
RPE. Hence, this might in theory result in either qualitative or functional 
differences in MMP release between porcine and human samples. 
Apart from the rapid and early decrease in Pro-MMP9 in porcine samples, there 
was little difference in the time-related changes in Pro-MMPs in comparison to 
human samples. The most important difference was the secretion of active-
MMP2 in human samples compared to porcine.  From this experimental series, 
there were minimal differences in characteristics of Pro MMP 2 and 9 release 
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between porcine and human. However, there was secretion of active-MMP 2 
which was absent in porcine eyes. Our results agree with Treumer et al, where 
porcine cultures were noted to secrete isoforms of both Pro MMP9 and 
2.(Treumer et al., 2012) However, human RPE-BrM explant culture only 
secreted isoforms of pro MMP9. It was noted that the isoforms did not appear in 
BrM-choroid culture. It is possible that since the high MW Pro-MMP9 isoform 
was in low concentration, it might have been lost in the BrM preparation or it 
may have been below the detection limit. Whereas in the RPE-BrM preparation, 
it would have been continuously synthesized.  
The current results show the bi-directional release of ProMMPs 2&9 for both 
species and active-MMP2 for human explant culture. It is essential to determine 
secretion on the basal end as the BrM is the ultimate target for MMP release to 
facilitate regulation of the extracellular matrix. 
In this sample, only macular RPE-BrM explant samples were used in both 
porcine and human samples.  This is because prior studies have shown 
differences in RPE characteristics as well as MMP profile in macular and 
peripheral regions. Hence, using only macular samples allowed comparison 
between the 2 species.  
Guo et al has shown from immunochemistry the presence of MMP 1, 3, 2 and 9 
in BrM and a higher level of active-MMP 2 and 9 in periphery but not macular 
region of BrM.(Kumar et al., 2010, Guo et al., 1999b) In this study, active-MMP2 
was found to be secreted by RPE in the macular region in the human species. 
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3.5 Conclusions 
In conclusion, from the current control dataset, porcine and human RPE-
Bruch’s-choroid MMP profile has been compared over a time period of minimum 
7 days. In essence, this current dataset shows that there is an equal 
bidirectional secretion of MMPs over a time series for both porcine and human 
species. Secretion profiles of pro MMP 2 and 9 were found to be similar for both 
porcine and human species, but human species have a low level of active-MMP 
2 release in both directions. No active-MMP9 was noted in either species.  
Hence, the results of this chapter would form the basis of which further laser 
intervention to RPE/retina in subsequent chapters may be accurately 
interpreted. 
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Chapter 4. Effect of Nanosecond Laser on the Release of 
Metalloproteinases from Porcine RPE-Bruch’s choroid Explants 
4.1 Introduction 
Having established the boundary conditions of release of MMPs as a function of 
time in the organ culture conditions, it was then possible to evaluate the release 
of MMPs induced by laser in different exposures (ie, difference in laser number 
spots).  
It is widely accepted that structural and molecular changes of BrM contribute to 
the ageing of the human eye. (Kumar et al., 2010, Hillenkamp et al., 2004, 
Moore et al., 1995a, Ramrattan et al., 1994b) This structural modulation 
compromises the transportation pathway for nutrient supply and metabolic 
waste removal between the photoreceptors and choroidal blood supply and may 
over time result in degeneration of the RPE layer as mentioned in the earlier 
chapter. The tightly regulated remodelling pathway for continuous turnover of 
the extracellular matrix (ECM) of Bruch’s is controlled by a family of extracellular 
enzymes, known as the matrix metalloproteinase (MMPs) coupled with their 
tissue inhibitors (TIMPs).  In particular, MMPs 1, 2, 3 and 9 and TIMPs 1, 2 and 
3 were shown to be secreted by the RPE and were found in BrM (Alexander et 
al., 1991). Ageing of Bruch’s was associated with increased polymerisation and 
sequestration of Pro MMPs 2 and 9 into high molecular weight species and this 
was suggested to decrease the availability of free Pro-MMPs the activation 
process.(Hussain et al., 2011, Kumar et al., 2010) 
Active MMPs are potent proteases and have been shown to increase the 
hydraulic conductivity of BrM, with active-MMP9 being more effective than 
active-MMP2.(Ahir et al., 2002) Thus, lowered activity of the MMP system (due 
to MMP polymerisation, inhibition by advanced glycation end-products (AGEs) 
and by other oxidised and cross-linked collagen species was thought to underlie 
the ageing process within BrM and therefore in theory, improving MMP activity 
was expected to lead to reversal.   
Previous studies demonstrated that laser irradiation of RPE explants in culture 
resulted in MMP release.(Zhang et al., 2012, Treumer et al., 2012)  However, 
the results of the experiments have been contradictory regarding the release of 
activated MMP species. Treumer et al only found active-MMP 2 release from 
the basal side of porcine RPE-BM and a complete absence of active-MMP9 
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using a 1.7µs Nd: YLF laser (SRT) with a 200µm spot size and at threshold 
laser energies (Treumer et al., 2012). On the other hand,  Zhang et al., 2012  
found both active-MMPs 2&9 released from both apical and basal sides of aged 
human explant cultures using the prototype retinal rejuvenation therapy (2RT) 
system, with 3ns pulse width, 400µm spot size and at laser energy of 
0.3mJ/lesion. 
In the previous chapter, the baseline release profiles for MMPs in both young 
porcine and aged human RPE-Bruch’s choroid explant cultures over time have 
been determined.  In porcine samples, there was no release of active MMPs.  
Human samples consistently showed the time dependent release of active-
MMP2 but absence of activated-MMP9.  The volume of RPE damage is 
important for the levels of MMP release for clearing up debris. In chapter 2, it 
was shown that at lower energy levels (ie, between 0.1 to 0.2mJ), there was 
minimal change in diameter of laser damage. Hence, it may be assumed that 
the available circumference for RPE migration would be minimal in this energy 
range, and the only way to have a resultant increase in MMP release would be 
to increase the number of laser spots. Although this novel laser with an ultra 
short pulse was found to have a disappointingly regular beam distribution, it was 
still appropriate to evaluate the following: 
1. The effect of laser on the RPE with regards to active MMP release; 
2. The impact of RPE volume injury on MMP release, ie, would the number of 
laser spots have an impact on MMP release? 
3. The direction of release of MMP from the RPE post laser; 
4. The time course of MMP activity post laser 
The experiment set up in this chapter was performed using in vitro porcine 
RPE-BrM-choroid explant culture because of the constraints of getting human 
tissue. 
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4.2 Methods and Materials  
4.2.1 Set up of explant culture 
The set up procedure for explant culture had been described in the Methods 
section of Chapter 3.  
A total of 4 control and 8 lasered samples were set up. 
 
4.2.2 Laser application 
Explant cultures were kept in an incubator at 37o C with 5% CO2 and medium 
changed every 24 hours.  Laser procedure was performed at 48 hours post 
initiation of culture.  This was to allow stabilisation and regrowth of any possible 
RPE injury in the periphery of the chamber from the clamping process. Prior to 
laser procedure, the medium was removed from the apical and basal side of the 
chamber and replaced with PBS solution to prevent laser absorption by the 
medium and the aperture was covered with a clear film to prevent spillage.  For 
the laser procedure, the chamber was positioned vertically in a holding 
apparatus on the chin rest of the laser assembly. Probit data from an 
experiment noting visible lesion from varying laser energy, the ED50 visibility 
threshold of the laser was determined to be 0.22mJ for porcine eyes and the 
diameter of laser damage between 0.1 to 0.2mJ had shown minimal change 
(Chapter 2 of thesis).  Thus in this study energy levels between 0.1 to 0.15mJ 
was used. The laser lesions were delivered 1 spot size apart in a circumferential 
pattern. Number of laser spots applied ranged was 25 or 50 shots. To prevent 
lasering the same area twice, the following laser pattern was applied (Figure 
4.1). The entire procedure took approximately 3 minutes. Post laser, the PBS 
was replaced with culture medium and the Ussing chamber assembly returned 
to the incubator. 
In total, 8 explants were lasered. There were 4 explants with 25 laser shots, and 
4 explants with 50 laser shots. 	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Figure 4.1 Pattern of laser spot application in porcine explants  	   	  
 
 
 
4.2.3 Collection of samples 
Medium samples were collected from both apical and basal half-compartments 
every 24 hours and stored at -20oC until analysis of MMPs by zymography. 
 
4.2.4 Determination of MMPs (Gelatin zymography) 
The analytical procedure for gelatin zymography has been described in the 
methods and materials section of Chapter 3.  
4.2.5 Analysis of gelatin zymography 
Please refer to chapter 3. 
Statistics 
Statistical analysis was undertaken using SPSS version 19.0. The Mann 
Whitney U test was used to compare densitometric levels (y-axis) of Pro MMP2 
and 9, Active-MMP 2 and 9 from days 3 to 9 (x-axis), at each day of incubation, 
between 25 versus 50 laser spots. The reasoning for choosing this statistical 
methodology was because of these were independent random samples and the 
Mann Whiney U test is a nonparametric test which can also be used as a chi-
Figure 4.1 is a diagrammatic representation of approximate pattern of laser spot 
pattern application in this experiment. 
6mm#
Laser spots 
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square test in determining trends. Apical and Basal samples were analyzed 
separately. P<0.05 was considered statistically significant. 
4.2.6 Histology 
For light microscopy, the RPE-choroid preparations were fixed in 4% 
Gutaraldehyde, dehydrated in a graded series of ethanol and embedded in 
paraffin. Three um sections were stained with haematoxylin-eosin and 
examined under light microscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   139	  
4.3 Results 
4.3.1 Type of MMP release post laser as a Function of Time 
In this experimental series, the release and the time-course of release of the 
various MMP species from control explants was very similar to that obtained for 
baseline levels in the study of Chapter 3. Levels of Pro-MMP9 released were 
high at the start of the culture and then showed a steady decline. Released 
levels of Pro-MMP2 remained fairly steady throughout the culture period. There 
was no active MMP 2 or 9 released. 
Irradiation of RPE-BrM explants with the 2RT laser showed marked differences 
even on zymographic qualitative analysis as compared to controls(Figure 4.2). 
In the apical compartment of the Ussing chamber, the emerging presence of 
active-MMP2 was obvious at D4 (day 2 post laser, D2PL) with much increased 
levels being maintained over the next four days. The presence of active-MMP2 
in the basal compartment was obvious at D6 (D4PL) with increased levels being 
maintained over the next four days examined. The delay in the appearance of 
active-MMP2 in the basal compartment may be due to the presence of the large 
choroidal mass in such tissue preparations. However, active-MMP9 was not 
observed in any of the lasered explants.  
A quantitative assessment of the release of MMP species following laser 
irradiation is depicted in Fig 4.4 In both control and lasered samples, levels of 
Pro-MMP9 were relatively high at the start of the culture period followed by a 
decline to reach a lower plateau. However, in the lasered samples, Pro-MMP9 
levels were much higher for most of the culture period. 
Unlike control explants where Pro-MMP2 levels remained steady throughout the 
culture period, lasered explants showed a progressive increase peaking around 
D5 (D3PL) in the apical compartment and D6 (D4PL) in the basal compartment 
(p<0.05). A subsequent decline in the apical compartment allowed baseline 
levels to be reached by D9 (D7PL) but despite the declining phase, levels in the 
basal compartment remained elevated even at D9 (D7PL).  
Lasered samples had release of active-MMP2. Lasered samples have release 
of active-MMP2 in both apical and basal compartments with levels peaking 
around days 7 (D5PL) and 6.5 (D4.5PL) for apical and basal compartments 
respectively. A declining phase was then observed with active-MMP2 reaching 
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baseline by D9 (D7PL) in the apical compartment. Baseline levels were not 
reached in the basal compartment by the end of the experimental period.  
A subanalysis comparing 25 and 50 laser shots and controls is shown in Figure 
4.5. The difference between levels of ProMMP9 release is equivocal in both 
apical and basal ends.  There is higher levels of release of ProMMP 2 in 
samples with 50 laser shots both apically and basally, although it was noted that 
the MMP release prior to laser (ie, at days 1 and 2) were noted to be of a lower 
baseline in samples with 25 laser shots. For active-MMP2, there was no 
difference between number of laser shots in the apical end, although there was 
twice the levels of active-MMP2 release noted in the group with 50 laser shots 
on the basal end. Figure 4.6 shows the enlarged figure with a smaller scale to 
demonstrate the changes. Figure 4.7 shows the total quantity of active-MMP2 
released in the basal end in 4 samples of 25 spots and 50 spots (ie, 100 and 
200 laser lesions in total respectively) at day 7 of incubation. There were 
approximately twice the levels of total active-MMP2 release for 200 laser 
lesions as compared to 100 laser lesions. 
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Figure 4.2 Zymogram of apical release of MMP in porcine explant culture 
post laser 	  
 
 
Figure 4.3 Zymography of basal release of MMP in porcine explant culture 
post laser  
	  
  
 
 
 
 
 
 
 	    
FCS           D1            D2         D3        D4          D5        D6        D7         D8         D9      D10 
24#hour#post#laser#
Apical 
ProMMP9#
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AMMP2#
Figure 4.2 and 4.3 shows the zymogram of apical and basal release of MMPs 
post laser respectively. Note the release of active-MMP2 in both apical and 
basal compartments. 
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Figure 4.4 MMP profiles of explant culture post laser 
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Figure 4.4 shows the release profile of ProMMP 9 and 2, Active-MMP2 both 
apically and basally of lasered samples(N=8) as compared to controls.(N=4) 
Laser was performed at Day 2.  
There is a similar decreasing trend noted for ProMMP9 in both apical and basal 
ends for both lasered and control samples although lasered samples have 
higher levels of MMP release. 
There is increase in release of ProMMP2 post laser . Apically, it was noted that 
there is a peak release at day 4 post, whilst basally, the release had a stable 
peak which remained between days 3 to 5 post laser. The levels of increased 
ProMMP 2 release remained elevated even by Day 9 of incubation (end of 
experiment). 
Post laser, there is increase in Active-MMP2 noted in lasered samples both 
apically and basally. The levels remain elevated by end of experiment (Day 
9/Day 7 post laser).  Apical sample had a peak release which was 
approximately twice that of basal release. This could be because of possible 
modulation in the interphotoreceptor matrix and time taken for diffusion through 
the choroid on the basal side. 
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Figure 4.5 MMP profiles of porcine explant culture post laser in varying 
number of laser shots 	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Active-MMP 2 
 	  
 
 
 
 
 
 
 	  	  	  	  
 
Figure 4.5 represent the MMP (Pro MMP 9, 2 and Active MMP 2) release profile of 
25 versus 50 laser shots (n=4, n=4) as compared to control samples (n=4). Active-
MMP9 was not plotted as it was not released in this experimental series. Graphs are 
plotted as lasered samples against controls (legend within graph) over a series of 9 
days in both directions. 
Means of graphs and the respective SEM was plotted (as above). Laser was applied 
at 48 hours and media was collected 24 hours post laser from D3.  
Pro MMP9 shows a decreasing trend for both lasered samples and control in both 
compartments. Lasered samples had higher levels of ProMMP 9 in both directions. 
There was higher release of Pro MMP 2 from lasered samples with 50 laser spots as 
compared to 25 laser spots in both directions. 
Comparing active-MMP2 release, there was a higher release of active-MMP2 in the 
samples with 50 laser spots as compared to 25 laser spots in both apical and basal 
compartments. In the basal compartment, it was noted that there is approximately 
twice the level of active-MMP 2 levels with 50 laser spots as compared to 25 spots.  
Release of active-MMP2 started from D3 (D1 post laser) and remained elevated by 
end of experimental incubation period in both lasered samples.  	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Figure 4.6 Levels of active-MMP2 basal release with different number of 
laser spots. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Total quantity of active-MMP2 release at Day 7 of incubation 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
 
 
Figure 4.6 and 4.7 shows that higher number of laser lesions release higher levels of 
active-MMP2 on the basal end. 
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4.3.2 Description of Histology of Laser Lesion at End of Incubation 
Period 
Histological examination for the laser lesion was undertaken at day 10 of 
incubation. The laser lesion was identified by the loss of RPE cells. The current 
histology did not show a discrete pattern of RPE cell death. There was also no 
multi-layering of RPE cells as expected for this period of wound healing.   
There were areas of lifting of the RPE cells adjacent to the laser lesion, which 
may suggest either possible extension of laser injury to the periphery or poor 
RPE health at day 10 of incubation. Although the latter was less likely because 
of intact RPE layer in other areas not lasered. 
There were areas of decreased intensity of staining extending beyond the RPE, 
into the BrM and choroidal capillaries. This suggest possible extension into the 
outer retina. (Figure 4.8) 
 
Figure 4.8 Histology of laser lesion at day 10 of incubation/ day 8 post 
laser 
	  
 
 
  
 
 
Figure 4.8 shows histology of porcine RPE-BrM-choroid explant culture at day 10 post 
incubation.  The above histology was taken from a sample of 0.15mJ laser lesion. Note the 
crater created by the laser lesion with loss of RPE cells. Contrary to the postulated 
mechanisms of action of the 2RT laser, the current histology does not show a discrete 
pattern of RPE cell death.  There were areas of decreased intensity of staining extending 
beyond the RPE, into the BrM and choroidal capillaries. This suggest possible extension into 
the outer retina. 
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4.4 Discussion 
The results from this experimental series have several significant findings and 
implications. First, laser increased the levels of both pro MMP 9 and 2 as 
compared to laser under our organ culture conditions. Second, there was 
increase in active-MMP2 from day 3 of incubation (D1PL), which remained 
elevated beyond end of experimental incubation period. Third, this increase in 
MMP release was noted in both apical and basal compartments of the organ 
culture. More importantly, comparing the impact of varying number of laser 
spots on MMP release, the current results demonstrate that there was higher 
release of proMMP 2 and active-MMP2 in both apical and basal ends in 
samples with the higher number of laser spots. In the basal end, there was 
approximately twice the level of active-MMP2 release in 50 lasered spots as 
compared to 25 spots. 
In the current experiment, it was noted that there was lower quantity of active-
MMP2 release as compared to pro MMP2.This is because activation of MMP2 
happens in stepwise fashion from ProMMP2. The activation mechanism for pro-
MMP2 was previously found to be mediated by 2 molecules of transmembrane 
enzyme MMP-14, and TIMP2, on the basolateral surface of the RPE. The first 
MMP14 molecule will bind to TIMP2 and form a ternary complex with pro-
MMP2. A second MMP14 molecule then cleaves this complex to release active 
MMP2.(Alcazar et al., 2007, Strongin et al., 1995, Smine and Plantner, 1997, 
Butler et al., 1998)  
In this study, the levels of Pro MMP 9 show a decreasing trend and there was 
an absence of active-MMP9. This result replicated previous findings of increase 
active MMP 2 post laser in explant culture by Treumer et al.(Zhang et al., 2012, 
Treumer et al., 2012) The current result was in contrast with Zhang et al, where 
there was an increased Active-MMP 9 in aged human sample.(Zhang et al., 
2012) The differences in the results maybe attributed species differences of the 
experimental explant sample.  In our prior chapter, the difference in MMP profile 
between porcine and human explant culture had been demonstrated. In porcine 
explant culture controls, there was neither release of activated MMP2 nor 9, 
whilst in aged human samples, there was release of Active-MMP2. Some 
investigators have correlated the increase in pro MMP 9 with AMD in plasma 
samples.(Chau et al., 2007) This brings about the question of balance of risk of 
the activity of MMP 9, considering MMP9, being a powerful gelatinase, causes 
	   149	  
massive increases of hydraulic conductivity, especially in the elderly (as 
compared to Active-MMP2); however, in overloaded doses, may tip to cause a 
negative feedback response to increase anti VEGF from the RPE. That 
mentioned, one should bare in mind that human BrM contains active-MMP9 and 
together with active MMP2 is responsible for turning over the matrix of the 
membrane. Also the results of Ahir et al showed that aged Bruch’s contain 
abnormal constituents that are the substrates of active MMP9. Despite the 
presence of active MMP9, the control population does not show 
neovascularization.(Ahir et al., 2002) It is hence, the unregulated synthesis of 
active MMP9 that results in a problem. 
MMP activity was found to be increased in both apical and basal directions of 
the RPE. Deposits from ageing, have been found to lie external to the RPE 
basally (Basal linear deposits) and within the BrM (Basal laminar deposits), 
hence, the basal directional release of active-MMP2 would be necessary for 
‘cleaning’ up the debris to improve transport across the BrM. Having a 
basolateral release of MMP was not surprising as this was a known activity 
even amongst other epithelial cells. For example, in mammary epithelial cells 
and aortic endothelial cells, MMP secretion had been found to be mainly from 
the basolateral surfaces.(Unemori et al., 1990, Talhouk et al., 1991) That said, 
in this study, we have found MMP release in the apical surface. These results 
concur with Treumer et al and Zhang et al, using porcine and human RPE-BrM 
explant models respectively.  Some investigators have hypothesized the role of 
MMPs in the turnover rate of the interphotoreceptor matrix (IPM) which was 
required to maintain health of the photoreceptor cells.(Padgett et al., 1997, 
Plantner et al., 1998b) MMPs and TIMPs have been found in the IPM and were 
suggested to clear old IPM for the daily synthesis of new components as well as 
for digesting photoreceptor outer segment tips for preparation of phagocytosis 
by RPE. Hence, the apical release of MMP can be explained by 2 theories; first, 
during the process of removal of the retina from the RPE, the tightly attached 
photoreceptor cell outer segments with the accompanying inter photoreceptor 
matrix may remain and inherent MMP may diffuse out during the time course of 
the experiment. However, this may not explain the increase of active-MMP with 
time post laser. Besides, there was no active-MMP in our controls. Hence, this 
explanation is unlikely. The more likely theory could be that the RPE releases 
MMP bidirectionally physiologically for 1. extracellular matrix turnover in the 
	   150	  
interphotoreceptor matrix, 2. extracellular matrix turnover of the BrM. Thus, 
laser induced a bidirectional effect on the RPE migratory release of active-MMP 
which had a direct impact on rejuvenating health of the photoreceptor cells and 
an indirect impact through clearing of the BrM for increased transportation. It 
was also noted that basal chamber had quantitatively lower levels of release 
than the apical chamber. This could be explained by the slower diffusion of 
MMPs through the choroidal layer. 
In this study, higher number of laser spots was shown to secrete higher levels 
of activated MMP2 in both directions, and this was more clearly defined in the 
basal compartment.  The levels of active-MMP2 release was approximately 
twice for samples with 50 laser spots as compared to 25 laser spots. It is 
important to note this change as it is the basal end MMP activity that is critical to 
effect on the BrM which lies on the basal end of RPE cells. In this experiment, it 
was assumed that there was neglible effects from the energy differences in the 
range between 0.10 to 0.15mJ based on the previous finding of equivocal 
diameter of laser damage. Hence, the current profile of MMP release can be 
wholly attributed to the differences between laser spots. As mentioned earlier, 
the level of MMP release was highly dependent upon the volume of RPE injury 
and this may be achieved by either laser energy or number of laser spots. Thus, 
the ideal scenario would be to use the lowest possible laser energy (ie, 0.1 to 
0.15mJ) with a larger number of laser spots for maximal effect. In this 
experiment, it was shown that higher number of laser spots resulted in higher 
release of MMP. 
The histological data was expected to show a multi-layered RPE layer at day 9 
post incubation (day 7 post laser) across the laser lesion with no extension of 
damage beyond the RPE. However, as shown in Figure 4.8, the current results 
showed disintegrate migration of discrete RPE cells in the laser lesion. The 
histological images show extension of the laser impact to beyond the BrM.  The 
histological results may be interpreted 2 ways. The results may indicate a 
complete wipe out of the RPE cell in the center, which concurs with the flat 
mount results in chapter 2 or as complete RPE cell death from poor survival 
rates in explant cultures which had previously been shown by Treumer et al to 
be limited to 5 days. (Treumer et al.) The latter was less likely because the 
surrounding RPE cells appeared to still be relatively healthy. 
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The current results are critical as it indicates a more profound biochemical effect 
with higher number of laser spots. This has significant clinical implications. At 3 
nanosecond time domain and Q switched, it was presumed from prior laser 
studies that the mechanism of action of the current 2RT laser causes micro 
cavitational effects with a limited extension of damage. Lund et al had 
previously shown that variation of laser spot sizes had limited effects in the ultra 
short pulse duration with micro cavitational mechanism of action. Hence, the 
only variability for changes in this case would be either laser energy or number 
of laser spots. In theory, a higher level of activity of MMP 2 may result in 
increases in hydraulic conductivity. However, a higher release of active-MMP2 
can only presumably happen should there be a larger proportion of RPE cell 
migration. From the flat mount histological experiment in chapter 2, it was found 
that with a higher laser energy (>0.25mJ) there was a larger zone of damage, 
hence, it would be reasonable to assume that high energy levels may also 
result in higher MMP release. However, considering that there was 
disappointingly no discrete beam distribution, a higher laser energy would 
cause secondary damage from apoptosis of the photoreceptor cells. Thus, it 
seems the only way to circumvent this issue would be to use as low an energy 
as possible and to increase the number of laser spots. However, if the 
discontinuous beam configuration were intact, then there would be a higher 
release of MMPs per laser lesion, which in effect will negate the need for larger 
number of laser spots. 
In this study, it has been established that the 2RT in the nanosecond time 
domain did cause release in MMP in porcine eyes and this was dependent on 
number of laser spots. This indicated that a larger total volume of RPE injury 
resulted in a quantitatively higher release of MMP. In particular, this study had 
demonstrated that at the lowest possible energy of 0.1mJ for this laser, there 
was sufficient impact to the RPE to cause a release of active-MMP. 
In this study, there were a good number of lasered samples and controls.  A 
standardised modified using chamber was used which allowed the 
differentiation of measurements of MMP in medium in apical and basal sides. It 
also allowed a standardised area of exposure of explant to medium and 
facilitate calculation of concentrated levels of medium with the volume chamber.   
It could perhaps be useful to repeat the experiment with high energy and low 
number of shots and vice verssa. For example, it would be useful to repeat the 
	   152	  
experiment with 3 or 4 explants at 0.1, 0.15, 0.20, 0.25mJ and 25 laser spots, 
50 spots and 75 spots each to fully define the treatment thresholds for this 
laser.  	  
4.5 Conclusions  
In conclusion, the current data showed that laser may be a plausible modality to 
manipulate the extracellular protease profile that would be beneficial in 
rejuvenating the retina. Higher number of laser spots resulted in higher release 
of activated MMP 2 and the levels of MMP2 activity is sustained beyond day 9 
of incubation on the basal end. This could have an implication for the design of 
clinical trials.  
With the results, it was then vital to investigate the impact of varying levels of 
MMP activity on increasing transport across the BrM.  	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Chapter 5. The effect of exogenously applied MMPs on 
hydraulic conductivity across the Aged Bruch’s membrane. 
5.1 Introduction 
The previous chapter established that the 2RT laser increased the levels of 
active-MMP in a directional and time-dependent sequence.  The results have 
also shown that the profile of MMP release was dependent on the number of 
laser spots. Thus, it would be crucial to determine the impact of different levels 
of MMP activity on hydraulic conductivity in the aged BrM. 
The neural retina undergoes a very high rate of oxidative metabolism as 
compared to other tissues in the body, hence requiring a sophisticated transport 
support system to provide it with the necessary nutrients and waste removal 
from release of the free radicals generated in this process. (Cohen and Noell, 
1960, Ahmed et al., 1993, BS, 1983) For decades, it was known that the rate 
limiting anatomical structures for transport were the blood retinal barriers 
between the endothelial cells of retinal capillaries in the inner retina and the 
single layer RPE cells in the outer retina.(Cunha-Vaz et al., 1966, Foulds, 1990) 
more recently, Hussain et al have demonstrated the contribution of the inner 
collagenous layer of the BrM to resistance in the aged population. (Starita et al., 
1997)  
The BrM is a complex acellular pentalaminar structure made up of collagenous 
and elastic fibers which sits between the RPE and choroid layer. Although not a 
cause of the ageing retina, the BrM itself had been found to host a wealth of 
changes secondary to aging and itself compromises further downstream effects 
of the ageing macular. Structurally, it was known that the BrM increases from 
2um in thickness in the first decade of age to 7um by the 10th decade.(A, 1985, 
Sarks, 1976b, Ramrattan et al., 1994b). Furthermore, Marshall and Bird have 
previously found an increase in lipid content in the inner collagenous layer of 
the BM, hence introducing a hydrophobic barrier amongst aged eyes.(Bird and 
Marshall, 1986) Furthermore, these changes were found to be more 
pronounced in the macula as compared to the periphery. Clinical evidence 
correlated these changes to a decreased rate of visual pigments recycling 
(Eisner et al., 1987, Coile and Baker, 1992, Sandberg and Gaudio, 1995) and 
delayed visual adaptation of receptors both in normal ageing and early AMD. 
From various experimental data, the formation of dysfunctional collagen from 
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AGEs  and ALEs crosslinking play a significant role in causing this resistance 
and decrease in transportation function across the BrM with age. Hussain et al 
have developed a ‘pore’ model which explained the transportation pathways 
across the Bruch’s membrane and Starita et al had demonstrated that the layer 
of highest resistance across the BrM which increased exponentially with age. 
Earlier experiments have also demonstrated age related decrease in hydraulic 
conductivity and molecular transport. (Starita et al., 1997) 
Biochemical data from experiments by the same team also found increased 
sequestration of latent MMPs in aged BrM. As mentioned in the Introduction 
chapter, MMPs are one of the two groups of extracellular proteases, which 
function to regulate extracellular matrix in the human body. With a sequestration 
of latent MMPs, there is less availability for conversion into its active form for 
matrix regulation. Furthermore, preliminary studies conducted by Ahir et al have 
found addition of both activated MMP 2 and 9 to increase hydraulic conductivity 
across BrM. In these experiments, a more pronounced effect with activated 
MMP 9 was found in aged eyes whilst that of MMP 2 was more significant in 
eyes of younger donor age group. (Ahir et al., 2002) This implied that MMP 
activation play a crucial role in regulating turnover of the extracellular matrix of 
the BrM, which had important implications for a structurally and biochemically 
compromised aged Bruch’s. 
The abnormalities of the regulatory coupling of degradation and synthesis can 
cause structural and functional changes to the BrM. 
In the earlier chapter, it was established that the 2RT nanosecond laser resulted 
in release of MMP in porcine RPE-BrM choroid explant culture and there was a 
higher quantity of active-MMP release with larger RPE volume damage. Given 
that previous pilot study have indicated that active-MMP9 resulted in larger 
improvements of hydraulic conductivity as compared to active-MMP2, it may be 
appropriate to refer to active-MMP9 as the ‘emergency’ enzyme and active-
MM2 as the ‘maintenance’ enzyme. At the first instance, it would be crucial to 
determine the impact of changes from the ‘maintenance’ enzyme on the 
functional capacities across the aged BrM. As such, commercially available 
active-MMP2 in different levels was chosen as the exogenous MMP added in 
this experiment. Thus, in the following experiment, the main objectives were to 
1. assess the effect of MMP 2 activity (if any) on hydraulic conductivity across 
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the aged BrM; and 2. to determine the impact of different levels of MMP2 
activity on hydraulic conductivity across the aged BrM. 
5.2 Methods and materials 
5.2.1 Preparation of Human Bruch’s-Choroid sample 
44 human eyes from 22 donors aged 34 to 80 years of age were used.(UK 
Transplant Support Service, Moorfields Lion Eye Bank, London, UK). Donor 
eyes were obtained and used in accordance with the provisions of the 
Declaration of Helsinki for research involving human tissue. Whole globes were 
dissected in a Petri dish lined with filter paper (Grade 50; Whatman, Maidstone, 
UK), moistened with phosphate-buffered saline, (PBS, composition: NaCl, 90 g; 
NaH2PO4, 13.65 g; and KH2PO4.2H2O, 2.43 g dissolved in distilled water with 
final volume adjusted to 1 L [pH 7.4]; Sigma-Aldrich, Poole, UK) containing 100 
U/mL penicillin and 100µg/mL streptomycin. The anterior portion of the eye was 
carefully removed by a circumferential incision at the pars plana, and the 
cornea, together with the lens, iris, and vitreous, were discarded. The posterior 
globe was inspected for any evidence of subretinal blood, extensive drusen, or 
irregular pigmentation of the RPE or any gross disease of the retina, and those 
exhibiting any abnormal appearance were discarded. The neural retina was 
gently peeled away from the underlying RPE and cut at the optic nerve head.  
One single sample was obtained from the macular of each eyecup with an 8-
mm trephine (Stiefel Laboratories, Buckinghamshire, UK). The RPE was 
carefully brushed away with a fine sable-hair brush, and the Bruch’s membrane-
choroid complex was gently teased away from the underlying sclera. 
The isolated preparation was mounted between the two halves of a Perspex 
modified Ussing chamber. Both surfaces were rinsed several times with PBS. 
Altogether, 44 macular samples of Bruch’s-choroid from 44 eyes of 22 donors 
age ranged 34 to 79 years were used. 
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5.2.2  Activation of MMP 
Commercial human pro MMP2 (Sigma-M9070) was used for this experiment. 
ProMMP2 was prepared as an enzyme stock solution (100µg/mL) using Tris-
buffer. Enzyme stock is diluted with buffer into 1:1000, 1:500, 1:200, 1:100 and 
1:50 concentrations of ProMMP2.  
 
Table 5.1 Dilution and concentration of active-MMP2  
Dilution: MMP2 concentration: 
µg/ml 
1:50 2 
1:100 1 
1:200 0.5 
1:500 0.2 
1:1000 0.1 
 
Pro MMP2 was activated with APMA in DMSO to give a concentration of 1mM 
APMA. The solution is incubated at 37 ° C for 2 hours.  
An initial gelatin zymography (methodology as described in chapter 3) with 
range of MMP concentration was done to check that the commercial protocol 
activated the ProMMP2 solution in varying concentrations defined above. 
Quantification of Pro MMP2 and active-MMP2 levels is performed as described 
previously and normalized against prior zymography results (chapter 3 and 4). 
(Figure 5.1) 
A comparison between zymographic densitometric quantity and concentration 
of MMP was made semi-quantitatively. This will allow cross comparison of 
previous zymographic results in terms of densitometric quantity by conversion 
to concentration of MMP. (Figure 5.2) 
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Figure 5.1 Representative zymogram of APMA activated MMP2 in varying 
concentrations 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 shows the representative zymogram of Active-MMP2 post APMA 
activation of varying concentrations of commercially available ProMMP2 (Sigma). 
Note the decreasing levels of Active-MMP2 with decreasing levels of proMMP2 
concentration. 
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Figure 5.2 Graph comparing MMP densitometric quantity with 
concentration of active MMP2. 
 
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  
Figure 5.2 shows a graph comparing the levels of MMP in terms of densitometric 
quantification with the actual concentration of enzymes. (Refer to table 5.1 for 
concentration in µg/mL) 
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5.2.3 Measurement of hydraulic conductivity 
Filter-mounted Bruch’s-choroid tissue samples were secured in the Ussing 
chamber. Both compartments were flushed three times with PBS before being 
slowly filled to avoid any air bubbles. The compartment appositional to the 
Bruch’s membrane surface was then coupled to a reservoir of PBS.  
This arrangement allowed the hydraulic conductivity of the sample to be 
determined. Briefly, pressure was applied to the Bruch’s membrane surface by 
the PBS reservoir at a fixed height of 220 mm, which applied a constant 
pressure of 2156 Pa. Once the tissue was under pressure, if a hole was present 
in the membrane, it became readily apparent because of the speed of 
movement of fluid into the apical chamber and such samples were discarded. 
Of the samples collected, fewer than five discs were found to have holes. Intact 
samples were allowed to equilibrate for 30 to 60 minutes under constant 
pressure. To measure the fluid outflow, fluid from the Bruch’s membrane 
surface was pipetted and weighed every 15 minutes for 60minutes, after which 
time, the Ussing chamber was disconnected and both compartments were 
washed with PBS. This provided the baseline hydraulic conductivity of the 
preparation. 
The HC was calculated as follows: 
          Flow/Unit area 
HC=       Pressure 
Where Flow is referred to as volume collected as a measure of time per second. 
Thereafter, activated MMP2 would be added on the apical surface (Bruch’s 
membrane surface) of the chamber and incubated for 18 hours. 60 minutes was 
chosen as the time for HC measurements as per prior published experiment by 
Ahir et al (Ahir 2005) using 60 minutes for HC measurements and 18 hour 
incubation period. 
Post incubation, the same procedure would be repeated to measure the HC. 
Change in HC was calculated as HC minus baseline HC of tissue sample. 
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Figure 5.3 Schematic diagram of modified Ussing chamber for 
measurements of HC 	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
Figure 5.4 Photographic diagram of Ussing chamber water tank 
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5.3 Results 
5.3.1 Baseline Hydraulic Conductivity 
Baseline hydraulic conductivity of a total of 44 macular samples from 22 donor 
eyes aged 34 to 79 years of age were measured and plotted against the 
hydraulic conductivity in age-matched regression curve as measured by Starita 
et al previously. (Figure 5.5)  In this experimental subset, it was noted that all 
except two donor samples (both aged 55 years) were higher than the expected 
measurements of hydraulic conductivity within 2 standard deviations. 
 
Figure 5.5 Baseline Hydraulic Conductivity of samples  
 
 
 
 	  	  
Baseline HC 
 
Regression data plots from regression 
graph by Starita et al 
 
Figure 5.5 shows the distribution of the baseline HC in the current experiment 
with donor age ranging between 34 to79 years.(n=44) The HC were measured 
against the age related standards measured by Staritia et al, as shown in the 
regression model. 
Other than 2 samples (both donor age 55 years) which are out of the range of 
HC, the others were within the normal range, age-matched.  
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5.3.2 Change in Hydraulic Conductivity 
The current results showed an increase in hydraulic conductivity after addition 
of active-MMP2 (Figure 5.6a).   
Further analysis of samples in the graded level of activity of MMP2 showed that 
younger donor aged samples were susceptible to increases in HC even with 
minimum levels of active-MMP2 added, but changes in the aged donor samples 
(>65years) were only quantifiable with addition of higher levels of active MMP2. 
(Figure 5.6b) 
The ratio of change in HC was increased with the addition of a higher level of 
active MMP2. (Figure 5.7). The ratio of change with addition of 0.1µg/mL of 
ActiveMMP2 ranged between 0 to 3.32, of which only 1sample had a ratio 
change above 1.5. At 0.2µg/mL of activeMMP2 added, the ratio of change was 
between 1.20 to 1.85.  At higher levels of activeMMP2 added, higher increases 
of ratio change were noted, particularly in the elderly (>60 to 2.55; whilst at 
1µg/mL was 1.27 to 3.3.  At 2µg/mL active-MMP2 added, the ratio change 
increased further to 1.80 to 3.82.  
A linear plot was obtained which showed difference in the younger and older 
age group in terms of increases in ratio of HC change with active-MMP2 
concentration. Mean donor age of the 44 samples was 63 years, as such, 
analysis was done for the young age group, taken as age below 63 year and 
the older age group, taken as above or equal to 63 years. From the graph in 
Figure 5.7, the results showed that there was a greater change in HC in the 
older age group with higher doses of active-MMP2 added. The linear regression 
model obtained for the samples with donor age less than 63 years of age was 
not statistically significant. The linear regression model for samples with the 
older donors had a calculated R2 =0.196, but was statistically significant.  
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Figure 5.6a Plot of pre and post HC with addition of varying dosage of 
Active-MMP-2  
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Figure 5.6b Change in HC versus concentration of Active-MMP2  	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Figure 5.6a demonstrates the pre and post HC upon addition of varying levels of 
active MMP2 (0.1 to 2µg/mL) with age as compared to the regression model for 
age-related HC by Starita et al. Note the increase in HC after addition of activated 
MMP2.  Increase in HC was noted to be dose-dependent. 
 
Figure 5.6b shows a series of plots of HC pre and post addition of graded levels 
of activated MMP2 in the macular. With addition of 0.1 and 0.2µg/mL of activated 
MMP2, increases in HC was only noted in the younger donor age group. In the 
older donor aged samples, there was minimal increase in HC. With addition of 
0.5, 1 and 2µg/mL of activated MMP2, there was higher increases of HC.  
The increase of HC was found to be both dose and age-dependent.  
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Figure 5.7 Linear plot of ratio of change in HC versus concentration of 
active MMP2 in young and older age group 
 
	  
	  	  	  	  	  	  	  	  	  	   	  	  
 
 
 
 
 	  
Figure 5.7 shows that in the older donor age samples, there was more 
pronounced increases in HC (ratio of change) with addition of higher doses 
of active-MMP2, as compared to the younger age group. Regression model 
was perfomed for each of the 2 groups. The linear regression model was not 
significant for samples <63 years of age. The linear regression model was 
significant for samples>63 years of age, although the R2 =0.196. 
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5.4 Discussion 
Results from the prior experiment have shown that higher number of laser spots 
were associated with a greater increase in active-MMP2. Given that the main 
action of MMP activity was to clear debris in the extracellular matrix within the 
BrM, the release of active-MMP in the basal end would be of greater value in 
this instance. The results from chapter 4 seem to indicate that the increase in 
levels of active MMP2 on the basal end was proportional to the number of laser 
spots (ie, 50 laser spot samples had a mean release of twice the levels of 
active-MMP2 as compared to 25 laser spots).  
Starita et al previously demonstrated a correlation between the quantity of lipids 
and the decline of hydraulic conductivity in the elderly population.(Starita et al., 
1996a) In vitro experiments from the same team have previously found that 
hydraulic conductivity and taurine (and all other amino acids) transport were 
compromised across the BrM with age.(Hillenkamp et al., 2006) Pilot studies by 
Ahir et al have also found that the addition of activated MMP from RPE cell 
culture increases hydraulic conductivity.(Ahir et al., 2002) In this experimental 
subset, the age-defined baseline hydraulic conductivity was comparable to prior 
results at the age range that have been used. (Ahir et al., 2002) There were 2 
main findings from the current results: 1. A minimal increase in activity of MMP 
2 was required before there was any noticeable effect on the older aged donor 
samples; and 2. activity of MMP 2 on BrM was both age and dose dependent. 
Hence, it may be assumed from the results that age plays a major role in the 
debris clearing effect by MMP activity.  
The use of an intact Bruch’s-choroid sample had been justified previously with 
several studies. First, Starita et al had previously shown that the removal of 
choroidal fibres post-mounting of the explant sample did not result in changes to 
HC. Also, the same team had demonstrated that the greatest resistance to 
transport was located in the inner collagenous layer of the BM using excimer 
laser removal of adjacent layers. (Starita et al., 1997)Furthermore, in 
experiments conducted by Hillenkamp et al using young bovine eyes and aged 
human BrM, the authors have concluded that despite age related changes in 
the choroid, the choroidal layer itself played minimal role in the transport in 
aging retina. (Hillenkamp et al., 2006)In addition, there were several benefits of 
keeping the current BrM-choroid explant sample. First, there was thus far, 
limited literature in the technical success in isolation of BrM. Microdissection 
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resulted in formation of holes and tears whilst, although Schutt and Holz 
previously successfully used excimer laser to debulk most of choroidal tissue, 
they were not able to isolate the Bruch’s without structural damage. (Schutt and 
Holz, 2002) Second, there was a lack of identifiable anatomical border because 
the posterior border of the BM expands to form intercapillary border of the 
choriocapillaries. (Olver ARVO poster 1990) Taken into totality, there would be 
further benefits to use BrM-choroid explant as a system. 
There exist several in vitro methods for measuring fluid transport across the 
Bruch’s membrane. Hydraulic conductivity could be measured from a static 
pressure (as per current experiment) or at various pressures and a flow-
pressure profile (dynamic) obtained. Hussain et al had previously shown that in 
rigid membranes (BrM), both these profiles are linear and pressure-
independent, whilst in non rigid membranes (Descemet’s and basement 
membrane of lens capsule), which undergo compressure with raised pressure, 
(Fisher, 1982, Fisher, 1987b), the differences in pressure would result in a 
nonlinear flow-pressure plot. Preliminary experiments by Hussein et al with BrM 
using both young and old human BrM sample did not observe signs of 
compression over a large pressure range. Hence, a linear and/or static pressure 
measurement would suffice to obtain accuracy of results in this experiment.(A.A 
Hussain, 2004)  
Gelatinase A and B (MMP 2 and 9) regulates the activity of Collagen type IV, V, 
laminin, fibronectin. (Birkedal-Hansen et al., 1993) In the ageing Bruch’s, 
investigators have found increase in dysfunctional collagen and type IV collagen 
lining the focal infoldings of basal membrane lining choriocapillaries in aged 
donors. Further more, increased laminin was found in drusen.  There was found 
to be an increase in striated denatured collagen in both inner and outer 
collagenous layers of BrM and can be attributed to the increased in crosslinking 
with AGE and advanced lipoxidation products.  Hence, the current results which 
show that the increasing HC from increased addition of active-MMP in aged 
Bruch’s may be a function of increased degradation of the inherent nature of 
structural changes involved in an aged BrM.  However, it is important to keep in 
mind that this was an artificially designed invitro experiment which was aimed to 
mimic a ‘life’ scenario by addition of activated MMP 2.  The gelatinase scenario 
in an elderly outer retina is far more complex with TIMP and other MMP 
involvement.  In this study, the focus had been on MMP 2 which is a 
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maintenance enzyme and had been found to have less exaggerated effects in 
previous studies. Nonetheless, it was still important to determine the impact of 
this enzyme on the aged BrM.  
In this study, several major conclusions may be drawn. First, this study had 
shown that the older age group would require a higher level of MMP activity to 
increase its hydraulic conductivity, and second, a minimal level of MMP activity 
was required before any effect on hydraulic conductivity was noted. 
Scientifically, our prior porcine eye laser experiment showed that higher RPE 
volume injury resulted in higher active-MMP 2 release and this experiment 
showed that higher levels of MMP2 activity increases HC to a greater extend, 
particularly in the elderly population. Several theories may account for this 
phenomena, first, it may well be that aged Bruch’s with a higher content of 
debris would require a higher quantity of MMP activity to enhance its hydraulic 
conductivity for any rejuvenative effect; however, the results can also be 
explained by the fact that diffusional status is severely compromised in elderly 
subjects, and that since active-MMP2 had to move into the membrane via 
diffusional processes before it can act, and hence, higher levels of active MMP2 
are required to achieve results. Perhaps, in the second scenario, incubations 
should then be prolonged to allow entry of sufficient quantities of these 
enzymes. Whichever of the two theories, certainly, the results show that higher 
levels of MMP2 activity is required to enhance transport across the Bruch’s 
membrane, and this is especially so in the elderly population. 
Although it must be kept in mind that different species were used in 
experimental models in chapter 4 and 5, direct comparisons can still be made 
between the results from the 2 chapters. The following calculations were 
simplified for comparative and estimation purposes. In a real-life situation, the 
mathematics behind the biochemical release and physical remodeling of the 
ECM in BrM for transport would be far more complex. In chapter 4, 50 laser 
spots at very low laser energy (0.1 to 0.15mJ) released approximately 0.1µg/mL 
of active-MMP2 in the basal compartment. From this chapter, a minimum level 
of 0.5µg/mL concentration of active-MMP2 was required before any effect was 
noted on hydraulic conductivity in the older age group. Hence, the number of 
laser spots required for sufficient impact on hydraulic conductivity would have to 
be in excess of 50 laser spots, and to be exact, a calculated number of 88 laser 
spots (Please refer to figure 5.2). Furthermore, based on the results, the release 
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of active-MMP2 is calculated to be 2ng/mL per laser lesion. Ultimately, there is 
a requirement to produce a database, which will allow future prediction of the 
potential volume of MMP release per unit laser insults. 
Given the current results, it would be reasonable to design a clinical trial laser 
protocol with the use of minimal laser energy, with a larger number of laser 
spots. 
5.5 Chapter conclusion 
Several conclusions can be drawn from the current results. First, the findings 
suggest that the older population would require a higher concentration of active-
MMP2 to improve transport across the BrM. In addition, active-MMP2 release 
from the 2RT laser would require an approximate of at least 88 laser spots to 
increase the hydraulic conductivity in the elderly population. 	  
In part 1 of the thesis, laboratory experiments were designed to determine the 
beam profile of the 2RT laser and to evaluate the impact of this nanosecond 
laser on the RPE-BrM choroid explant in terms of biological release of MMP and 
its consequential effect on the transport across the BrM. First, in terms of the 
laser design, the laser was not found to have a viable speckled beam 
distribution which was initially designed to prevent secondary laser damage. 
Second, in terms of the biochemical impact of the laser on RPE-BrM organ 
culture, it may be concluded that the nanosecond 2RT laser increased the 
activity of MMPs which in turn increased the fluid transport across the BrM in a 
dose-dependent fashion. It would be essential to translate the current results 
into clinical research and determine if similar effects would be noted in human 
subjects and if so, to assess the efficacy of the laser in retarding the onset 
and/or progression of early AMD; and to determine the impact of the ultrashort 
pulse of the laser clinically. 
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Part 2 
Chapter 6. Efficacy and safety of retinal rejuvenation using 
Ellex 2RT laser in age-related maculopathy (RETILASE trial)-
background to investigation plan 
6.1 Summary of Investigation plan 
Part 1 of this thesis has addressed several problems identified. In summary, the 
following findings were apparent: 
1. The 2RT laser in the current form does not have a viable discontinuous 
beam profile; 
2. Active-MMP2 levels were increased with the application of the 2RT laser 
on RPE-BrM choroid explant culture; 
3. Levels of active-MMP2 increase was a function of dose of laser (ie, 
number of laser spots), and was time and direction-dependent; 
4. Addition of active-MMP2 increased hydraulic conductivity across the 
human BrM; 
5. This increase in hydraulic conductivity was both age and dose-
dependent (active-MMP2). 
Having established the above findings, it was then important to evaluate the 
impact of the 2RT laser in human subjects, as a prophylactic treatment modality 
for preventing or retarding onset of AMD. 
This sole purpose of this chapter was to evaluate the clinical study design as to 
allow some understanding of the clinical parameters set for further evaluation of 
the data (chapter 7 and 8). 
 
The full title of the King’s College Hospital/Moorfields Eye Hospital trial was 
called “Laser prophylaxis to prevent AMD” with the working title of “RETILASE 
trial” was designed to assess the efficacy and safety of the 2RT laser in 
improving visual function in patients diagnosed with early AMD. The RETILASE 
trial itself was a blinded randomized clinical trial over 24 months, however, this 
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thesis only evaluates the findings at 6 and 12 months due to time constraints for 
submission of thesis which was prior to the end of trial.  
During the process of the clinical trial protocol design, the company was 
involved as the laser sponsor as this was the first clinical trial conducted in the 
UK for the 2RT laser in early AMD. At time of protocol design and start of trial, 
the laser was not CE marked for AMD, as such, this protocol was subject to 
approval by ethics and MHRA. The design of the clinical protocol was limited by 
constraints demanded by the commercial company which included the type of 
patients recruited, laser treatment protocol and the 6 monthly follow up regime.   
The following highlights an abbreviated version of the clinical trial protocol for 
the purposes of discussion and scientific evaluation of this thesis. The full 
clinical protocol can be found under the Appendix. 
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Table 6.1 Summary of RETILASE investigation plan 
Title Efficacy and safety of retinal rejuvenation with Ellex 2RT 
laser in age related maculopathy (RETILASE trial).  
Objectives To determine the efficacy and safety of Ellex 2RT laser in 
improving visual function and retinal morphology amongst 
patients with age related maculopathy. 
 
Study Design A blinded randomized controlled trial to evaluate the 
efficacy and safety of Ellex 2RT compared to standard 
care in patients with age-related maculopathy.  
After informed consent, patients underwent baseline 
examinations of best corrected visual acuity, contrast 
sensitivity, microperimetry and flicker sensitivity. 
Structural changes was assessed by OCT, 2- field retina 
colour photographs, autofluorosence and fundus 
fluorescein angiography. Follow up visits was at 6 and 12 
months.  
Planned Sample Size 80 patients – randomized 1:1 to treatment versus no 
treatment group. 
Patient selection Patients of either gender aged 55 or above with large 
drusen (≥125µ) in at least one eye (AREDS simple 
severity grade 2 to 3). Best corrected visual acuity in the 
study eye was between 50 to 90 ETDRS letters. 
Treatment protocols 1) Treatment one: Ellex 2RT, 400µm diameter spot, 2 
rings of concentric subthreshold laser spots 
applied  at 2000µm (5 ½ spots sizes out from the 
fovea) and 2800µm (7 ½ spot sizes out from the 
fovea).  So a total of at least 25 spots was applied.    
OR  
2) Standard care (No treatment but observed 
regularly). 
Treatment was performed by the principal investigators of 
each site. Other than the principal investigators, patients 
and all other investigators were blinded to randomized 
arm. 
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Clinical Outcome 
Measures 
 
Comparison of the outcomes of Ellex 2RT compared to 
observation (standard care) will be done on the following 
parameters at 12 months: 
Efficacy analyses: 
1. Primary outcome: Mean change in visual acuity at 
12 months. 
2. Secondary outcomes:  
a. Mean change in visual acuity at 12 months.  
b. Mean change in contrast sensitivity, 
microperimetry and flicker sensitivity at 6 and 
12 months.  
c. Changes in fundus morphology as measured 
by optical coherence tomography, colour 
fundus photographs at 6 and 12 months. 
Safety analyses by comparing the following between the 
two arms: 
1. Proportion of patients developing CNV at 12 
months. 
2. Proportion of patients developing retinal atrophy 
as measured by autofluorescence and OCT at 12 
months 
3. Proportion of patients who lost more than 15 
ETDRS letters at 12 months. 
4. Proportion of patients who lost more than 30 
ETDRS letters at 12 months. 
5. Any other complications observed at 12 months. 	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6.2 Background to design of RETILASE trial 
6.2.1 Introduction 
Age Related Macular Degeneration (AMD) is the leading cause of blindness in the 
elderly in the western society. In the United Kingdom, an estimated 608, 213 people 
have been diagnosed with AMD.  This number is expected to increase to 755, 867 by 
the end of the next decade.  This attributes to 22.5% of the ageing 
population.(Minassian et al., 2011) Clinically, “dry” or early AMD is characterised by 
large drusen and RPE pigmentary changes that can progress to an advanced stage, 
geographic atrophy. “Wet” or neovascular AMD, another manifestation of advanced 
disease, is characterised by choroidal neovascularisation (CNV). Clinical classification 
of early AMD such as the AREDS simplified severity scale (Table 6.2) based on 
photographic assessment of drusen size and pigment changes in the macula. 	  
Table 6.2 AREDS simplified severity scale grading table 
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6.2.2  The International grading of age related maculopathy 
The progression of the disease is monitored by classifying the morphological changes 
in the fundus as per International Classification (IC) grading system: 
Standard circles for grading ARM related fundus changes.  Circles should be reduced 
on a transparent sheet according to the fundus camera used so that they are 1/24, 
1/12, 1/8.6, 1/6 and 1/3 disk diameter.  This results in an approximate diameter of the 
fundus of 63,125,175, 250 and 500 um. 
C0: differentiates small from large drusen 
C1 and C2: measuring area of hyper or hypopigmentation of RPE 
C2: minimum area of geographic atrophy 
C3 and C4: geographic atrophy and neovascularization 
Spokes: locating centre point and estimating size of lesion. 
 
Figure 6.1 Pictorial demonstration of druse size grading, International 
Classification 	  
Grading of Drusen 
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Drusen morphology. Grade highest present within outer circle. 
0) absent  
1) questionable  
2) hard drusen (<C1, 125um)  
3) intermediate, soft drusen (>C0_<C1; >63um<125gm)  
4) large, soft distinct drusen (>C1, 125um) 
5) large, soft indistinct drusen (>C1, 125gin) 
5a) crystalline/calcified/glistening 5b) semisolid 5c) serogranular 
7) cannot grade, obscuring lesions 
8) cannot grade, photo quality 
Number of drusen 
0) absent  
1) questionable  
2) 1-9 
3) 10-19  
4) >20  
7) cannot grade, obscuring lesions  
8) cannot grade, photo quality 
Drusen size 
1) <Co (<63um)  
2) >C0<C1 (>63um,<125um) 
3) >CI<C2 (>125um, <175um) 
4) >C2<C3 (>175um,<250um)  
5) >C3(>250um) 
7) cannot grade, obscuring lesions 
8) cannot grade, photo quality 
Main location of drusen 
Drusen may not be central to indicated subfield, but may be more to periphery.  
1) outside outer circle (mid-peripheral subfield)  
2) in outer subfield  
3) in middle subfield  
4) in central subfield 
4a) outside fovea (center point) 
4b) in fovea  
7) cannot grade, obscuring lesions 
8) cannot grade, photo quality 
Area covered by drusen in subfield  
1) <10% 2)<25% 3)<50% 4) >50%  
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7) cannot grade, obscuring lesions  8)cannot grade, photo quality 
Hyper and Hypopigmentation of the Retina 
Hyperpigmentation 
0) absent 
1) questionable 
2) present <Co (<63um) 
3) present >Co(>63um) 
7) cannot grade, obscuring lesions 
8) cannot grade, photo quality 
Hypopigmentation 
0) absent 
1) questionable 
2) present <Co (<63 um)  
3) present >Co(>63um) 
7) cannot grade, obscuring lesions 
8) cannot grade, photo quality 
Main location hyper / hypopigmentation. 
This may not be central to indicated subfield, but may be more to periphery. Choose 
most central location.  
1) outside outer circle (mid-peripheral subfield) 
2) in outer subfield 
3) in middle subfield 4) in central subfield 
4a) outside fovea (center point) 
4b) in fovea  
7) cannot grade, obscuring lesions  
8) cannot grade, photo quality 
Neovascular AMD 
Presence 
0) absent 1) questionable 2) present  
7) cannot grade, obscuring lesions 8) cannot grade, photo quality 
Typifying features 
1) hard exudates 2) serous neuroretinal detachment 3) serous RPE detachment 4) 
hemorrhagic RPE detachment 5) retinal hemorrhage 
5a) subretinal 5b) in plane of retina 5c) subhyaloid 5d) intravitreal 
6) scar/glial/fibrous tissue  
6a) subretinal 6b) preretinal  
7) cannot grade, obscuring lesions 8) cannot grade, photo quality 
Location. Choose most central location. 
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1) outside outer circle (mid-peripheral subfield) 2) in outer subfield  
3) in middle subfield 4) in central subfield 
4a) not underlying (in) fovea (center point) 
4b) underlying (in) fovea  
7) cannot grade, obscuring lesions 8) cannot grade, photo quality 
Area covered 
1) >C2<C3(>175um<250um) 2) >C3<C4(->250um<500utm)  
3) >C4and < 1000um (-central circle of grid) 
4) >1000um <3000um (-middle circle) 5) ->3000um <6000um (-outer circle) 
6) >6000um 
7) cannot grade, obscuring lesions 8) cannot grade, photo quality 
Geographic Atrophy 
Presence 
0) absent 1) questionable 2) present: ->C2 7) cannot grade, 8) cannot grade, 
Location. Choose most central location.  
1) outside outer circle (mid-peripheral subfield) 2) in outer subfield  
3) in middle subfield 4) in central subfield 
4a) not underlying (in) fovea (center point) 4b) underlying (in) fovea  
7) cannot grade, obscuring lesions 8) cannot grade, photo quality 
Area covered 
1) >C1<C3(>175um<250um) 
2) ->C3<C4(->250um<500um)  
3) >C4 and < 1000um (central circle of grid)  
4) >1000um and <3000um (-middle circle) 5)>3000um and <6000um (outer circle)  
6) >6000um  
7) cannot grade, obscuring lesions 
8) cannot grade, photo quality 
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6.2.3 Summary of Current Clinical Understanding of Pathology of 
AMD 
AMD is a degenerative disease that affects the outer neural retina, retinal 
pigment epithelium (RPE), Bruch's membrane (BrM), and the choroid. The 
clinical hallmark of the disease are the accumulation of yellow deposits called 
drusen in the fundus and this may be associated with hypo- and hyper-
pigmented areas of RPE, the former signifying areas of RPE cell loss.(Sarks, 
1976b) Since photoreceptors depend on the RPE and the choroidal circulation 
for nutrients as well as for the clearance of metabolic end-products, impairment 
of transport across BrM could contribute to abnormalities associated with late 
AMD. These may include photoreceptor dysfunction, atrophy, RPE detachment 
and sub-RPE neovascularisation (Vujosevic et al.) 
 
6.2.4  Bruch’s Membrane (BrM) 
BrM is an important pentalaminar layer, located between the choriocapillaries 
and the RPE, contributing to the transport of nutrients and waste products into 
and out of the photoreceptor layer. BM thickness has been found to have a 
marginal increase with age. (Ramrattan et al., 1994b) A more significant 
observation is the build up of debris within this layer.(Grindle and Marshall, 
1978) 
Prior histological studies of aged BM have demonstrated the following: 
1. Increases in collagen content and cross-linking(Newsome et al., 1987b, 
Karwatowski et al., 1995b)   
2. Increased content and altered composition of proteoglycans has also 
been noted.(Kliffen et al., 1996a) 
3. A higher total lipid content in BrM. (Fisher, 1987b) Lipid- and protein-rich 
debris has been found accumulating under the RPE and within BM. This 
contributes to the formation of focal (drusen) and diffuse (basal laminar 
and linear) deposits found in AMD.(Pauleikhoff et al., 1990, Green and 
Enger, 1993, Green, 1999a)  
Taken in totality, this results in a structural disorganization of the collagen 
fibers and thinning as well as fragmentation of the elastic layer.(Hogan and 
Alvarado, 1967a, Spraul et al., 1999a)  
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There are several pieces of evidence for the contribution of metalloproteinases 
(MMPs) to the thickening of BM, and hence, AMD.  
First, both genetic and serum studies of inhibitors of MMPs (e.g. TIMP3) which 
is produced by the RPE, has been studied and found to have an increased in 
AMD patients compared to age matched controls.(Fariss et al., 1997a, Kamei 
and Hollyfield, 1999b) Higher levels of TIMP-3 may contribute to the thickening 
of BM observed in AMD. 
Also, whilst there is a known increase in inactive forms MMP 2 and 9 levels in 
the subretinal space as well as BrM of AMD, the accumulation of inactive forms 
of MMPs are hypothesized to be a consequence of remodeling of BrM in aged 
eyes.(Plantner et al., 1998b, Guo et al., 1999b) Increased deposition of collagen 
and other ECM components induces synthesis of MMPs; however, increased 
concentration of TIMPs or decreased porosity of BrM prevents its activation. 
Hence, from the gathered evidence, we postulate that BrM thickening is 
correlated to AMD and an inactivation of MMPs result in increased BrM 
thickening. 
6.2.5   Ellex 2RT laser 
The retinal rejuvenation therapy (Ellex 2RT) uses nanosecond duration pulses 
and a discontinous beam energy distribution, which should not harm the 
photoreceptors (unlike previous conventional thermal lasers).  It uses energy 
levels 500 times lower than current standard laser treatment.  It was previously 
shown to be effective as an alternative to conventional laser in treatment of 
other retinal diseases such as diabetic macular edema (DMO).(Pelosini et al., 
2013)  	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6.2.6  Prior  research work  
Preliminary laboratory work 
Light sensitive cells of the human retina (photoreceptors) require high level of 
energy support and waste removal for optimal functioning.  RPE is a single 
layer of epithelial cells which separates the photoreceptor layer from the choroid 
and controls many bi-directional support functions.  RPE is attached to a 
basement membrane which is a matrix of collagen otherwise known as the BrM.  
This acts as a semi permeable barrier between the RPE cells and the choroids. 
Prior work by Professor John Marshall and Dr Ali Hussain and team has shown 
that debris within the BrM is a precursor of AMD with a resultant age related 
decreased hydraulic conductivity. (Hussain et al., 2010c, Kumar et al., 2010) 
Further work was done which explored treatment possibilities with migration of 
RPE cells across BM with an associated improvement in hydraulic conductivity.  
Ellex 2RT was shown to be able to induce a wound healing response in the 
RPE which induces migration and release of metalloproteinases (MMPs). (Guo 
et al., 1999b) This had a subsequent effect on improvement of transport across 
the BrM, with a postulated delay in onset of age related macular degeneration 
 
Preliminary clinical work done with Ellex 2RT system.  
Clinical results from a pilot study on Ellex 2RT for DME were presented at 
ARVO 2008. The results should be treated with caution as only 18 of the 29 
patients completed the 6 months study. But the results showed that 43% of 
patients showed 2 or more lines gain in visual acuity and the central macular 
thickness decreased by more than 5% from baseline in 46% of patients. The 
laser lesions from the pilot study were shown to be completely subthreshold 
with no laser scars or any other complications. These results were subsequently 
published. (Pelosini et al., 2013) 
A second randomized controlled study was conducted on Ellex 2RT for DME 
was presented at ARVO 2010.  The laser is currently undergoing clinical trials at 
CERA, Centre of Eye Research Australia.  A 12 month report which includes 50 
patients at 12 month follow up showed that the patients had a reduction in 
drusen.  Drusen decreased in 70% of treated eyes. Using flicker and color 
thresholds, the trial showed these central visual functions improved in 38% of 
treated eyes.((Guymer et al., 2014) 
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6.3 Theoretical Concepts for Delaying Ageing in the Outer 
Retina  
In ageing and AMD, the accumulation of lipid- and protein-rich deposits in BM 
results in an overall thickening and a structural re-organisation of 
BM.(Ramrattan et al., 1994b) A consequent decrease in hydraulic conductivity 
and impairment of transport through BM may play a central role in the 
pathogenesis of AMD. So improvement of the hydraulic conductivity across the 
BrM should improve the transport to and from the choroid to the outer retina.  
2RT is a nanosecond pulsed laser, which uses very low energy levels to 
produce limited effects that selectively target melanosomes within the RPE 
cells. This laser energy absorption by melanosomes within RPE cells causes 
microbubbles and cavitations to form, damaging a percentage of RPE cells 
within the laser spots without rupture of the cell membranes.  The resultant 
effects are an upregulation of MMPs and cytokines and RPE cell migration. This 
should improve the hydraulic conductivity across BrM to and from 
photoreceptors and delay the progression of AMD in terms of reduction of 
clinical markers(dursen, pigment abnormality), improvement in visual function 
(visual acuity, color and contrast sensitivity and rod and cone recovery 
dynamics). 
Figure 6.2 Pictorial demonstration of biochemical impact of nanosecond 
laser on the RPE 	  
Days 4 to 7                 Days 7 to 14 
     
<-- RPE cell loss       <--RPE cell migration             Bruch’s clearance. 
                                      àMMP 2 and 9 upregulation          Overall improved HC 
                                      àcytokines release                                                      
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6.4 Objectives of RETILASE trial in reference to this thesis 
To assess the efficacy and safety of retina rejuvenation therapy (Ellex 2RT) in 
patients with large drusen (≥125 µm) in at least one eye compared to standard 
care (no treatment).  Comparison of the outcomes of Ellex 2RT compared to 
observation (standard care) was done on the following parameters at 6 and 12 
months: 
Efficacy analyses: 
1. Primary outcome: Mean change in visual acuity at 12 months. 
2. Secondary outcomes:  
a. Mean change in visual acuity at 6 months.  
b. Mean change in contrast sensitivity, microperimetry and flicker 
sensitivity at 6 and 12 months 
c. Changes in fundus morphology as measured by optical coherence 
tomography, colour fundus photographs at 6 and 12 months 
Safety analyses will be done by comparing the following between the two arms: 
6. Proportion of patients developing CNV at 12 months 
7. Proportion of patients developing retinal atrophy as measured by 
autofluorescence and OCT at 12 months 
8. Proportion of patients who lost more than 15 ETDRS letters at 12 
months. 
9. Proportion of patients who lost more than 30 ETDRS letters at 12 
months. 
10. Any other complications observed at 12. 
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6.5 Study Design 
6.5.1 Study Design 
Plan of investigation and statistical power of the trial 
This is a prospective randomized controlled trial that will compare the mean 
change in visual acuity at 12 months between the treatment group treated with 
Ellex 2RT and the observation group (standard care) in patients with age 
related maculopathy  
Sample size (Statistical Power of the study of 80%)  
A control sample of size 33, with a baseline ETDRS letters in the range 70-95, 
and 12 months ETDRS letters was used to provide estimates for the sample 
size calculation.  
The mean score at baseline was 79.7, and the SD of the one year change from 
baseline EDTRS was 7.59. To be able to detect a difference of 5 EDTRS 
between arms, in the mean change from baseline to 12 months, based on t-test, 
at the 5% level of significance, and with an 80% power, would need 76 patients 
to be recruited. Allowing for 5% dropout the required sample size would be 80 
patients, 40 in each arm using a 1:1 ratio. The data will be analysed using 
analysis of covariance which involves adjusting for baseline in order to increase 
the power and to provide narrower confidence intervals. 
 
Patient Enrolment 
It is expected that 90% of the patients will be recruited from Medical Retina 
Clinics in King’s College Hospital and Moorfields Eye Hospital. The rest of the 
patients will be obtained from referrals from local optometrists and other 
ophthalmologists. 
The local optometrists will be made aware of this study and patients with age 
related maculopathy will be informed about the study and referred to the 
screening clinics in the research department of both institutions. Suitable 
patients will be informed of the study verbally and by means of a Patient 
Information Sheet at the research clinics. Patients will be invited to attend a 
clinic dedicated to the study at both institutions after at least 24 hours. At this 
baseline visits written informed consent will be obtained from patients wishing to 
enter the study, prior to enrolment. 
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Withdrawal from Study 
Patients have the right to withdraw from the study for any reason. The 
investigator also has the right to withdraw a patient at anytime due to failure to 
follow protocol, administrative or other reason. 
Randomisation 
Patients are randomised into 2 groups by means of an on-line computerised 
randomisation programme (randomization.com).  The follow-up investigators 
will be masked of the randomization. 
Patient Numbering 
Each patient is uniquely identified by a unique study number.  Once assigned to 
a patient, a number will not be reused. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   188	  
6.6 Population 
6.6.1 Inclusion Criteria 
1. Patients of either sex aged 55 years or over 
2. Diagnosis of age related maculopathy that meet the criteria of large drusen 
(≥125 µ) in at least 1 eye. 
3. Best corrected visual acuity in the study eye between 50 to 90 ETDRS letters 
at baseline visit.  
4. Media clarity, pupillary dilation, and subject cooperation sufficient for 
adequate fundus photographs.  
5. No previous macular laser therapy to study eye. 
6. Written informed consent and willingness and ability to be followed up length 
of study. 
6.6.2 Exclusion Criteria 
1. Drusenoid PED, Choroidal neovascularisation and geographic atrophy in the 
study eye. 
2.. Macular ischaemia (FAZ > 1000µm in diameter or moderate perifoveal 
capillary loss in fluorescein angiogram). 
3. Macular oedema of any cause such as wet AMD, diabetic macular oedema, 
pseudophakic macular oedema or taut posterior hyaloid.   
4. Co-existent ocular disease that in the investigator’s discretion would lead to 
decrease visual acuity by 3 lines or more by end of 12 months.   
5. No coexistent choroidal neovascularization or geographic atrophy in either 
eye.   
6. History of thermal lasers or treatment with intravitreal antiVEGF agents or 
steroids for any retinal conditions in the study eye. 
7. Participation in an investigational trial within 30 days of randomisation that 
involved treatment with any drug including those that has not received 
regulatory approval at the time of study entry.  
8. Anticipated major ocular surgery (including cataract extraction) for the period 
of the trial.  
9. Amblyopia in study eye. 
10. Known allergy to fluorescein dye or to any component of the study drug 
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11. Pregnancy at baseline and the patient will be withdrawn from the study if 
she becomes pregnant during the course of the study. 
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6.7 Summary of study assessments 
Table 6.3 Summary of RETILASE study assessments 
	  
$ at physician’s discretion in all other visits- if choroidal neovascularisation is suspected 
 
 
 
 
 
Time Screening #6 months 
post entry 
#12 months 
post entry  
Informed consent X   
Ophthalmic history  X X X 
Medical history X x X 
Visual acuity X x X 
Contrast sensitivity X x X 
Microperimetry X x X 
Flicker sensitivity X x X 
Ophthalmic 
examination 
X x X 
2 field photographs X x X 
Autofluorescence X x X 
Fluorescein 
angiography$ 
X   
OCT  X x X 
Randomisation X   
Treatment 
X   
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Detailed protocol of study assessments can be found in complete RETILASE 
protocol in appendix. However, several assessments will be highlighted here. 	  
Assessment of Visual acuity 
 
The subjective refraction was performed at 6m using a Snellen chart with the room 
lights on. Following refraction the best VAs were measured at 4m using ETDRS Chart I 
for the right eye and Chart 2 for the left eye in a dark room. Both eyes were refracted at 
the baseline visit and at 12 months. 
The VA in the non-study eye were measured as outlined above and the score recorded 
on the score sheet. If, at one of the follow-up visits, the VA in the non-study eye differs 
by two lines or more from the VA found at the initial visit, the eye would be refracted as 
well, and the VA measurement repeated. 
At the baseline visit, the initial VA were measured with the patient wearing his/her own 
distance glasses or unaided (if patient doesn’t have distance glasses), using ETDRS 
Chart RJChart3. At all follow-up visits the previous study refraction were used with the 
fellow eye lightly patched with a tissue. 
 
Assessment of Contrast Sensitivity 
 
Contrast sensitivity measurements were performed using the Pelli-Robson chart 
(Clement Clarke Inc., Columbus, OH) at a distance of 1 m and chart luminance of 80 to 
120 cd/m2. The right eye will be tested followed by the left eye on charts 1 and 2, 
respectively, with +0.75 D added to the patient’s refraction. The patients were asked to 
name each letter on the chart, starting with the high-contrast letters on the upper left-
hand corner and reading horizontally across the entire line. As low-contrast letters 
could take some time to appear, the patients were given instructions to keep looking 
and not give up too soon. The optometrist would then circle each letter read correctly 
and cross out each letter read incorrectly, with letters not attempted left unmarked. The 
test would be stopped when the patient failed to correctly identify two or more letters in 
a triplet. The letter-by-letter scoring will be used.  
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Assessment of Microperimetry 
 
Microperimetry was performed using the Nidek MP 1 (Nidek Technologies, Padova, 
Italy) device. This instrument allowed the examiner to view the fundus on the computer 
monitor while it is imaged in real time by an infrared (IR) fundus camera (768 x 576 
pixels resolution; 45° field of view). Fixation target and stimuli were projected on to the 
liquid crystal display (LCD) within the MP1 for the subject to view. The examiner could 
also view the stimulus and fixation target as part of the IR image on the computer 
monitor.  
The study eye was tested whilst the contralateral eye was patched during the test. 
Pupils were dilated with one drop each of tropicamide 1% and phenylephrine 2.5% at 
least 15 minutes prior to microperimetry. Microperimetry was performed by an 
experienced examiner. The examination was conducted in a darkened room. The 
following parameters were used: a fixation target consisting of red ring, 1° in diameter; 
white, monochromatic background at 4 apostilb (asb), stimulus size Goldman III, with 
200 milliseconds projection time; and a customized radial grid of 20 stimuli covering the 
central 10° (centred on the fovea), 2° apart (outer stimuli). The starting stimulus light 
attenuation will be set at 10 dB. A 4-2-1 double-staircase strategy will be used with an 
automatic eye tracker that compensates for eye movements. Pretest training was 
performed, and a 5-minute mesopic visual adaptation was allowed before starting the 
test. The mean retinal sensitivity was evaluated within central 10°, covering 
approximately 3 mm of central retinal area on the OCT map. The “9 in 1 layout” printout 
page (or equivalent) produced by the Nidek MP1 software provides indices related to 
microperimetry performance, retinal sensitivity and fixation characteristics will be 
printed out and recorded. The duration of each microperimetry examination and the 
average eye motion speed (º/sec) will also be recorded as indicators of test 
performance. The change in fixation stability and retinal sensitivity were noted. 
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Figure 6.3 Microperimetry  
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Assessment of Flicker Perimetry 
 
The Medmont  perimeter was used to perform static and flicker visual field evaluation of 
the central 10°. The Macula pattern was used.  Targets were 0.5° in diameter, with a 
maximum spot brightness of 320 cd/m2 and was shown on a 3.2 cd/m2 background. 
Spot presentation occurred for 200 ms in static perimetry and for 800 ms in flicker 
perimetry. Thresholding was achieved with a 6/3 dB staircase. 
 
Figure 6.4 Flicker Perimetry 
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6.8 Treatment Regime 
The Principal Investigators of each trial site performed the 2RT treatment.  
Treatment spot size:     400 micron spot 
Total number of laser spots per eye:             A total of at least 25 laser spots  
Energy range:     70 – 120mJ/cm2  
Energy setting:  Energy increased while applying 
test nasal mid-peripheral area 
until a faintly visible spot is 
observed.  
 Reduce the energy to 70% of 
this setting then apply the grid 
pattern 
Contact lens: Area Centralis 1:1 laser contact 
lens (or equivalent) 
 
Treatment Protocol:  
1.   Treatment one: Ellex 2RT, 400µm diameter spot, 2 rings of 
concentric subthreshold laser spots applied, at 2000µm (5 ½ spots 
sizes out from the fovea) and 2800µm (7 ½ spot sizes out from the 
fovea).  So a total of at least 25 spots will be applied.    
OR  
2. No treatment or observation (standard care) 
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Chapter 7  
RETILASE results I. Efficacy Evaluation of RETILASE trial 
7.1 Introduction 
The background to the clinical trial protocol design and the important aspects of 
the clinical trial protocol such as inclusion/exclusion criteria, follow up regime, 
assessments as well as treatment regime have been highlighted. The following 
chapter examines the impact of the 2RT laser on visual function in patients with 
early AMD. 
The primary objective of the RETILASE trial was to determine if the 2RT 
nanosecond laser is a viable option to delay onset of AMD. Secondarily, the trial 
aimed to investigate the extent of the laser damage, in a group of patients with 
early AMD. 
Part 1, chapter 3 to 5 of this thesis demonstrated the release of active-MMP in 
invitro RPE-BrM choroid explants. Furthermore, the laboratory studies have 
correlated the addition of activated MMPs to the increase in hydraulic 
conductivity across the BrM in an age-dependent fashion. The current 
laboratory results have found that a higher level of active MMP was required for 
the same increase in hydraulic conductivity in the older age donor explant 
cultures as compared to the young.  With these earlier encouraging results, it 
would be prudent to ascertain the efficacy of this laser in rejuvenating the retina 
in the elderly human subjects.  
It must be stressed that this laser was theoretically designed to delay or reverse 
ageing changes in the outer retina and thereby possibly delay or retard the 
manifestations of AMD. Due to ethical constraints, the trial was designed to 
treat subjects with early AMD and no advanced AMD in fellow eye. Ideally, 
efficacy measures should have included measurements in changes of BrM or 
changes in transport across the outer retina, however, the only available device 
that allows intricate measurements of changes were the focal flash recovery or 
fundus reflectometer which were not available. Hence, the treatment response 
was monitored using devices that enabled a quantitative measurement of the 
health of the photoreceptor cells.  These included the measurements of visual 
acuity, contrast sensitivity, microperimetry and flicker perimetry.  
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This chapter will focus on evaluating the efficacy of the 2RT laser in 
‘rejuvenating’ the aged retina.  
7.2 Baseline characteristics of trial participants 
7.2.1 Data Sets Analysed 	  
At the onset of this result section, it should be emphasized that the RETILASE 
trial was suspended in 30 May 2012. The reason for suspension was due to 
concerns with regards to autoflorescent changes post laser in treated patients. 
The principal investigators of the trial, upon review of the clinical data collected 
at 6 with independent data monitoring committee (made up of 2 external 
consultants and an independent statistician) felt that the autoflorescent changes 
on FAF suggests that the laser energy applied was not subthreshold as 
previously conceived. (Discussion to follow in next chapter). 
A total of 23 patients have been recruited. 18 patients were recruited from KCH, 
5 patients from MEH.  Altogether, there were 11 treated cases and 12 controls. 
All 23 patients completed both 6 and 12 months follow up. Two controls had 
conversion to wet AMD in the non study eye. By contrast, no cases converted to 
advanced AMD in the treated eyes. 
7.2.2 Baseline Characteristics 
A total of 23 patients have been recruited into this study. Mean age of our 
patients was 72+/−8 years. 65% of the study cohort were females and 35% 
were male. Of the 23 patients recruited, 2 were of Indian ethnicity (9%) and the 
rest were Caucasians (91%). 
Of the 23 patients, 11 patients had been treated with 2RT laser according to 
protocol regime and 12 were controls. The mean age of the cases at time of 
recruitment were 70 +/-10 years whilst that of controls was 75+/-6 years. There 
was one case of Indian ethnicity in each case/control group. 
Overall baseline VA of study cohort was 81.26+/- 5.09 EDTRS letters, and 
baseline contrast sensitivity was 34.57+/-1.90 letters, baseline MP1 at 4 
degrees was 15.60+/-3.65 dB, at 12 degrees was 14.64+/-3.88 dB, and 
baseline flicker perimetry was 2.16 +/-1.79 dB. 
Mean baseline VA for cases was 78.64+/-4.52 letters, whilst that for controls 
was 83.67+/-4.48 letters. It should be noted that there was a problem apparent 
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with the randomization as from table 7.1, the control group had better VA than 
the treatment group. This randomization process was outside the control of the 
investigators. The difference between the groups for contrast sensitivity was 
equivocal. Baseline mean MP1 at 4 degrees was 16.02+/-2.70 dB and for 
controls 14.83+/-4.40dB, whilst the baseline mean MP1 at 12 degrees was 
14.18+-2.91dB for cases and 15.06+/-4.69 dB for controls.  For flicker 
perimetry, the baseline was -2.35+/-2.11 dB for cases and -1.98+/-1.50dB for 
controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   199	  
Table 7.1a Baseline characteristics of study cohort 
 Total No. 
of 
Patients 
(N) 
Mean 
age/  
years 
Ethnicity, 
Caucasia
n /% 
Ethnicity, 
Indian /% 
Ethnicity, 
Africo-
carribean /% 
Controls 12 75+/-6 92 8 0 
Cases 11 70+/-10 91 9 0 	  
Table 7.1b Baseline measurements of study cohort 
 Total 
No. of 
Patients 
(N) 
VA/ 
ETDRS 
letters 
Contrast 
Sensitivit
y/ letters 
MP1 (4 
Deg/dB) 
MP1(12 
Deg/dB) 
FP/dB 
Controls 12 83.67+/-
4.48 
34.83+/-
2.88 
14.83+/-
4.40 
15.06+/-
4.69 
-1.98+/-
1.50 
Cases 11 78.64+/-
4.52 
34.27+/-
3.04 
16.02+/-
2.70 
14.18+/-
2.91 
-2.35+/-
2.11 
 
7.2.3 Morphology of AMD status of patients recruited 
Of the 23 early AMD patients recruited, there were 7(30%) patients classified 
under the AREDS group 2 and 16(70%) in the AREDS group 3. In accordance 
to the IC classification, this translated into 6(26%) patients in the early group 
and 17 (74%) in the intermediate group. 
Of the patient cohort, 3 presented with pseudodruse and 20 had conventional 
hard and soft , confluent druse. 
Of the cases, 3 (27%) were classified as AREDS 2 and 8  (73%) were AREDS 
3, whilst using the IC, 2 (18%) were in the early stages and 9(82%) in the 
intermediate stages. There was 1 patient with psuedodruse. 
In the control group, there were 4 (33%) patients classified as AREDS 2 and 
early IC classification and 8 (67%) patients classified as AREDS 3 and 
intermediate stage of IC classification. 
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Table 7.2a Morphological profile of study cohort 
AREDS 
 
No. 
(n=23) 
IC No. 
(n=23) 
Pseudodruse No. 
(n=23) 
1 0 Early 6 Yes 3 
2 7 Intermediate 17 No 20 
3 16 Late 0   
 
Table 7.2b Morphological profile of cases cohort 
AREDS 
 
No. 
(n=11) 
IC No. 
(n=11) 
Pseudodruse No. 
(n=11) 
1 0 Early 2 Yes 1 
2 3 Intermediate 9 No 10 
3 8 Late 0   
 
Table 7.8c AMD Morphological profile of control cohort 
AREDS 
 
No. 
(n=12) 
IC No. 
(n=12) 
Pseudodruse No. 
(n=12) 
1 0 Early 4 Yes 2 
2 4 Intermediate 8 No 10 
3 8 Late 0   
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7.3 Methods of Analysis of efficacy 
7.3.1 Mean change in VA, Contrast Sensitivity, Microperimetry, 
Flicker Perimetry 
SPSS vers 19.0  was used for the statistics of this study. The mean and 
standard deviation of the entire study cohort was calculated at baseline for VA, 
contrast sensitivity, microperimetry and flicker perimetry. Means of controls and 
cases were calculated at baseline, 6 months and 12 months and change from 
baseline at 6 and 12 months were calculated for the above outcome measures.  
Correlation was done using nonparametric testing (Mann Whitney Tests) 
between controls and cases at 6 and 12 months. P<0.05 was considered 
significant.  
7.3.2 Changes in Fundus Morphology 
Changes in fundus morphology post laser amongst cases were qualified using 
clinical measures by the AREDS and IC classification. In particular, the 
following in terms of percentage change were tabulated: 1. Drusen morphology 
(ie, from soft confluent drusen to hard drusen); 2.Change in drusen size (larger 
to smaller) ; 3. Change in drusen number ; 4. change in area of drusen; 5. 
Change in IC classification; 6. Change in AREDS classification.  Comparison 
between changes in control group and cases were analyzed using the Fischer’s 
exact test. P value <0.05 was considered significant. 
 
Figure 7.1 is a pictorial description of the method of measuring drusen size and 
area. 
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Table 7.9 AREDS classification 
Age-Related Eye Disease Study Age-related Macular Degeneration Levels Defined for 
Eyes 
AMD Level                Criteria 
1                                Drusen maximum size _ circle C-0 (63 _m diameter) and total 
                                  area _circle C-1 (125 _m diameter) 
2                                Presence of one or more of the following: 
                                  (a) Drusen maximum size _ circle C-0 but _ circle C-1 
                                  (b) Drusen total area _ circle C-1 
                                  (c) Retinal pigment epithelial pigment abnormalities consistent 
                                       with AMD, defined as one or more of the following in the 
                                       central or inner subfields: 
                                       (1) Depigmentation present 
                                       (2) Increased pigment _ circle C-1 
                                       (3) Increased pigment present and depigmentation at least   
                                            questionable 
3                                 Presence of one or more of the following: 
                                   (a) Drusen maximum size _ circle C-1 
                                   (b) Drusen maximum size _ circle C-0 and total area _ circle I-2 
                                        and type is soft indistinct 
                                   (c) Drusen maximum size _ circle C-0 and total area _ circle O-2 
                                        and type is soft distinct 
                                   (d) Geographic atrophy within grid but none at center of macula 
4  (Advanced)          Presence of one or more of the following: 
                                (a) Geographic atrophy in central subfield with at least   
                                      questionable involvement of center of macula 
                                   (b) Evidence of neovascular AMD 
                                        (1) Fibrovascular/serous pigment epithelial detachment 
                                        (2) Serous (or hemorrhagic) sensory retinal detachment 
                                        (3) Subretinal/subretinal pigment epithelial hemorrhage 
                                        (4) Subretinal fibrous tissue (or fibrin) 
                                        (5) Photocoagulation for AMD 
Adapted from AREDS Report 6 
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The classification proposed in the ‘International Classification’ 
Method of druse measurement 
Drusen are deposits between the RPE and Bruch’ s membrane with a 
yellowish-whitish appearance on fundus photographs, Drusen appearance, 
ranges from small round, spots in the plane of the retinal pigment epithelium to 
large deposits that have that often become confluent with adjacent drusen. The 
following drusen features are evaluated within the grid (below): 
1. Drusen presence/maximum size:  maximum size (based on diameter, or if 
elliptical, longest dimension) by comparing them with circles C-0 (1/24 disc 
diameter), C-1 (1/12 disc diameter), and C-2 (1/6 disc diameter), nominally 
63µm, 125µm, and 250µm, respectively. 
 
2.  Morphology of drusen: Hard/soft drusen: drusen are placed in either a hard 
or soft category on the basis of uniformity of density (color) from center to 
periphery, sharpness of edges, and thickness: those with decreasing density 
from center to periphery and fuzzy edges are placed in the soft-indistinct 
category; those with uniform density, sharp edges, and a solid, thick 
appearance in the soft-distinct category; and those with sharp edges but without 
a solid, thick, nodular appearance in the hard category. 
 
3. Total number of drusen: Drusen (all types) number within the grid is 
calculated manually in each of the subfields and added together. Confluent 
drusen are considered one drusen if the edges of the druse are not well 
defined. 
 
4.Total area of drusen: Drusen area within the grid: total area covered by 
drusen is estimated by mentally moving together all definite drusen and 
comparing this composite area with those of standard circles and to the 
standard disk. Three areas are graded separately: the central subfield, the 
central zone, and the area within the grid. 
 
5.Reticular drusen:  yellowish material that looks like soft drusen arranged in ill-
defined networks of broad interlacing ribbons. 
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Figure 7.1 Photographic demonstration of measurement of druse size 
using AREDS maculopathy grading grid 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  
 	  	  	  	  	  	  	  
The Age-Related Eye Disease Study maculopathy grading grid, affixed to the 
photograph of left eye of one of the recruited patients at baseline.The grid is 
composed of three circles concentric with the center of the macula and four 
radial  lines in the 1:30, 4:30, 7:30, and 10:30 meridians. The radius of the inner 
circle corresponds to 1/3 disk diameter in the fundus of an average eye, the 
radius of the middle circle to 1 disc diameters, and the radius of the outer circle 
to 2 disc diameters, yielding areas of 4/9 disc diameter, 4 disc diameters, 
and 16 disc diameters, respectively. Nominally these distances are referred to as 
500 _m, 1500 _m, and 3000 _m, respectively, 
in accordance with longstanding clinical convention, even though a more 
accurate estimate of the average disc diameter is 1800 to 2000 _m. Thus, the 
grid defines nine subfields: central; inner superior, inner nasal, inner inferior, and 
inner temporal; and outer superior, outer nasal, outer inferior, and outer 
temporal. Two segments of a horizontal line project from the outermost circle so 
that the grid can be aligned with the horizontal meridian of the fundus as it is 
centered over the macula. 
	   205	  
7.4 Results 
7.4.1 Visual acuity outcome 
6 months outcome 
Comparison of change at 6 months in VA was made between controls and 
cases. A difference between baseline VA of 5.03 between the 2 study groups 
was noted but this was not found to be statistically significant.  
At 6 months, the mean VA of controls 83.33+/-3.73 ETRDS letters, with a 
change from baseline of -0.33 +/-3.28 ETDRS letters, the mean VA of cases 
was 83.73 +/-5.20 ETDRS letters, which was an increase of 5.09+/- 5.67 
ETDRS letters, p=0.023.  
In the control group, 1 (8%) subject had more than 5 letter improvements and 
no subjects had more than 10 letter improvements. 1 (8%) subject had more 
than 5 letter drop from baseline.(Figure 7.3a) 
From Figure 7.3b, at 6 months, there were 8 subjects with VA improvements as 
compared to baseline. 4 (36%) subjects had more than 5 ETDRS letter 
improvements, of which 1 (9%) subject had more than 15 letters improvements 
and 2 (18%) subjects had between 10 to 14 letters improvements. 
No subjects had more than 5 letters drop. In the subjects with more than 5 
EDTRS letter improvements, 3 out of 4 of these subjects had baseline VA< 77 
letters, whilst 1 had baseline VA of 85 letters. 
From Figure 7.2 and 7.3b, a definite trend of VA improvements at 6 months post 
laser treatment was noted amongst cases. 
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12 months VA outcome (Primary outcome) 
At 12 months (primary outcome), the change in VA from baseline for cases as 
compared to controls was 1.73+/-5.00 letters versus -0.25+/4.29 letters, 
P=0.449.  
Of the controls, 1(8%) had more than 5 letter improvement and 2(17%) had 
more than 5 letters drop in VA. 
Of the 11 subjects treated with laser, 7 showed improvements in VA. 4 of these 
7 cases (36%) had more than 5 letter improvements but none had more than 10 
letter improvements. 1 (10)% of patients had a 5 letter drop in VA. 
As compared to 6 months, the VA improvements decreased from 5.09+/-5.67 to 
1.73+/-5.00 letters at 12 months.(Figure 7.2, 7.3b)  
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Table 7.4a RETILASE: MEAN VA baseline, 6 and 12 months 
VA  N Mean SD SEM 
BASELINE 
Control 12 83.67 4.48 1.29 
Case 11 78.64 4.52 1.36 
VA 6 MONTHS 
Control 12 83.33 3.73 1.08 
Case 11 83.73 5.20 1.57 
VA 12 MONTHS 
Control 12 83.42 5.52 1.59 
Case 11 80.82 4.49 1.35 
 
Table 7.4b RETILASE: MEAN change of VA 6 and 12 months 
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  
Change VA  N Mean SD SEM Pvalue 
VA change 6 
MONTHS 
Control 12 -0.33 3.28 0.95  
Case 11 5.09 5.67 1.71 0.023 
VA change 
12 MONTHS 
Control 12 -0.25 4.29 1.24  
Case 11 1.73 5.00 1.51 0.449 
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Figure 7.2 Mean VA, cases versus controls 
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Figure 7.3a Individual plot of change in VA, controls 
	  
 
Figure 7.3b Individual plot of change in VA, cases 
	  
 
 
 
Figure 7.3 a and b shows the individual subject plot of change in VA 
from baseline to 6 and 12 months. A trend of increase in VA post laser 
treatment amongst cases at 6 months was noted. 8 of 11 subjects had 
improvements in VA post laser at 6 months. Of these, 7 of 11 subjects 
showed prolonged VA improvements at 12 months. 
	   210	  
7.4.2 Contrast Sensitivity 
The baseline, 6 months and 12 months difference between cases and controls 
in contrast sensitivity was equivocal. There were no statistically significant 
changes at 6 and 12 months. No definite patterns nor trends were noted from 
the individual patient plot as per Figure 7.4a,b. 
 
Table 7.5a RETILASE: Mean Contrast Sensitivity baseline, 6 and 12 
months 
CONTRAST 
SENSITIVITY 
 N Mean SD SEM 
CONTRAST 
BASELINE 
Control 12 34.83 2.89 0.83 
Case 11 34.27 3.04 0.92 
CONTRAST 6 
MONTHS 
Control 12 34.17 3.43 0.99 
Case 11 34.18 2.89 0.87 
CONTRAST 12 
MONTHS 
Control 12 35.67 3.42 0.99 
Case 11 34.91 4.13 1.25 
 
Table 7.5b RETILASE: Change in Contrast Sensitivity 6 and 12 months 
CHANGE 
CONTRAST  
 N Mean SD SEM Pvalue 
Contrast change 
6 MONTHS 
Control 12 -0.67 1.78 0.51  
Case 11 -0.09 2.66 0.80 0.428 
Contrast change 
12 MONTHS 
Control 12 0.83 2.92 0.84  
Case 11 0.64 3.36 1.01 0.928 
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Figure 7.2a Individual plot of change in CS, controls 
	  
 
Figure 7.4b Individual plot of change in CS, cases 
 
 
 
Figures 7.4a and b shows change in contrast sensitivity of controls and 
cases at baseline, 6 and 12 months. No significant changes at 6 and 12 
months were noted. 
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7.4.3 Microperimetry 
Functional changes can be interpreted as either improvements to the 
photoreceptors as an effect of treatment or defects from laser damage. In this 
study, functional changes was analyzed using microperimetry by assessing 
1. Stability of fixation;  
2. Means at central 4 degrees; 
3. Changes at central 4 degrees;  
4. Means at central 12 degrees and;  
5. Changes at central 12 degrees.  
In all controls and cases, recruited subjects demonstrated central and stable 
fixation at all microperimetric measurements at baseline, 6 and 12 months.  
Means for MP1 at central 4 degrees for controls were noted to have slight 
improvements at 12 months. Baseline MP1 at 4 degrees was 14.83+/-4.40 dB 
which improved to 15.10+/-4.84dB and 16.52+/-2.36dB at 6 and 12 months 
respectively.  
3 of 12 (25%) and 2 of 12 (17%) subjects had more than 2.00dB 
microperimetric defect from baseline at 6 and 12 months.  The results were 
however not statistically significant. 
In contrast, at central 4 degrees, the mean for cases was 16.02+/-2.70 dB at 
baseline, 15.80+/-3.00 dB at 6 months and decreased to 14.61+/-3.43 dB at 12 
months. (Table 7.10, 7.11) Changes between baseline, 6 and 12 months were 
both not clinically and statistically significant. 
At 6 months, 2 of 11 (18%) subjects had more than -2.00dB changes from 
baseline.(Figure 7.5b) At 12 months, 3 of 11 cases had more than -2.00dB 
changes as compared to baseline. (Figure 7.5b) 
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At paracentral 12 degrees, the mean baseline, 6 and 12 month microperimetry 
for controls were 15.06+/-4.68, 14.25 +/- 4.67 and 15.81 +/-3.16 respectively, 
whilst that of cases were 14.18+/- 2.91 dB, 13.51 +/-4.07 and 13.55+/- 3.55 
respectively.  
Mean changes in the control arm was -0.81+/-3.02 dB at 6 months which 
showed slight increase to -0.39+/-2.09 dB at 12 months, p>0.05. For cases, the 
mean changes at both 6 and 12 months were equivocal (-0.67+/-1.86 dB versus 
-0.64+/-2.03 dB). (Table 7.7a,b)  
Mean changes between cases and controls at paracentral 12 degrees were 
neither clinically nor statistically significant. 
Looking at individual patient plot profile, there was apparent pattern of 
improvements in the controls at 12 months, 4 degrees (6 patients improved for 
controls versus 2 for cases 12 months). However, this may be related to the 
‘non-randomization’ process of the recruited subjects. (Figures 7.5a,b; 7.6a,b) 
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Table 7.6a RETILASE: Microperimetry Analysis at 4 degrees, Baseline,6 
and 12 months 
MICROPERIMETRY 
(4) 
 N Mean SD SEM 
MP 1 (4)/dB 
Control 12 14.83 4.40 1.269 
Case 11 16.02 2.70 0.815 
MP 1(4) /dB  
6 MONTHS 
Control 12 15.10 4.84 1.398 
Case 11 15.80 3.00 0.906 
MP1 (4) /dB 
12 MONTHS 
Control 11 16.52 2.36 0.711 
     
Case 11 14.61 3.43 1.035 
 
Table 7.6b RETILASE: Change in microperimetry at 4 degrees at 6 and 12 
months 
 
 
 
 	  
 
 
 
 
 
MICROPERIMETRY 
CHANGE 
 N Mean SD SEM P value 
Change MP1(4) /dB 
6MONTHS 
Control 12 0.271 2.642 .763  
Case 11 -0.227 3.163 .954 0.608 
Change MP1(4)/dB 
12MONTHS 
Control 11 0.610 2.592 .781  
Case 11 -1.41 3.169 .955 0.133 
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Figure 7.3a Individual plot of change in MP1 at 4 degrees, controls 
	  
 
Figure 7.4b Individual plot of change in MP1 at 4 degrees, cases 
 
	  
 
Figure 7.5a, b shows the graphs of changes at 6 and 12 months of individual 
subjects. In the control arm, 6 subjects showed improvements at 12 months 
compared to 2 in cases. However, the poor randomization process may account 
this for. 
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Table 7.7a RETILASE: Microperimetry analysis at 12 degrees, baseline, 6 
and 12 months 
 
MICROPERIMETRY 
(12) 
 N Mean SD SEM 
MP 1(12) /dB 
Control 12 15.06 4.69 1.352 
Case 11 14.18 2.91 0.878 
MP1(12)/dB 
6 MONTHS 
Control 12 14.25 4.67 1.358 
Case 11 13.51 4.07 1.229 
MP1(12)/dB 
12 MONTHS 
Control 11 15.81 3.16 0.953 
Case 11 13.55 3.55 1.070 
 
Table 7.7b RETILASE: Change in microperimetry at 12 degrees, 6 and 12 
months 
Microperimetry 
change 
 N Mean SD SEM P 
value 
Change MP1(12)/dB 
6MONTHS 
Control 12 -0.81 3.02 .871  
Case 11 -0.67 1.86 .560 0.833 
Change MP1(12) /dB 
12 MONTHS 
Control 11 -0.39 2.09 .629  
Case 11 -0.64 2.03 .612 0.748 
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Figure 7.6a Individual plot of change in MP1 at 12 degrees, controls 
 
Figure 7.6b Individual plot of change in MP1 at 12 degrees, cases 
	  	   	  
 
Figure 7.6a and b shows individual patient plot of microperimetric analysis at 
the 12 degrees paracentral macular region at baseline, 6 and 12 months for 
cases and controls respectively. No obvious patterns of changes in 
microperimetry were noted in both cases and controls. 
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7.4.4 Flicker Perimetry 
Flicker perimetric results showed minimal improvements for both controls and 
cases at 6 and 12 months. For controls, the mean change at 6 months was 
+0.28+/-2.195 dB and +0.20+/-2.908 dB at 12 months. 
For cases, at baseline, the mean change at 6 months was +0.37+/-2.59 dB and 
+0.73+/-2.57dB at 12 months. 
Differences between controls and cases were not statistically significant. From 
the plots in 7.7a, b, no definite trends can be elucidated. 
Table 7.8a RETILASE: Flicker perimetry analysis at baseline, 6 and 12 
months 
FLICKER 
PERIMETRY 
 N Mean SD SEM 
BASELINE 
Control 12 -1.98 1.50 0.432 
Case 11 -2.35 2.11 0.636 
6 MONTHS 
Control 12 -1.70 2.26 0.651 
Case 11 -1.98 2.36 0.711 
12 MONTHS 
Control 12 -1.78 3.05 0.881 
Case 11 -1.62 2.40 0.724 
 
Table 7.8b RETILASE: change in Flicker perimetry 
FLICKER CHANGE  N Mean SD SEM P value 
6MONTHS 
Control 12 +0.28 2.20 0.634  
Case 11 +0.37 2.60 0.782 0.833 
12 MONTHS 
Control 12 +0.20 2.91 0.834  
Case 11 +0.74 2.57 0.774 0.347 
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Figure 7.7a Individual plot of change in Flicker perimetry for controls 
 
 
Figure 7.7b Individual plot of change in Flicker perimetry, cases 
	  	  
 
Figure 7.7 a and b shows changes in flicker perimetric analysis for controls and 
cases at baseline, 6 and 12 months. No definite trends were noted in either 
controls or cases. 
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7.4.5 Changes in Fundus Morphology 
Post laser, at 6 months, 3 cases showed changes in drusen morphology, whilst 
5 had decrease in drusen size (as compared to 2 in controls arm).  5 cases had 
a decrease in number of drusen and location of drusen. In terms of 
classification, 2 cases improved from AREDS 3 to AREDS 2, and 3 from the 
intermediate to early groups using the IC classification. 
At 12 months, 2 of 11 of cases showed a change in drusen morphology, whilst 4 
versus 3 cases and controls had decrease in drusen size. 2 cases had 
decrease in drusen number and 5 demonstrated change in drusen location. 
Only 1 case had changed from intermediate to early group under IC 
classification, whilst 2 cases improved from AREDS 3 to AREDS 2. 2 controls 
had worsening in classification status from AREDS 2 to 3, and 3 controls from 
early to intermediate AMD under the IC classification. 
Using the Fisher-exact test, comparision of morphological change in drusen at 6 
and 12 months between controls and cases did not yield statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7.9a RETILASE: Morphological change in drusen at 6 months  
	   221	  
 Morph-
ology  
Size 
(p=0.069) 
Number 
(p=0.069) 
Location  
 
Area  
 
Change 
in IC  
Change 
in 
AREDS  
Con-
trols, 
(n=12) 
6 2 2 6 3 2 1 
Cases 
(n=11) 
3 5 5 5 4 3 2 
 
Table 7.9b RETILASE: Morphological change in drusen at 12 months 
	  
	  
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 Morp-
hology  
Size  Number  Location 
  
Area of  Change 
in IC  
Change 
in 
AREDS  
Controls 
(n=12) 
4 3 1 6 5 3 2 
Cases 
(n=11)  
2 4 2 5 3 2 1 
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7.5 Statistical/analytical issues 
In the analysis of the current dataset, few statistical issues were identified.  
First the study was suspended and hence the number of patients recruited was 
25% of target of a calculated sample size of 80 patients.  Although the number 
of cases versus controls was almost equal, it was difficult to get a statistically 
valuable significance in view of the small numbers in each group. 
Second, we have found a statistically significant improvement in visual acuity at 
6 months in cases. However, the baseline VA was lower in this subgroup 
compared to controls. Despite the early suspension of the study, there was 
clearly a poor randomization process in this study. Randomization was based 
on a computer software (assigned to Kings College Hospital, London, UK, 
Clinical Trial Unit) which allocates each recruited patient in accordance to high 
and low VA to the case and control group randomly.  
Also, the study design did not account for variability in refraction, and each 
patient underwent refraction by single optometrist once. 
Third, we have used the first generation Nidek MP 1 which did not incorporate 
an SLO-tracking system. Hence, it was prone to subjective technician error from 
poor recognition of veins/arteries.  Hence, the comparison of follow up tests 
may not yield accurate results. Furthermore, no repeated testing was performed 
and the results may be subject to an improved learning effect. This also applies 
to flicker perimetry.  
Also, the point-to-point measurement of microperimetric defect may not have 
incorporated areas where the laser was applied. The means of results tabulated 
from the means of 4 readings from and individual at 4 and 12 degrees 
respectively and then averaged amongst the 11 cases and 12 controls. Studies 
have shown the association between structural changes in early AMD such as 
druse and pigmentation and microperimetric defects at individual 
lesions.(Midena et al., 2007) The averaging of results will negate effect of 
abnormal results of individual regions or areas. Hence, graphs has been plotted 
to show the individual patient trend in microperimetric change at 4 and12 
degrees respectively to give an approximate gauge of the status of central 
retinal function of individual patient. 
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7.6 Discussion 
There were 2 aims of this trial, first to determine the efficacy of 2RT in delaying 
or renovating ageing changes in the outer retina, with the hope that if present, 
such changes could delay the onset of AMD; and second, to determine the 
safety of the 2RT laser. The term ‘efficacy’ used here was defined as the effect 
of the laser on visual function and ‘safety’ was defined as proportion of patients 
that converted to advanced AMD or losing vision post laser. In the context of 
this PhD, further detailed analysis was done (for example, evaluating changes 
in AMD morphology) to get more valuable scientific results. At this preliminary 
stage of using the 2RT on human subjects, it was also vital to ascertain the 
impact of the laser on the retina and this would be discussed in the next 
chapter.  
As mentioned earlier in the introduction chapter, the main purpose of laser was 
to rejuvenate the retina at the stage of physiological ageing, however, the 
ethical limits of this clinical trial only permitted the recruitment of patients with 
signs of early AMD, ie, drusen or pigmentary changes. Hence, the results of the 
RETILASE trial could be interpreted as either an improvement in the status or 
AMD or macular function and defects attributable to laser damage.  
The RETILASE trial demonstrated several important findings: 
First, there was trend of visual acuity improvements post 2RT laser in early 
AMD patients at 6 months.  This trend was noted to be both clinically and 
statistically significant. However, the trial showed that the visual effects were 
short lasting, as the VA improvements returned almost to baseline at 12 
months. 
Second, the results did not yield statistically and clinically significant changes in 
visual function tests such as microperimetric analysis and flicker perimetry.  
There were no obvious trends of change noted amongst cases in either visual 
function tests. The current results were different to Guymer and team in 
Melbourne who found improvements in flicker perimetry. This may be attributed 
to the small number of cases analyzed.(Pelosini et al., 2013, Guymer et al., 
2013) 
The current results were surprising considering the good baseline visual acuity 
in our study cohort. A 5 letter increase in this baseline visual acuity may be 
considered clinically significant considering the possible ceiling effect of visual 
improvements in this visual bracket. This improvement in visual acuity was 
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coupled with changes in drusen morphology, number and individual druse size, 
although there were no significant changes in the overall drusen area and the 
respective classification gradings. Visual acuity measurements in early AMD 
subjects are usually 20/20 or within the normal range. Hence, VA 
measurements have not been known to be a sensitive indicator of change in 
this disease subset, especially since only 44% of normal cone complement is 
required for a normal vision.(Midena et al., 2010) Such improvements in VA 
post laser treatment amongst subjects with normal VA may suggest 
improvements in cone function from perhaps the increased nutritional support 
from increased transport across the BrM.  
It may be argued that the difference in visual outcome could be because of the 
lower baseline VA for cases group as compared controls, although this was not 
found to be statistically significant. To account for this difference in baseline VA, 
a graph of individual patient changes was plotted to determine a trend in VA 
change post laser at 6 and 12 months. 
In the RETILASE study, there was no noticeable trend in contrast sensitivity 
over 1 year in both cases and controls. This trial has used the Pelli Robson 
contrast sensitivity chart which contains 16 triplets of 4.9x4.9cm letters. At the 
test distance (1metre), these letters gives a spatial frequency of 1 to 2 cycles 
per degree and there is same contrast within each set of 3 letters. Every letter 
on the chart decreases the scoring results by 0.05 log units. In most 
publications for contrast sensitivity studies, the units of measurements were 
noted to be in log units, however, the RETILASE trial protocol was designed to 
tabulate data in number of letters. That said, reliability studies performed earlier 
on found a significant change in contrast sensitivity score to be 0.30log units or 
6 letters.(Elliott et al., 1990) As such, the current results in the trial did not yield 
both statistical and clinical significance.  Results for contrast sensitivity in early 
AMD has been controversial. Sjostrand and Frisen in 1977 first found 
decreases in high and intermediate frequencies across early AMD, whereas 
Loshin and White in 1984 found decreases in contrast sensitivity across all 
frequencies.(Sjostrand and Frisen, 1977, Loshin and White, 1984) Brown and 
Lovie-Kithchin found depressed contrast sensitivity across all frequencies in 
patients with early AMD as compared to normal, but at all eccentricities 
including the fovea, although a greater loss was noted in higher frequencies 
spectrum.(Brown and Lovie-Kitchin, 1989) In a review by Professor 
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Charkravarthy analyzing results from various studies, they concluded that 
contrast sensitivity was not a good prognostic indicator for progression of 
AMD.(Hogg and Chakravarthy, 2006) 
In this small population, there was no conversion to advanced AMD at 1 year. 
However, it must be considered that the rate of progression of early AMD 
ranges from 0.5% to 50 in 5 years.(Ferris et al., 2013) In a small subset of 
patients followed up, it is not surprising that there is 0% of conversion to 
advanced AMD in the study eye. Hence, the current results must be interpreted 
with caution.  
Microperimetry was measured at central 4 and paracentral 12 degrees in this 
clinical study. Studies have shown the decrease in perimetric means in the 
central 0 to 5 degrees as compared to outer eccentricities.(Parisi et al., 2007) 
These findings were coupled with histological evidence of parafoveal rod death 
and decreased density of photoreceptors noted even in early AMD 
patients.(Curcio et al., 1996, Owsley et al., 2000) In this study, firstly, the mean 
microperimetric analysis was higher than findings in other studies. (15.60 at 4 
degrees and 14.64 at 12 degrees as compared to 5.83 and 6.43 dB in central 
and paracentral retina)(Parisi et al., 2007) but lower than the normal age-
matched population as determined in a normative study by Sabates et 
al.(Sabates et al., 2011) This could be because of the earlier stages of early 
AMD in this current patient cohort as compared to previous studies. Second, in 
keeping with the current knowledge of age related changes in photoreceptor 
cells in different eccentricities, the mean microperimetric analysis for both cases 
and controls at baseline were noted to be lower at the central 4 degrees as 
compared to 12 degrees. However, there was no observable trend of 
improvements at 6 or 12 months in both cases and controls. The current results 
were taken as means of 4 individual points in each of the annular ring of 4 and 
12 degrees and as such, any individual points of defects secondary to druse or 
pigmentary changes may be averaged out. This is because the deposits from 
druse will cause a loss of contact between photoreceptors and RPE and hence 
discrete photoreceptor cell loss.  The concept as introduced earlier in this thesis 
is based on the previous findings that deposits are found diffusely in the BrM, 
causing a hydrophobic layer and decreased nutrient load to photoreceptor 
cells.(Chen et al., 1992) Thus, in theory, there should be a diffuse decrease in 
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macular function even in very early stages of AMD before visualization of any 
clinical hallmarks of AMD. 
Flicker sensitivity has been used in research previously as a measure of early 
AMD. However, the results have not been convincing. Flicker sensitivity is 
based on the theory on adding stress to photoreceptor cells by increasing 
metabolic demand from the flicker. In the RETILASE study, there was no 
obvious pattern or trend discernable both in cases and controls. 
It would have been ideal to grade total drusen area on not only on CFP on our 
study cases, however, in our study cohort, there were few patients with 
countable drusen to determine a viable outcome. Another novel option would be 
to determine drusen volume on OCT and/or BrM thickness. However, current 
OCT technology has a X-Y axis of maximum resolution of 7µm, which first 
would not be reliable and accurate in determining the Bruch’s as it is on an 
average in the elderly age group without advanced AMD between 5 to 7µm. 
Also, considering the anatomy of druse to be between RPE and inner 
collagenous layer of Bruch’s, without defining the base of drusen, it would be 
impossible to accurately determine drusen volume. 
Given the concoction of all the various ways to analyze improvement in visual 
function and retinal morphology post 2RT last, it appears that the only objective 
result obtained is the improvements in visual acuity at 6 months amongst cases. 
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7.7 Conclusions 
In conclusion, despite the small number of participants in this clinical trial, the 
results suggest a possible benefit of using the nanosecond laser technology as 
a therapy. The clinical elements has drawn the following conclusions: 
1. Randomization process in this trial has compromised the validity of the 
results;  
2. The results showed benefit at 6 months which tailed off by 12 months, 
which imply that repeat lasers can possibly be required. 
Further larger scale trial and dose escalation studies are required to define the 
laser parameters for maximal effects.  
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Chapter 8 
 RETILASE Results II. Safety of the 2RT laser in patients with 
early AMD 
8.1 Introduction 
In the last chapter, the 6 and 12 months visual function data of the RETILASE 
trial data was analyzed. Despite the small numbers, there was a positive trend 
in visual improvements post laser treatment at 6 months. Analysis undertaken in 
this chapter aimed to determine the ‘safety’ of the 2RT laser as a prophylactic 
therapy in AMD.  The analysis of ‘safety outcome’ as per the original RETILASE 
trial protocol (chapter 6) was based on the measurements of the following 
between the cases and controls: 
1. Proportion of patients developing CNV at 12 months. 
2. Proportion of patients developing retinal atrophy as measured by 
autofluorescence and OCT at 12 months 
3. Proportion of patients who lost more than 15 ETDRS letters at 12 
months. 
4. Proportion of patients who lost more than 30 ETDRS letters at 12 
months. 
5. Any other complications observed at 12 months. 
However, due to the early termination of the study, this analysis would not yield 
any sensible results. In fact, none of the subjects that underwent laser 
developed any of the above. 
Despite this, it was still crucial to evaluate the impact of the nanosecond laser 
on the retina, particularly as no studies had yet undertaken a detailed clinical 
analysis of the use of the 2RT laser in human subjects. As such, analysis in this 
chapter was undertaken to define the structural and functional impact of the 
laser in human subjects with early AMD.  
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8.2 Methods of Analysis of Safety 
Analysis attempted in this chapter evaluated the clinical imaging obtained 
during the study for structural and functional changes post laser. Images 
obtained from FAF (Heiderlberg, Germany), OCT (Spectralis, Heiderlberg) and 
CFP (Topcon) were analyzed for any structural changes, whilst functional 
changes were assessed using the Microperimetry (Nidek, MP1) According to 
the protocol, our 23 recruited patients had at least baseline, 6 months and 12 
months clinical imaging acquired. However, in the interim leading to suspension 
of the study, some patients were recalled for monitoring purposes. Altogether, 2 
patients had further 1 month follow and 2 patients had further 3 month follow up 
images taken. 
 
8.2.1 Fundus Autoflorescence 
Parameters of the FAF images obtained were in accordance to the RETILASE 
trial protocol. (Appendix) 
FAF changes were analyzed both qualitatively. FAF images were obtained from 
the Heiderlberg software on the FAF machines and saved as JPEG images. 
Saved images were imported into image J(NIH) for viewing and analysis.  
Changes were described as hypo or hyperflorescence. Hypoflorescence was 
defined as reduction of normal florescence whilst hyperflorescence was defined 
as increase of normal florescence.  
6 and 12 month images were compared to baseline images to identify changes 
due to laser. 
8.2.2 Optical Coherence Tomography 
Parameters of the OCT images obtained using the Spectralis OCT machine can 
be found in the RETILASE trial protocol. (Appendix) 
OCT images were initially viewed on the Spectralis machine and exported as a 
series of JPEG images. Saved images were imported into image J(NIH). 
To compare changes noted on FAF images and corresponding OCT, FAF 
images were overlayed on the infra-red segment of the spectralis OCT scan 
using the overlay modality on image J(NIH). (Figure 8.2) Both FAF images and 
the infra-red scans were both taken at 40 degrees field of view mode. FAF 
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image was adjusted to align the retinal vasculature between the 2 images. This 
method can only give an approximate alignment of corresponding location. 
Each line scan of the 49 OCT scans were analysed for approximate 
corresponding changes to laser lesions noted on FAF. When grading images, it 
was noted that segmentation of outer retina is currently impossible as the 
highest resolution of OCT is in the range of 10-14µm (despite claims of a 3µm 
resolution as noted in investigator’s brochure from Heiderlberg). Hence, the 
analysis presumed and grouped structures as a complex such as the RPE-BrM 
complex. (Figure 8.3) In particular, structural defects were graded in 
accordance to the following: 
Changes to neurosensory layer 
1. Disruption of presumbed IS/OS junction 
2. Disruption of presumbed ELM 
3. Increased reflectivity of INL 
Changes to outer retina 
4. Changes to RPE-Bruch’s membrane complex 
5. Increased transmission to choriocapillaries 
OCT Changes corresponding to hyper and hypoflorescent areas on FAF were 
described separately. 
 
Figure 8.1 OCT and infra-red image obtained from Spectralis 
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Figure 8.2 FAF and infrared overlay 
     
 
 
Figure 8.3 Presumed OCT anatomical layers as defined in this thesis 
(Magnified image) 	  
 
 
 
Overlay of FAF and infra-red 
image of OCT. 
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8.2.3 Color Fundus Photography 
FAF images were taken at 40 degrees field of view, whilst CFP images in this 
study were taken at 30 degrees.  
Hence, laser lesions on CFP were recognized and compared to FAF changes 
by approximating its location in terms of proximity to the different retinal 
vasculature. 
CFP images were saved as JPEG and imported into image J(NIH). Using 
known scales, diameter of individual laser lesions were measured using the 
semi-automated ‘analyze’, ‘measure’ function on image J. 
Corresponding laser lesion on FAF were described for the visibility of laser 
lesion on CFP, size and association with pigmentation. 
8.2.4 Microperimetry 
Functional changes post laser were measured across individual laser lesion. 
This analysis was undertaken in 2 ways. First, means of perimetric changes at 4 
degrees and 12 degrees respectively for each of the types of laser lesion as 
recognized on FAF were tabulated (assuming that there would be different 
patterns of laser lesions). In this thesis, a term ‘global functional defect’, which 
‘means overall effect from laser’ was coined to refer to this.  
Second, perimetric changes at 6 and 12 months across individual laser lesions 
were tabulated. 
It was noted that the location of test-retest reliability using this MP1 system 
(NAVIS software, 1.72, Nidek Technologies) did not correspond in many of the 
follow up images, although an exact proportion was not calculated here. Hence, 
to ensure accurate tabulation of results, 2 main criteria must be met. 
First, to ensure measurements were taken at the correct target, distance 
between the nasal 12 degree MP 1 target was measured from the optic disc at 
baseline. Similar measurements were taken at the exact location for the 6 and 
12 month MP 1 images. Only images with exact corresponding distances were 
analyzed.  
Second, to determine corresponding perimetric results across individual laser 
lesion, the ‘overlay’ technique using image J (NIH) was used. By comparing 
images of FAF and the MP1, only perimetric stimulus that corresponded exactly 
with laser lesions were tabulated. (Figure 8.4) 
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Figure 8.4 Demonstration of MP1 analysis 
Figure 8.4a 
 
Figure 8.4b 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
Figure 8.4a,b demonstrates the analysis of functional changes across individual 
laser lesion using the Microperimetry system (MP1, Nidek Technologies). 
2 criterias must be met for the analysis. 1. MP1 images to be compared must 
have the stimulus directed at exact point-to-point location, ie,  all 20 points on 
MP1 must be taken at the same location. For example, in Figure 8.4a, the 
distance from nasal edge of optic disc to stimulus must be same in both 
comparing images. (Distance of A=B) 
Figure 8.4b shows overlayed FAF and MP1 images. Individual points of 
perimetric measurements were taken only if they were directly corresponding to 
laser lesion.  
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8.3 Summary of Results of Safety Analysis 
Due to constraints of the design of the clinical trial, images were obtained 
mainly at 6monthly intervals for 12months. Hence, the results and following 
images were at most reflections of possible temporal changes at 6 months and 
beyond. In the following, it was not possible to assess the dynamic wound 
recovery process.  
Although there were mainly 6 monthly follow up images for 12 months, during 
the recall period, additional follow up images, one of which extended to an 18-
month period had been taken and analyzed. Of the cases analyzed, only 1 was 
of Indian ethnicity, others were Caucasian with average pigmentation of the 
patients, 7 had 0.1mJ of energy per laser spot, 2 had 0.3mJ, 1 had 0.17mJ and 
1 had 0.19mJ. Number of laser shots ranged between 52 to 102 shots. 
8.3.1 Changes on Fundus Autoflorescence 
FAF laser lesions were described as hyperflorescent or hypoflorescent. Inferring 
from Marshall’s findings on the zones of laser damage on the RPE, laser 
lesions undergo dynamic changes with time as per figure 8.5a. In the early or 
acute phase post laser, there is a whorl of disintegrated RPE structure from 
laser damage in the center (zone 1), RPE migration in surrounding zone (zone 
2) and distinct shrinkage of cells in the periphery (zone 3), (figure 8.5b). With 
recovery, the laser damage center area decreases with a larger zone of 
migrating RPE. The size of laser lesion was notably reduced. Complete laser 
recovery involved complete wound healing with reestablishment of single 
amelanotic RPE layer.  
3 Distinct types of laser lesion patterns on FAF were observed. These patterns 
corresponded to the changes described above at different time points. This 
indicated a varying severity of laser damage and recovery which might have 
been laser dose dependent. These laser lesion patterns were broadly classified 
into the following (Table 8.1, Figure 8.6) 
Figure 8.7 shows a full fields FAF demonstrating the effect of varying energy 
levels on the uptake on FAF. Suprathreshold laser lesions were noted at 12 
months as hyperflorescent type I pattern with evidence of zone 1, 2 and 3 laser 
damage, whilst threshold lesion were comparable to hyperflorescent type II 
lesion with evidence of zone 1 and 2 and subthreshold lesions (70% of 
threshold, as per protocol) were noted as hypoflorescent laser lesion. 
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Of the 11 subjects treated, 6 presented with mainly the first pattern 
(hyperflorescent type I laser lesion), 3 with mainly the second pattern 
(hyperflorescent type II lesion); and 2 subjects had hypoflorescent laser lesions. 
The 3 types of FAF patterns did not demonstrate a direct relation to visual effect 
but when compared with MP1 changes at 12 degrees: type II and III showed 
improvements at 12 months, as compared to group I. (further described below) 
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Figure 8.5a Recovery of RPE damage post laser 
	  
	  
 
 
 
 
Figure 8.5a shows the temporal recovery of RPE laser damage in different time series. 
Zone A is the zone of highest energy from the incident laser beam with degenerate RPE 
cells in the center; Zone B shows a ring of pigmentation and zone C shows an area of 
hyperflorescence from shrinkage of cells and oedema in the periphery. From day 2, zone 
A becomes smaller. Note that from day 4, the ring of pigmentation disappears and is 
replaced by a few layers of pigmented cells, which represents cell migration. This layer 
increases in size with the recovery period.  (Marshall 1967) 
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Figure 8.5b Dynamic Process of RPE laser lesion recovery   	  
 
 
 
Table 8.1 FAF classification of 2RT laser lesions 
Classification Description 
Hyperflorescent 
type I 
Visible areas of zone 1 + 2 + 3. 
Hyperflorescent 
type II 
Visible areas of zone 1+ 2 only 
Hypoflorescent Visible areas of zone 2 only 
 
 
 
 
 
 
 
 
 
 
	   	   	   1. 2. 
3. 
	  	   	  
A. B. C. 
	  
Figure 8.5b , A to C shows the dynamic process of RPE wound healing post laser induced 
injury.  Arrows point 1. Illustrates zone of laser damage and was seen as hyperflorescence 
on FAF; 2. shows zone of RPE migration which was noted as rim of less intense 
hyperflorescence on FAF and zone 3. demonstrates cell shrinkage and ‘pulling away’ which 
was seen as intensely dark hypoflorescence on FAF.  
A. shows the initial or acute phase where there was centre laser damage with surrounding 
migrating RPE cells and shrinkage in the periphery.  
B. shows mid-recovery of laser lesion with larger zone of migrating RPE cells and smaller 
laser lesion. 
C. shows recovery of laser lesion with complete zone of single layer of amelanotic RPE cells. 
The zones of recovery are similar to the flat mount histology of RPE laser damage in figure 
8.5a with increase in RPE migration with increasing recovery period. 
 
	   238	  
 
Figure 8.6 A-C FAF classification of laser lesions  
 
 
 
Figure 8.7 Full fields FAF image at 15 months post laser 	  
 
 
 
 
 	  
Figure 8.7 shows a fullfields FAF image taken at 15 months 
post laser. T: threshold lesion; SubT: Subthreshold lesion 
with laser energy at 70% of threshold energy; ST: 
suprathreshold lesion 
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8.3.2 Optical Coherence tomography 
FAF superimposed on OCT allowed an approximate analysis of individual laser 
lesion. There were notable differences in OCT patterns in each of the different 
FAF groups.  
All laser lesions showed effects limited to the RPE-BrM complex at 6 months. 
There were no involvement of the INL nor CC and no loss of photoreceptor cell 
layers (ie, ELM, IS/OS layer). Main changes were described as a focal elevation 
of the RPE-BrM complex which appeared intensely florescent. 
Differences between the types of laser lesions can be described in terms of the 
depth of the focal elevation of the RPE-BrM complex. 
Laser lesions in type I showed focal the elevations of the RPE-Bruch’s 
membrane complex with a larger depth. These lesions have a ‘dome-shape’ 
which decreased in size with time. Hyperflorescent oval lesions were noted 
above some laser lesions. These were similar to lesions previously described 
by Duker et al as pigment migration. Furthermore, there were few defects noted 
in the presumed IS/OS junction and if so, these changes recovered by 12 
months. There was no involvement of the INL nor CC. There were no obvious 
signs of atrophy. Although in the single patient with Indian ethnicity, there was 
‘scalloping’ of the inner retina, which worsened at 12 months. There was no 
notable coinciding hypoflorescence on FAF, however the functional change on 
MP1 for this particular lesion was not mapped. (Figure 8.10a) 
The OCT changes for type II was subtler, with a smaller depth of the focal 
elevation whose appearance was better described as ‘ripples’ of the RPE-
Bruch’s membrane layer. These changes decreased in size at 12 months. 
(Figure 8.10b) 
Hypoflorescent laser lesions were either not visible or showed mild ‘ripples’ at 6 
months (smaller depth than hyperflorescent lesions) which again decreased in 
size or disappeared by 12 months. (Figure 8.10c) 
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8.3.3 Color Fundus Photography 
In FAF type I classification, laser lesions were noted as pale laser marks with or 
without central pigmentation at 6 months. 4 of the 6 patients had lesions with 
central pigmentation at 6 months, some of which disappeared by 12 months. 
The lesions remained stable in size at 12 months (266 to 269µm). It is of note 
that the mean of laser lesion size was smaller than the 400µm spot size of the 
laser beam. 
In type II lesions, smaller laser lesions were noted at 6months which decreased 
in size at 12 months (159µm vs 129µm). None of the lesions showed 
pigmentation. 
In hypoflorescent laser lesions, no visible laser lesions were noted on CFP.  
 
Figure 8.8 Comparison of laser lesion on CFP and FAF 
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Figure 8.9 Evolution of laser scars on CFP 	  
	  	  	  	  
 
 
Table 8.2 RETILASE: Mean diameter of laser lesion on CFP 
FAF 
classification 
No. of laser 
lesions 
measured, 6 
months 
Mean of 
laser lesions 
at 6months 
+/- SD/µm 
No. of laser 
lesions 
measured, 
12 months 
Mean of 
lesions at 12 
months +/-
SD/µm 
Type I 91 265.98+/-
88.15 
91 269.55+/-
105.66 
Type II 33 159.58+/-
38.55 
28 129.18+/-
34.86 
 	    
	  
Figure 8.9 shows color fundus photographs of patient with type I laser lesion at 
baseline, 1, 6 and 12 months. 
At one month, some laser lesions had central pigmentation. By 6 months, 
pigmentation disappeared. There was a decrease in size and number of visible 
laser lesions. At 12 months, size of individual laser lesion decreased further. 	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Figure 8.10a Example of Hyperflorescent type I laser lesion 
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Figure 8.10a shows the CFP, FAF and OCT images of hyperflorescent type 
I laser lesions. 
Figures labeled A,B,C shows temporal sequence post laser at baseline, 1 
month ,6 months and 12 months respectively. This patient is of Indian 
ethnicity and has confluent soft druse on fundus examination at baseline. 
A1-3 shows 1. decrease in drusen load over time and 2. pale laser lesion 
which becomes smaller over time. (White arrow points to laser lesion) 
FAF shows hyperflorescent laser uptake of various shapes and sizes. Note 
increase of hypoflorescent rim over time 
C1-3 shows infrared image on right and OCT on left. Infra-red shows 
hyperflorescent laser lesion. 
Note the involvement of inner nuclear ayer without FAF changes of atrophy. 
(white arrow) Also note the hyperflorescent discrete lesion above a laser 
lesion which has decreased in size by month 12 (yellow arrow). Boxed areas 
are laser lesions which show a decrease in size both axially and laterally 
with time. 
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Figure 8.10b Example of hyperflorescent type II laser lesion 
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Figure 8.10b shows CFP, FAF and OCT of type II hyperflorescent laser 
lesions. A2-3 shows faint laser lesions (arrow). Not all laser lesions on 
FAF showed up on CFP.  
B2 shows laser lesion on FAF at 6 months. Note the comparatively 
thicker rim of hypoflorescence (as compared to type I laser lesions). C2-
3 shows laser lesion as hyperflorescence on the infrared images. Note 
the hyperintense thickening or ‘rippling’ of the RPE-BrM complex 
(magnified image) at 6 months. This hyperintense thickening decreased 
in size at 12 months. 
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Figure 8.10c Example of hypoflorescent laser lesion 
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Figure 8.10c shows the CFP, FAF and OCT images of hypoflorescent laser 
lesions.  
A1-3 did not show any obvious laser lesions. B1-3 FAF image shows laser lesion 
uptake as hypoflorescence. Arrow pointing to laser lesion. C1-2, infrared did not 
show any change at 6 months. No obvious OCT structural changes was noted at 
6 months. 
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8.3.4 Microperimetric analysis of laser lesions 
Type I hyperflorescent laser lesions were found to have “global functional 
defect” at 12 months at both 4 and 12 degrees. However, type II lesions showed 
improvements in function at 12 months only at 12 degrees, +1.27+/-0.74, 
p<0.05. Hypoflorescent laser lesion also showed mild improvements at 12 
months at 12 degrees. Although this was statistically significant, it was not 
clinically significant, +0.40+/-0.42, P<0.05. (Table 8.2a,b) 
Tabulating data from individual laser lesions, type I lesions showed significant 
defects at 12 months, -0.86+/-2.74, p<0.05. Type II and hypoflorescent patterns 
were found to have functional improvements both at 6 and 12 months, of which 
type II lesions demonstrated greater improvements quantitatively. (+2.64+/-2.29 
vs +1.00+/-2.83 at 6months) and (+2.80+/-1.81 vs +0.70+/-2.67 at 12 months) 
(Table 8.3) 
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Table 8.3a RETILASE: change in MP1 at 4 degrees for laser lesions 
 N (no. 
patient
) 
MP1 
baseline 
MP1 6 
months 
MP1 12 
months 
MP1 
Change 
6month 
MP1 
change 
12 
month 
Hyperflorescent 
I 
6 15.79+/-
3.52 
16.46+/-
3.23 
13.42+/-
4.10 
+0.67+/-
2.71 
-2.38+/-
3.28 
Hyperflorescent 
II 
3 16.17+/-
2.27 
16.17+/-
2.45 
16.25+/-
2.39 
0+/-3.88 +0.08+/
-3.89 
Hypoflorescent 2 16.50+/-
0.00 
13.25+/-
3.18 
15.75+/-
1.77 
-2.75+/-
2.48 
-0.75+/-
1.77 
P value     0.254 0.604 
 
Table 8.3b RETILASE: change in MP1 at 12 degrees for laser lesions 
 N (no. 
patient) 
MP1 
baseline 
MP1 6 
months 
MP1 12 
months 
MP1 
Change 
6month 
MP1 
change 
12 
month 
Hyperflorescent 
I 
6 14.57+/-
3.61 
14.15+/-
4.34 
12.63+/-
4.27 
-0.42+/-
1.34 
-1.93+/-
1.84 
Hyperflorescent 
II 
3 13.60+/-
2.91 
12.87+/-
5.73 
14.87+/-
3.33 
+0.93+/-
3.25 
+1.27+/-
0.74 
Hypoflorescent 2 13.90+/-
0.71 
12.55+/-
0.78 
14.30+/-
1.13 
-1.35+/-
1.49 
+0.40+/-
0.42 
P value     0.591 0.018 
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Table 8.4 Individual laser lesion MP1 defect 
 N (no. lesion) MP1 
baseline 
MP1 6 
months 
MP1 12 
months 
MP1 
Change 
6month 
MP1 
change 
12 
month 
Hyper-
florescent I 
n=20(6months); 
n=14(12months) 
13.25+/-
5.37 
13.25+/-
5.29 
14.57+/-
4.11 
+0.5+/-
3.36 
-0.86+/-
2.74 
Hyper-
florescent 
II 
n=11(6months); 
n=10(12months) 
13.73+/-
5.48 
16.36+/-
6.15 
16.10+/-
4.28 
+2.64+/-
2.29 
+2.80+/-
1.81 
Hypo-
florescent 
n=10 (6, 12 
months) 
14.4+/-
1.58 
15.4+/-
2.80 
15.1+/-
2.56 
+1.00+/-
2.83 
+0.70+/-
2.70 
P value     0.056 0.008 
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8.4 Discussion 
In this study, different noninvasive retinal clinical imaging modalities such as 
FAF, OCT, CFP and Microperimetry were used to identify both structural and 
functional changes post laser. The analysis of the current data was a reflection 
of the static wound healing process at 6 and 12 months, which may well 
implicate the longer-term prognosis of laser effects. However, the current 
results did not allow a definition of the temporal-dynamic wound healing process 
because of the study design.    
Based on observations of laser changes on FAF, laser lesions were classified 
into 3 patterns: 1. hyperflorescent type I; 2. Hyperflorescent type II and 3. 
Hypoflorescent type-lesions. 
Hyperflorescent type I lesions showed variable degree of damage on the 
photoreceptor cells, as demonstrated structurally and functionally. This 
indicates overtreatment of subjects. Type II laser lesions demonstrated partial 
wound healing with a less exaggerated damage profile. There was no 
involvement of photoreceptor cells. Hypoflorescent laser lesions were probably 
ideal and could have represented almost complete healing at 6 months. 
This classification reflects the differential wound healing response, which gives 
an indication of the severity of the initial impact of laser upon the individual 
subjects. 
From the OCT data, it was observed that most changes were focal to the RPE-
Bruch’s membrane complex. There was limited extension beyond the IS/OS 
junction and into the choriocapillaries. Previous histological evidence using cw 
argon laser of monkey and human retina demonstrated necrosis of RPE and 
lifting of RPE from BrM with subsequent budding, migration and proliferation of 
RPE cells to form multi-layered RPE in area of laser irradiation 7 days post 
treatment.(Marshall and Mellerio, 1967, Marshall and Mellerio, 1968) There was 
evidence of intrusion into the choroidal layers. In an animal model that 
underwent selective RPE photocoagulation, the initial wound healing 
histological results were similar to those described above. This suggests all 
retinal lasers, regardless of time domain, undergo a similar wound healing 
process.(Framme et al., 2008) Thus, the OCT changes observed in the current 
results could be a reflection of the histological changes observed previously, 
with ‘thickening of RPE-BrM complex’ represents part of the healing process 
which led to the formation of a multilayered RPE structure.  
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Previous studies have shown that autoflorescence noted on FAF was from the 
lipofuscin within RPE as a byproduct of phagocytosis of photoreceptors. In 
general, fundus autoflorescence changes may be described as hyper or 
hypoflorescent. Previous studies with conventional lasers, patterned lasers and 
selective retinal therapy(SRT) have found laser lesions to be immediately 
hypoflorescent and then hyperflorescent and back to hypoflorescent over a 
period of 1 week to 15 months. (Midena et al., 2007, Vujosevic et al., 2010) This 
was presumed to be RPE atrophy because of irreversible denaturation of 
photoreceptor cells.  
In the case of the hyperflorescence noted after the 2RT laser, an alternative 
explanation may be suggested. The current observations may be because of 
increased metabolic activity from the wound healing process which resulted in 
increased turnover and higher quantity of lipofuscin formation. This increased 
lipofuscin levels were noted as hyperflorescence on FAF.  
Conventional lasers were found to become hypoflorescent with time with 
corresponding atrophic changes. This was not noted in the data set over a 12 
month period in this study. 
Microperimetric analysis on individual laser lesions have found minimal defects 
in type I lesions, but improvements in type II and hypoflorescent lesions. It was 
noted that type II lesions had greater perimetric improvements than 
hypoflorescent lesions. This reason for this is unknown but may be explained if 
type II lesions had sufficient energy to cause a larger impact than 
hypoflorescent lesion but limited enough not to result in over-treatment as in 
type I lesions.  
It was noted that in this study, the energy laser levels have been limited to 
within a small range, hence, such changes can only be accounted for by the 
differences in individual and intra-individual melanin and perhaps lipofuscin 
content, the latter exaggerated in this subgroup of patient profile. 
There was a single patient with extension between inner retina and outer retina 
on OCT which extended beyond 12 months. There was no corresponding FAF 
hypoflorescence to suggest atrophy. This changes may be explained as a gliotic 
change instead of atrophy as previously described by Tso et al or longer term 
atrophic changes where FAF changes would become obvious over 
years.(Wallow and Tso, 1973a) This was the only patient in this study subset of 
Indian ethnicity and it was noted that almost his entire macular was covered 
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with soft confluent druse. This suggests that first the level of melanin and 
second, the impact of lipofuscin plays a crucial role in energy absorption and 
subsequent impact of these selective modern lasers.  
The full fields image with peripheral laser test shots of supra threshold, 
threshold and subthreshold energy demonstrated the impact of energy levels 
with FAF changes, with suprathreshold as hyperflorescence with rim of 
hypoflorescence and subtreshold as hypoflorescence. Hence, in the same light, 
the FAF changes may be secondary to varying levels of laser energy 
absorption. 
The design of this laser with the speckled beam profile initially aimed to prevent 
secondary death of photoreceptor cells. The large spot size of the nanosecond 
laser was designed to circumvent the problem of narrow therapeutic index from 
ultra-short pulsed lasers. Although results from chapter 2 did not find a 
‘speckled’ laser beam configuration, the current data did not demonstrate gross 
structural nor functional defects even with the presumed overtreated subjects 
(ie, type I laser lesions). 
Several caveats were identified in the analysis of this study. First, the study had 
a very small sample size and majority of the laser energy and number of laser 
spots applied was within the same range. Analysis was attempted but failed to 
show an association between laser spot numbers, laser energy, laser lesion 
pattern and VA. Hence, it was not possible to determine the effects of varying 
laser energy and/or number of laser spots in this pilot study.  Also, the study did 
not have a huge variation in ethnicity to account for the changes secondary to 
pigmentation. More importantly, other than the few images obtained during 1 
and 3 month from subject recall, most of the earliest images were acquired at 
the 6th month when most of the effects of laser would have settled. It would 
have been ideal to determine changes acutely at 24 hours, 3 days, 1 week, 1 
month and every 3-month thereafter where the laser healing process may be 
properly monitored. 	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Table 8.5 Classification of Q switched nanosecond laser changes based 
on FAF findings 
FAF 
classification 
Structural changes Functional 
Changes 
 OCT CFP Infra-red Micro-
perimetry 
Hyperflorescent 
type I 
 
At 6 months, 
thickening of 
RPE-Bruch’s 
membrane 
complex 
noted which 
decreases 
with time. 
Variable 
disruption of 
IS/OS 
junction. No 
involvement 
beyond IS/OS 
junction.  
Pale laser 
lesion with or 
without central 
pigmentation, 
which is stable 
in size at 12 
months. 
Hyperflorescent 
laser lesion. 
Functional 
defect in laser 
lesion noted 
at 12 months. 
Hyerflorescent 
type II 
At 6 months, 
‘mild 
thickening’ of 
RPE-Bruch’s 
membrane 
complex. No 
involvement of 
IS/OS 
junction. At 12 
months, 
changes 
become less 
obvious. 
Variable uptake 
of pale laser 
lesion. Laser 
scar smaller in 
size than type I. 
Absence of 
pigmentation. 
Lesion 
decrease in 
size at 12 
months. 
Laser lesions 
noted as hyper-
florescence. 
Improvements 
in function 
both at 6 and 
12 months. 
Hypoflorescent At 6 months, 
either no 
change or 
mild ‘rippling’ 
at RPE-
Bruch’s 
membrane 
complex with 
no 
involvement of 
IS/OS 
junction. 
Changes no 
longer 
apparent at 12 
months. 
No visible laser 
lesion. 
No visible 
lesion 
Functional 
improvements 
in individual 
laser lesions 
at 6 and 12 
months. 
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Table 8.6 FAF classification and implications 
FAF 
Classification 
IMPLICATIONS 
Hyperflorescent 
type I 
1. Laser wound healing effects may be prolonged. 
Damage mainly limited to RPE ,with variable effects 
on IS/OS.  
2. Wound healing effects may be prolonged. 
3. Threshold of damage limited by inter and intra 
patient variability. 
4. May result in functional defects long term in highly 
pigmented patients. 
 
Suggest Gross Laser overtreatment 
Hyperflorescent 
type II 
Milder response than type I with faster wound healing 
response and improvements in function. 
Mild laser overtreatment 
Hypoflorescent 
lesion 
Mild response, damage limited to RPE with no effects on 
IS/OS. 
Ideal laser treatment 
 
8.5 Conclusions 
In summary, the above results demonstrated that the nanosecond laser 
technology has a limited damage profile. The results indicate that 
1. The current laser energy settings led to over-treatment of most patients 
with prolonged RPE wound recovery period, although no clinically 
significant functional defects were found over a 12 month period.  
2. The beam profile was not discontinuous in nature, which concurred with 
results from chapter 2. 
Hence, it would be necessary to lower the laser settings and address the beam 
profile for optimal use in human subjects. 
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Chapter 9. Discussion  
9.1 Discussion 
The main purpose of this thesis was to determine the potential of the 2RT (3 
nanosecond, 400µm, speckled laser beam) as a rejuvenative therapy to reverse 
the ageing of the outer retina, thereby retarding the onset of AMD. Several 
problems identified at the beginning of this thesis have been addressed through 
a series of laboratory and clinical studies. In summary, the following findings 
may be concluded from this thesis:  
In laboratory studies undertaken, 
1.The unique laser beam configuration was evaluated and found not to have a  
speckled beam profile; 
2.The 2RT laser does cause increase in levels of active-MMP2 in a porcine 
explant culture model in both a time and directional-dependent response; 
3. Higher levels of active-MMP2 were released with a larger number of laser 
spots; 
4. Active-MMP2 increases hydraulic conductivity across the BrM in an age and 
dose-dependent fashion. 
From the clinical studies, the following were concluded: 
1.Application of the 2RT laser results in a short-term improvement in vision. 
This indicates that repeat laser may be required. 
2.The laser in its current settings were too high and caused over treatment of 
subjects; 
3. Despite this, the structural defects were limited and there were no gross 
functional defects. This indicates that although there was no ‘speckled’ beam 
profile, there was also limited secondary laser damage. 
The following will discuss the findings from the laboratory and clinical studies in 
this thesis. Earlier in the introduction, the problem of choosing a sensitive and 
easily available clinical device to follow up on patients with early AMD and good 
vision was identified. In the RETILASE trial, the team also encountered initial 
problems with choosing a viable primary outcome measure. Hence, although it 
was not within the remits of this thesis to evaluate the use of outcome measures 
for AMD, this problem is sufficiently important to warrant a short discussion in 
the following. 	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9.2 The Role of the 2RT Laser in Rejuvenating the Aged Outer 
Retina 
Laboratory studies have shown that the nanosecond laser application resulted 
in increased levels of active-MMP 2 in both the apical and basal end of the RPE 
BrM choroid explant.  The release of active-MMP2 peaked at day 4 post laser 
and remained elevated beyond 9 days post laser. Furthermore, there was 
higher release of active-MMP2 with higher number of laser spots.  Current 
findings concurred with the results from Treumer et al who also used porcine 
RPE-Bruch’s explant.(Treumer et al., 2012) However, the current results 
differed from Zhang et al who demonstrated release of active-MMP 9 in addition 
to active-MMP2 in aged human RPE-Bruch’s explant culture.(Zhang et al., 
2012) This could be because of species differentiation between porcine and 
human eyes. A less likely reason could be that the porcine eyes were taken 
from young pigs, although this point has not being proven. Previous 
experiments have shown that active-MMP 9 resulted in higher levels of 
increases in hydraulic conductivity than active-MMP 2 in aged BrM.(Ahir et al., 
2002) On the other hand, clinical studies have found association between MMP 
9 and neovascularization, although these studies did not differentiate between 
pro and active-MMP9.(Chau et al., 2007) Hence, it may be postulated that there 
is a spectrum of MMP activity in terms of directional release, topographical and 
quantity of which one end results in rejuvenative therapy and the other as a 
precursor to AMD.  
The series of studies involving explant cultures in this thesis extended beyond 7 
days. Previous studies have demonstrated that the RPE layer forms its full layer 
with intact tight junction by 7 days post laser. Other invitro explant study also 
shown that the optimal period of explant incubation was 5 days. Histology from 
the control experiments have shown a possible lifting of the RPE from the BrM 
at day 7 of incubation, which may indicate cell death. Hence, although there had 
been conclusive evidence of raised active-MMP levels beyond 9 days in the 
laboratory experiments, the exact levels of enzyme quantity may be subject to 
question. Repeat experiments using in-vivo models may be a solution. In the 
current experimental set up, it was not possible to measure the transepithelial 
resistance of the RPE-BrM explant because the electrical probes which was 
designed in this using chamber were placed in the upper and lower chamber, 
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first would measure trans resistance across RPE, BrM, choroid and the filter 
membrane which gets clogged up with debris within days. Despite this, the 
current results with the increase of MMPs with laser and stabilization of MMP 
levels with controls does indicate that the RPE cells are intact. In this study, 
laser was applied on day 3 post initiation of culture, which aims to allow 
stabilization of the explant culture. Hence, it can be safely concluded that the 
release of active-MMP2 is an effect of laser. 
Findings from chapter 5 have shown that the impact of MMP on hydraulic 
conductivity increases was both age and dose dependent. This suggested that 
the elderly population would require higher dose of the laser application for any 
effect. This may be achieved by either higher laser energy or a larger number of 
laser spots. Given that the current histological and clinical data results seemed 
to indicate that this laser energy was insufficiently low, it would be only wise to 
increase dosage of active-MMP release via increasing number of laser spots 
using lowered energy levels. From the experiments, the release of active-MMP2 
per laser lesion in the range of 0.10 to 0.15mJ was calculated to be 2ng/mL.  
Unfortunately, in the current laser prototype, there was a failure in the speckled 
beam configuration. In theory, should the speckled beam configuration be 
functioning, there would be further release of active-MMP per laser lesion, 
hence, decreasing the need for a large number of laser spots.  
The key concept here would be to define the ‘balance’ between the wound 
healing period of the laser lesion, maximal beneficial transport improvements 
and the appropriate balance from increased laser energy such as to prevent 
secondary apoptosis of the photoreceptor cells. 
Thus, from the laboratory data, it was concluded that the 2RT laser in the 
nanosecond domain increased levels of activated MMP. This increase in active-
MMP2 resulted in improvements in hydraulic conductivity across the BrM in a 
dose-related fashion, thereby forming part of the basis of which Gass first 
observed the decrease in drusen post laser.  
Translating the laboratory results to human subjects, several important findings 
were noted. 
Unfortunately, in the clinical trial, the study was terminated early and the 
remaining recruited subjects appeared to have undergone a randomization 
process, which for some reason seemed to have failed. Despite this, the current 
data found improvements in visual acuity in treated eyes at 6 months. This data 
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was not ever noted in previous laser AMD studies nor the study conducted by 
Guymer and team in Melbourne.  
There had been difficulties defining the primary endpoint for the clinical trial, 
considering that patients with early AMD generally retain good vision. The first 
submission to ethics of the RETILASE trial protocol with flicker perimetry as the 
primary end point had resulted in ethics failure due to the lack in publications 
and common use of this device in the United Kingdom. The decision to use 
flicker perimetry then was made by the commercial firm due to the limited 
findings of flicker perimetry improvements in the study by the Melbourne team. 
Flicker perimetry is a relatively novel concept with minimal established data in 
regards to early AMD and being a continuous measurement, would require a 
calculated sample size in the range of 10,000 patients. Correspondence 
between international AMD experts at the Macular of Paris conference 2012, 
this very same issue was discussed and decided that visual acuity remains the 
best primary end point measurement at the moment. In this study, there was a 
short term improvement in visual acuity at 5.09+/- 5.67 ETDRS letters. This 
visual improvement was not sustained by 12 months. This suggested that the 
effect of laser was short term and a repeat treatment would be necessary.  The 
results however were based on a very small sample size of patient because of 
early termination of recruitment.  It was also noted that the baseline visual 
acuity of cases were lower than control which allowed for a larger improvements 
in visual acuity because of threshold effects with vision. Furthermore, due to 
constraints of the trial protocol, refraction was only done at every follow up visit, 
which might have been subject to further technical or subjective error. Despite 
this, as an initial study, the current results are encouraging and further 
explorative pilot dose escalation studies will need to be carried out. 
Because of the small size of the RETILASE study and that the inclusion criteria 
was confined to patients with AREDS 2 and 3, there were only few patients that 
showed obvious decrease in drusen load. Most of the patients did not begin 
with a high drusen load to begin with. 
The application of laser in the current study was limited by the lower threshold 
energy of 0.1mJ on the laser machine. Hence, 7 out of 11 of treated cases were 
at 0.1mJ, which did not allow calculation of dosing effect. 
The main purpose of the use of the 2RT laser was to rejuvenate the aged outer 
retina. The main risk factor of AMD is ageing and it would be ideal to target 
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individuals at an earlier age (ie, in the 40s) when the hydraulic conductivity 
would have been compromised but before manifestations of signs of AMD. By 
doing so, the physiological process of ageing is retarded and the onset of AMD 
delayed. (Figure 9.1) Hence, the initial results from this thesis have 
demonstrated that the nanosecond laser was effective at preventing AMD by 
enhancing transport across the Bruch’s membrane via the MMP pathway and 
this resulted in improvements of the visual outcome in affected patients. Thus, 
the 2RT laser is a potential therapeutic modality to rejuvenate the aged outer 
retina.	  	  	  
Figure 9.1 Demonstration of possible effects of rejuvenating the aged 
outer retina 	  
	   	  
 	  
 
 	  	  	  	  
Figure 9.1 is a pictorial demonstration of the possible effect of 
rejuvenating the aged outer retina. By prophylactically renovating the 
process of physiological ageing of the macular, the HC has been 
shown to increase, thereby delaying the age of onset of AMD   
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9.3 Safety profile of the 2RT laser 
The design of the 2RT laser was unique in that it was the first laser which 
functions as  
1. a 3 nanosecond pulse laser, 
2. it operates in the Q switched mode,  
3. it has a speckled laser beam topography which targets discrete groups of 
RPE cells in a 400um beam spot size.  
The combination of this unique design, if in the exact operational mode, was 
hypothesized to prevent both primary thermal damage to inner retina and 
secondary damage by photoreceptor apoptosis. The operational mode of the 
2RT laser may be explained by figure 9.2. The ‘cut off’ threshold for speckling 
has been predetermined based on thermal relaxation time of the RPE. The 
peak energies above the ‘cut off’ as shown below would induce RPE cell death. 
At lower energies, a smaller number of peaks meet the ‘cut off’ and hence 
resulting in discrete groups of RPE cell death from the few energy peaks. From 
B, with higher laser energy, more individual peaks surpass the relaxation 
energy ‘cut off’, hence, resulting in a wider area of cell death. It must be noted 
that although Figure 9.2 was used in this instance to explain the operation of the 
2RT laser, this figure, which was adapted from Wood et al, must be reviewed 
with caution for the following reasons. First, the image did not show 
discontinuous laser beam profile, ie, the ‘dead’ cells which appeared black were 
in groups of RPE cells death. Also, there were areas of dark green which was in 
between the ‘black’ and ‘bright green’ cells which indicated dead and living cells 
respectively. This could be due to poor experimental technique. Lastly, the ‘cut 
off’ zones demarcated in the figure did not correlate with the areas of RPE cell 
death or injury.  
Based on current findings from the laser beam analysis and flat mount 
histology, it was concluded that the laser beam topography was likely set at too 
high an energy ‘cut off’, hence, resulting in an insufficiently separated spatial 
distance between the energy peaks and inadequate differential damage to RPE 
cells. (Figure 9.3) 
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Figure 9.2 Demonstration of speckling of 2RT laser beam 
 
(Figure from J Wood et al) 
 
Figure 9.3 Pictorial demonstration of impact of energy levels on speckling 
of 2RT laser beam 	  
 
 
 
 
!!
C.#
A.#
!!!
!"!"!"!"!"!"!"!"!"!"!"!"!"!"
400um#
Speckled#
beam#
proﬁle#at#
0.1mJ#
Current#
peak#cut#
oﬀ#
se;ngs#
Recommended#
peak#cut#oﬀ#
B.#
Figure A refers to speckled laser beam profile at 0.1mJ. Current laser settings are too 
high, resulting in multiple peaks and multiple groups of RPE damage, which coalesce 
into a gaussian like beam damage (B.). A lower beam cut off will result in few peaks , 
figure C, with well separated and discrete RPE damage. 
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The structural and functional impact of the 2RT laser on human subjects was 
also evaluated using various clinical imaging modalities such as the FAF, OCT, 
CFP and microperimetry. The study protocol was designed with limited 
information from Guymer and team and the commercial company, Ellex. Then, 
most of the subjects in Melbourne have undergone laser treatment with energy 
levels 0.3mJ with no adverse effects. Hence, an energy level with an arbituary 
30% below peripheral threshold lesion energy was taken as the laser treatment 
protocol. ED 50 studies on porcine eyes subsequently indicate that a better 
estimate of visual damage was closer to 0.22mJ. That said, the lowest energy 
range on the laser machine was 0.1mJ, and it would not have been possible to 
turn the energy even lower for most of the subjects treated.  
The advent of the OCT has allowed virtual invivo analysis of the human retina. 
In the RETILASE trial, the Spectralis OCT was used (Heiderlgberg Germany). 
Previous study by Marshall et al has demonstrated the agreement of OCT 
analysis and histology in the neurosensory layer, but the segmentation of outer 
retina still proves contradictory.(Chauhan and Marshall, 1999) In the study and 
based on prior histological knowledge, it can only be assumed the hyper-
reflective bands in the outer retina is part of the IS/OS-ellipsoid layer, followed 
by the RPE-Bruch’s membrane layer and the choroid. The purpose of using the 
OCT in the study was to evaluate damage both in the direction of the inner and 
the outer retina.  
The fundus autoflorescence fluoresces with fluorophores, in particular, the 
lipofuscin which is contained within the RPE. This imaging modality allowed the 
analysis of laser impact on the RPE layer. Both the flicker and microperimetric 
testing investigated the functional effect of laser on the photoreceptor cells. 
In the RETILASE study, there were interesting results and a distinctive pattern 
associated with wound recovery. Laser lesions were classified based on 
observations on FAF into hyper and hypoflorescence patterns and 
hyperflorescent lesions were further sub classified based on the stage of wound 
recovery. Given the clinical data, the current laser settings of the 2RT laser was 
safe as compared to conventional laser with limited damage profile, but still too 
high to accommodate variations between inter and intra individual melanin 
and/or lipofuscin contents. This resulted in what was described as 
overtreatment of several subjects.  
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Unfortunately, as mentioned, the sample size of this study was too small to 
allow calculation in terms of laser energy and spot numbers. Based on the 
findings, the ideal pattern may be that of hyperflorescent type II laser lesion 
which demonstrated improvements in function on microperimetric analysis and 
limited damage to the RPE.  
Subthreshold lasers have gained interest in the last 5 years. There are several 
lasers in the market currently which uses the concept of ‘selective 
photothermolysis’. The following table summarizes the damage profile of the 
‘newer age’ lasers in humans using a variety of clinical imaging modalities. The 
cw millisecond wave laser(PASCAL) has the most severe effect with immediate 
changes extending to the outer nuclear layer on OCT. Over long term, both 
micropulse laser and cw millisecond laser(PASCAL) demonstrate atrophic laser 
lesion with disruption of photoreceptor cells.(Muqit et al., 2010a, Mojana et al., 
2011) The working mechanism of action and wound healing process of these 
lasers compared to the Q switched 2RT laser is clearly different. Whilst FAF 
findings were similar during the initial phase, ie, both were hyperflorescent at 3 
months, earlier CW argon type lasers became hypoflorescent over time with 
corresponding atrophy. This was further shown in a recent human 
histopathological study which showed extension of PASCAL laser 
(20milisecond) into the inner retina and further extension into the outer retina 
with RPE atrophy and disorganization of choriocapillaries.(Paulus et al., 2013)  
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Figure 9.4 Damage profile of lasers in mili to nanosecond time domain on 
OCT 	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Table 9.1 Clinical assessment of laser damage in varying laser time 
domains 
Time- 
Domain 
Pulse Laser Clinical 
Imaging 
  Functional 
assessme
nt 
   FAF OCT CFP  
Milli-
second 
CW, 
patterne
d laser 
Pascal 
(Muqit et 
al., 2009, 
Muqit et 
al., 
2010a, 
Muqit et 
al., 
2010b)  
Hyper-
florescent 
at 1 week 
to 3 
months. 
Increased 
optical 
reflectivity 
within OPL 
and defect 
at level of 
the IS/OS 
and upper 
surface of 
RPE 
immediatel
y post 
laser. 4 
weeks post 
laser, the 
localised 
defects at 
the IS/OS 
but sparing 
of 
photorecep
tors and 
RPE 
adjacent to 
either side 
of each 
burn. 
Pale 
laser 
lesion 
which did 
not 
enlarge 
over time. 
Diameter 
of burns 
decrease
d with 
decreasin
g time 
domain 
up to 
35%.(20
ms vs 
100ms)  
No 
published 
literature  
 Micro-
second 
Pulsed Micro-
pulse 
(IRIS 
Medical 
Oculight 
SLx))-
subthresh
old laser 
(Mojana 
et al., 
2011) 
(Ohkoshi 
and 
Yamaguc
hi, 2010, 
Figueira 
et al., 
2009, 
Vujosevic 
et al., 
2010) 
Hyper-
florescent 
laser 
lesions at 3 
months 
Variable 
involve-
ment of 
IS/OS, 
ONL 
(PRL). 
Pale 
laser 
lesion 
Improve-
ments at 12 
months at 4 
and 12 
degrees. 
Better 
preser-
vation of 
mfERG. (as 
compared 
to 
convention
al laser) 
    . 	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Q- 
switche
d  
SRT 
(Framme 
et al., 
2009, 
Roider et 
al., 1999, 
Roider et 
al., 1992) 
Hypo-
florescent 
immediatel
y post laser 
and 
remains 
hyper-
florescent 
from 1 
week to 15 
months. 
Variable 
thickening 
of RPE 
layer. No 
involveme
nt of 
neuro-
sensory 
layer. 
- Micro-
perimetric 
changes 
detectable 
with higher 
number of 
pulses and 
energy 
(500 pulse 
and 100uJ 
vs 100 
pulse and 
70uJ). 
Nano-
second 
Q 
switche
d 
2RT Hypo-
florescent 
laser lesion 
and hyper-
florescent 
lesion 
which 
decreases 
in size over 
time. 
Variable 
thickening 
of RPE 
layer. 
Recovery 
period 
between 6 
months to 
beyond 18 
months. 
Pale 
laser 
lesion 
with or 
without 
central 
pigmentat
ion. 
Decrease
s in size 
over time. 
No 
significant 
defect on 
MP 1 in 
both DME 
and AMD 
patients. 
 
The 2RT laser selectively targets the RPE cell likely through mechanical 
microbubble formation which results in microcavitation and disruption of 
individual RPE cells. Unlike conventional lasers, there was less disruption on 
the inner retina. In contrast to prior AMD laser prophylaxis trials, there was no 
increased rate of conversion in our AMD patients although the numbers were 
very small and were in the early stage of disease which in theory has a rate of 
conversion between 0.5 to 50% over 5 years.(Ferris et al., 2013) In the current 
study, there was a noticeable decrease in drusen load in some the few patients 
with a higher drusen load at baseline. However, there were no quantitative 
calculations of the proportionate decrease due to the small numbers.  
Previously, studies have been conducted and have failed to demonstrate both 
efficacy and safety of laser prophylaxis in AMD. The major clinical trials 
included the CNVPT ,CAPT and PTAMD (USA), DLS (Talhouk et al.), and 
Nordic study.(Frennesson et al., 2009, Friberg et al., 2006, 2003, 2006) These 
trials were divided into either bilateral arm study (both eyes with early 
maculopathy) or unilateral eye study (fellow eye has exudative AMD). Common 
endpoints of the studies included change in BCVA, either continuous or 
proportional (number of lines improvements or decreased) and rates of CNV 
formation. Conclusions based on these studies have found increased rates of 
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CNV formation in the unilateral arm studies. Results for bilateral arm studies 
have however been equivocal. Olk et al and CNVPT have found increase with 
vision that is correlated with drusen decrease at 12 months, however PTAMD 
have found higher proportion of visual loss of > 2 lines amongst treated 
patients. Hence, the concept of laser prophylaxis of AMD was largely aborted.  
Subanalysis of the CNVPT study of the unilateral arm have found that higher 
intensity laser resulted in higher rates of CNV formation, most of which were 
occult in nature, at the site of laser application. Table 9.2 highlights the laser 
treatment parameters. It is noteworthy that most of the laser used in the 
previous trials were continuous wave in nature and were of significantly higher 
laser time domain as compared to our nanosecond laser technology. In theory, 
it may be argued that higher intensity laser burns resulted in higher rates of 
conversion to wet AMD, which was likely secondary to a break in BrM as a 
consequence of laser therapy. This is especially so in unilateral patients, where 
the eye may have higher levels of lipofuscin due to the more advanced stage of 
the disease. In this special group of patients, it is important to stress that most 
lipofuscin and melanin plays important role as laser energy scavenger and 
hence is exposed to higher laser impact than younger patients. 
The RETILASE trial was a bilateral arm study. In addition to the main outcomes 
such as change in BCVA and rates of CNV conversion, we have measured the 
qualitative changes on OCT, FAF and functional defects on perimetric analysis 
using microperimetry and flicker perimetry. Guymer et al have shown 
improvements in flicker perimetry at 12 months in using the 2RT laser on 
bilateral AMD patients using 12 laser spots. No visual improvements were 
however reported.(Guymer et al., 2013) The use of flicker perimetry to 
determine cone functions is still debatable; hence, the results from the flicker 
perimetry must be interpreted with caution. Perimetry results were analyzed as 
improvements in a global function of the retina at 4 and 12 degrees and at 
individual laser lesions.  Based on these results, the nanosecond laser did not 
demonstrate defects structurally and functionally. There was no comparison for 
the previous AMD trials for this subgroup of patients as these earlier studies did 
not incorporate these retinal imaging. Although the RETILASE trial had a very 
small sample size, the results are encouraging and may prove to circumvent the 
previous problems in prior studies. 
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Table 9.10 Laser protocols used in prior laser-drusen studies 
  Laser type Spots Spot size (µm) 
Time 
(seconds) 
Intensity 
CNVPT Argon green 20 100 0.1 Grey/white 
DLS Green/yellow 12 200 0.2 Faint uptake 
PTAMD 810-nm diode 48 125 0.2 
Sub-
threshold 
CAPT Argon green 60 100 0.1 Barely visible 
Frennesson 
(Nordic) 
Argon green 100 200 0.05 
Sub-
threshold/ 
barely visible 
RETILASE 
Nd: YAG 
(doubled 
frequency) 
>55 
400um(speckled 
beam) 
3ns Subthreshold 
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Table 9.3 Summary of study design and outcome of laser-drusen studies 
Ref Laser Treatment 
protocol 
Study Design 
Bilateral/unilateral 
study 
Follow up period 
Outcome 
measurements 
Results/ 
Conclusion 
Olk 
1999 
(basis 
for 
PTAM
D) 
810nm, 
diode, 
sub-
threshold 
and 
minimally 
threshold 
lesions. 
48 laser 
spots, 125 
µm size.  
4 concentric 
circles 
outside the 
FAZ in a 
scatter or 
grid pattern 
between 750 
µm and 2250 
µm from the 
center of the 
FAZ 
24 months follow up. 
Bilateral and unilateral 
arm. 
 
Outcome measures: 
• Reduction of 
drusen 
• Change in visual 
acuity 
• Rate of CNV 
development 
 
At 24 months, 
11.4% of treated 
patients had >2 
lines improvements 
of VA. 
62% treated eyes 
showed reduction 
in drusen in 
threshold lesion at 
12 months and 
65% for 
subthreshold lesion 
at 18 months. 
PT-
AMD 
2006 
810nm 
diode sub-
threshold 
laser 
48 laser 
spots, 
extrafovea, 
125 um 
diameter. 
Single 
treatment 
Total of 36 months follow 
up. 
Unilateral eye study 
Outcome measures: 
• Development of 
CNV 
• Change in BCVA. 
 
Increased rates of 
CNV at 1year 
(15.5% vs 1.4% 
controls). Treated 
eyes showed 
higher rates of VA 
loss of more than 3 
lines at 3 and 6 
months. 
CNVP
T 1999 
(basis 
for 
CAPT) 
Argon 
laser 0.1s, 
100um 
Multiple, 
100µm laser 
spots, 750µm 
from fovea 
12 months outcome. 
Bilateral and Unilateral 
eye study. 
Primary outcome: 
• Change in visual 
acuity  
Secondary outcome: 
• Change in 
contrast threshold  
• Change in critical 
print size 
 
At 12 months, 
laser-treated eyes 
with 50% or more 
drusen reduction 
had visual acuity 
improvements (1-
2lines) and less 
losses in visual 
acuity Similar 
improvements 
were noted for 
contrast threshold 
but not critical print 
size. 
Increased rates of 
CNV for unilateral 
arm, 
CAPT 
2006 
Argon 
laser 0.1s, 
100um 
spot size 
Initial 
treatment of 
60 barely 
visible burns 
in a grid 
pattern within 
an annulus 
between 
1500 and 
5 year follow up. Bilateral 
eye study 
Primary outcome: 
• Change in visual  
Acuity 
Secondary outcome: 
• Incidence of 
complications of 
20.5% of treated 
eyes and 20.5% of 
controls had > 3 
lines visual loss 
from baseline at 5 
years. 
No difference in 
occurance of wet 
or dry AMD at 5 
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2500 microns 
from the 
fovea  
Repeated 
treatment at 
12 months if 
10 or more 
large drusen 
remained in 
the treated 
eye within 
1500 microns 
of the foveal 
center 
AMD 
• Changes in 
contrast threshold 
and critical print 
size for reading 
years. 
Results for contrast 
threshold and 
critical print size 
were insignificant. 
Concluded no 
clinically significant 
benefits of laser 
photocoagulation. 
Drusen 
Laser 
study 
(DLS 
2003) 
Argon 
laser, 
0.2s, 
200um 
12 burns;4 
burns 750 
µm from the 
center of the 
fovea at 12, 
3, 6, and 9 
o’clock, and 
8 burns, 
1500 µm 
from the 
center of the 
fovea at 12, 
1:30, 3, 4:30, 
6, 7:30, 9, 
and 10:30 
o’clock. 
36 months follow up 
Unilateral and bilateral 
study. 
• BCVA 
• Development of 
CNV  
Unilateral group, 
vision loss 
occurred 28.8%of 
patients in laser vs 
19.7% (not 
significant) 
Incidence of CNV 
was 29.7% vs 
17.65%. 
Bilateral group, 
vision loss 8.3% of 
laser-treated 
patients vs 13.9% 
(not significant)  
CNV developed in 
11.6% vs 6.8%. 
Concluded that 
laser is not 
beneficial in 
unilateral arm 
treatment. 
Frenne
son 
2009 
Argon, 
0.05s, 
200µm 
spot size 
Scattered on 
and between 
drusen in the 
posterior 
pole. 
Subtreshold/
barely visible 
Follow up 3.7 years 
Bilateral and Unilateral 
arms 
 
Outcome measures: 
• Change in BCVA 
• Rate of CNV 
development 
More CNVs in 
treated group in 
unilateral arm; VA 
reduced from 
baseline although 
not different from 
controls in both 
arms. 
Laser treatment not 
beneficial nor 
harmful, not 
recommended. 
RETI-
LASE 
Doubled 
frequency 
Nd:YAG, 
400µm 
spot 
size(speck
led beam) 
>55 laser 
spots in 2 
annulus 
500µm from 
fovea 
24 months 
Unilateral arm 
Primary outcome: 
• Change in BCVA 
Secondary outcome: 
• Rates of CNV 
formation 
• Changes on 
FAF/OCT/MP1/ 
flicker perimetry 
6 months increase 
mean vision of 1 
line in treated 
patients. No 
conversion to CNV 
at 12 months. (11 
treated patients) 
MP 1 did not show 
laser defects at 4 
and 12 degrees. 
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9.4 Evaluation of tools to monitor early AMD 
Histological studies have shown changes in the photoreceptors to choroidal 
capillaries prior to clinical onset of AMD. These changes include the decrease in 
rod and cone density, especially in the macular, thickening of the Bruch’s 
membrane, lipoid-proteinaceous deposits sub-RPE or within the inner 
collagenous layers of the BrM and thinning of the choroidal capillaries. 
Transportation studies have also found age-dependent demise in hydraulic 
conductivity and amino acid transport across the BrM.  Currently, the diagnosis 
of early AMD is based on the identification of clinical hallmarks such as drusen 
and/or pigmentary abnormalities which are observed on clinical slit lamp 
ophthalmoscopy or color fundus photography.   AMD classifications (AREDS, 
IC) are largely based on these clinical markers as risk of developing late stages 
of AMD such as geographic atrophy or choroidal neovascularization (Dry or Wet 
AMD).   
Given that age-related changes mentioned above occur on a continual basis,  
the concept of aging macular is vital in introducing a preventative measure prior 
to the onset of clinical changes. Currently, there is a paucity of available 
modalities to first ascertain the diagnosis of very early aging macular or age 
related macular degeneration and to monitor its progression.  A good assay for 
clinical application must be sensitive and specific, reproducible, easy to use and 
economically viable for community diagnosis and monitoring purposes. 
Assays to evaluate status of early AMD can be broadly categorized into 2 
groups: structural and functional.  Structural assays include imaging modalities 
which allows static visualization of structures and follow up in time for 
quantification and/or qualification of changes such as number of size of druse, 
change in RPE layer, thickening of BrM, quantification of photoreceptors. The 
recent years have seen huge progress in retinal imaging modalities. There are 3 
main imaging modalities for the diagnosis of AMD, but mainly used in identifying 
the wet or dry AMD. First, fluorescein angiography(FFA) , remains the  current 
gold standard of diagnosis  which enables diagnosis via the visualization of 
leakage and staining concept of retinal vessels and tissues. Second, the 
indocyanine green (ICG), which uses the SLO technology enhances clarity of 
the deep, ill defined ‘occult or sub RPE’ CNV. It also enables differentiation of 
the etiology of CNV such as polypoidal choroidal vasculopathy and chorioretinal 
anastomosis can be made.(Yannuzzi et al., 1992, Hyvarinen and Flower, 1980) 
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Recently, investigators have found corresponding features on OCT and FFA 
which suggests the use of OCT as a noninvasive tool to diagnose neovascular 
AMD. (Mathew et al., 2014) OCT has allowed detection of subretinal and 
intraretinal fluid from CNV as well as the identification of various types of drusen 
in early AMD. (Huang et al., 1991, Schlanitz et al., 2010, Freeman et al., 2010, 
Leuschen et al., 2013) In the very early stages of AMD, FFA and ICG would 
play minimal roles.  Several authors such as Soubrane et al and Coscas et al 
has published in depth review articles and books on OCT features in 
AMD.(Coscas et al., 2004, Coscas, 2009) As the OCT is a relatively young 
technology with limited histo-pathological references, the numerous features 
described in current literature remains as inferences to the histopathology of 
disease states.(Stopa et al., 2008, Toth et al., 1997)  
The advent of OCT has provided useful information of the anatomical 
microstructure of the retina using the anteroposterior scans.(Huang et al., 1991) 
As an imaging modality itself, OCT has progressed tremendously, from the 
conventional(time domain TD OCT) to the modern day spectral domain(SD 
OCT) with a much higher resolution and better clarity from reduced noise levels 
and added advantage of faster image acquisition, hence allowing 3D 
compilation or mapping, patient eye motion tracking, as well as RPE 
segmentation, added advantage of combination modalities such as 
angiography/autoflorescence/microperimetry.(Coscas, 2009, Alam et al., 2006, 
Menke et al., 2006) Using OCT, we are able to both qualify and quantify the 
drusen deposits. Although the identification of drusen is relatively easy with 
other imaging modalities, with the high resolution SD OCT, clinicians are able to 
address several issues and qualify drusen in an unprecedented way.  On OCT, 
soft drusen are recognized as an elevation of the RPE with a moderately 
reflective drusen cavity. There is minimal posterior shadowing associated with 
it.  SD OCT also demonstrates better visibility of reticular drusen, as a thickened 
band and undulations of the RPE with no altered outer nuclear layer. Khanifar et 
al has evaluated and found 17 different types of drusen based on the shape, 
size, heterogenousity as well as internal reflectivity.(Khanifar et al., 2008) Other 
than drusen, the surrounding presumed RPE band, IS/OS interface, external 
limiting membrane as well as outer nuclear layer has been noted to be thinned. 
Johnson et al has demonstrated both structural and functional photoreceptor 
changes over drusen in postmortem eyes.  These include change in 
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photoreceptor cell density, gene expression and synapses over drusen. 
(Johnson et al., 2003, Johnson et al., 2005) Shuman et al studied the 
neurosensory retina abnormalities in sites relative to drusen in early AMD and 
found a decreased thickening of PRL over drusen, suggesting a focal 
degenerative process with postulated eventual progress to visual loss, even in 
early stage AMD.(Schuman et al., 2009) Other qualitative changes noted in 
relation to drusen include the absence of photoreceptor outer segment, 
disruption of the photoreceptor inner segment/outer segment junction, hyer-
reflective foci adjacent and over drusen, all of which were presumed anatomy 
defined by other investigators.(Schuman et al., 2009, Coscas, 2009) With 
further advancements to the latest SD OCT, which has a high axial resolution of 
5 um, high intensity and high speed acquisition, accounting for patient motion 
effects and hence decreases artifacts, several authors have continued the 
pursuit of drusen quantification, now in terms of even more specific drusen area 
and volume. There were up to 5 studies previously published on quantifying 
drusen using OCT using RPE segmentation. There are 2 issues with this 
technique, first, as mentioned several times in this thesis, there is a poor 
correlation between the presumed OCT structures currently defined by the 
ophthalmic community and the its true anatomy simply because of the x-y 
resolution current OCT technology has (Figure 9.5). Second, much focus has 
been put on drusen to define progress of AMD, laser prophylaxis studies of 
AMD also included drusen quantification as an outcome measure for 
determining effect of therapy. However, as per this thesis, it must be stressed 
that drusen is a late downstream consequence, which should not be taken as a 
target for progression or change. The ability to measure BrM thickness would 
have been ideal. BrM is at approximately 7µm in thickness in early stages of 
AMD and would not have been identifiable on the current OCT technology. A 
confocal coronal scan OCT enables en-face evaluation of the BrM, but this is 
not currently commercially available. A recent development of the Swept-source 
OCT uses a short cavity-swept laser (vs. a super-luminescent diode used in 
SD-OCT) to achieve superior acquisition rates at a longer wavelength (1,060 
nm), hence enabling the imaging of discrete photoreceptor cells. Using this 
OCT, investigators has also demonstrated thinning of choriocapillaries in 
relation to pseudoreticular druse.(Ueda-Arakawa et al., 2014) Enhanced depth 
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imaging (EDI)-OCT also allows better visualization of the choroid.(Spaide, 2009, 
Coscas et al., 2012, Querques et al., 2012)  	  
Figure 9.5 Pictorial demonstration of imaging resolution as compared to 
anatomical structure 
	  
Lipofuscin which fluorescence with short wavelength light accumulates in RPE 
cells with age.(Sugino et al., 2014) FAF emits light in the 500- to 750-nm range 
(peak∼630 nm). Lipofuscin signal mainly arises from the RPE, and the loss of 
FAF is associated with loss of RPE. FAF has been shown to be helpful in 
identifying severity in early AMD but again this focuses on later stages of early 
AMD with clinical identification of druse and pigmentary abnormalities. 
(Bindewald et al., 2005, Midena et al., 2007)  
Adaptive optics scanning laser ophthalmoscopy (AOSLO) as a technology is 
gaining popularity in recent years due to its ability to identify rods and cones 
and RPE.(Obata and Yanagi, 2014, Muthiah et al., 2014, Lombardo et al., 2013, 
Rossi et al., 2013) Adaptive optics allows a lateral image resolution of 2 µm, 
hence allowing visualization of individual cone photoreceptors.(Liang et al., 
1997, Roorda et al., 2002, Talcott et al., 2011) The use of AOSLO enables 
Layer Histology 
(µm) 
OCT 
(µm) 
 
NFL 17 17 
GCL 47.5 46 
IPL 37 35 
INL 40 38 
OPL 17 Single  
band 
25 
Henle’s  
layer 
16 
ONL 39 35 
ELM 0.5 12 
IS 25 15 
IS/OS 0.5 24 
OS 50 6 
RPE 10  
36 Bruch’s 1.5-3.5 
OCT Resolution  
14 - 7 µm 
Figure 9.5 Pictorial demonstration of resolution of OCT as compared to 
anatomical structure of the retina 
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visualization of individual cells but does not give further useful information 
regarding the health of the rods/cones and the photodynamics or integration 
between the photoreceptors-RPE-BrM. 
The second category of assay involves the functional assessments of 
rods/cones in relation to early AMD or aging macular.  This involves static and 
dynamic measurements of rod/cone functions using psychophysical tests. Static 
analysis involves the functional capacity of rods and cones and its post receptor 
elements, whilst dynamic analysis involves evaluation of the integration of PRL-
RPE-BrM complex, ie, regeneration of photopigment in photoreceptor layer.  
These tests range from the vision function tests such as visual acuity, color 
vision, contrast sensitivity to the more intricate tests such as microperimetry, 
flicker perimetry to dark adaptation, pigment densitometry and photostress 
tests. 
Visual acuity measurement is a simple assessment which can be used in a daily 
clinical setting. However, VA testing gives minimal information on retinal 
function in early AMD due to first, the wide range of variability of the test and 
second, involves cortical processing in the higher order.(Dimitrov et al., 2011, 
Siderov and Tiu, 1999) The Beaver Dam Eye Study shows minimal letter loss in 
early AMD, hence, although convenient and economically viable, is not a highly 
sensitive nor specific test for early AMD.(Klein et al., 1995)  Furthermore, there 
is a coefficient of repeatability of 12 letters in prior studies.(Aslam et al., 2014, 
Patel et al., 2008) 
Contrast sensitivity have been found to be decreased in early AMD. The 
coefficient of repeatability is approximately 7 letters.(Aslam et al., 2014, Patel et 
al., 2009) Reduced foveal contrast sensitivity, have been demonstrated in 
patients with early AMD.(Stangos et al., 1995) 
Color thresholds especially in the blue-yellow (titan) spectra have been shown 
to be affected in AMD patients in accordance to Kollner’s rule and allows for 
early diagnosis.(Hart, 1987, Bowman, 1980, Arden and Wolf, 2004, Holz et al., 
1995, Frennesson et al., 1995) Professor Arden has developed a computerized 
system integrating color thresholds with contrast thresholds, hence, maximizing 
the ability to detect functional losses from the disease. 
Conventional perimetry shows a good relation to drusen and pigmentary 
changes, but the quantification of retinal thresholds over time is difficult with the 
older system.(Sunness et al., 1995) A new SLO-implemented perimeter has 
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overcome this problem.(Midena et al., 2004) Repeatability of microperimetry is 
found to be 4.2dB in the macular region.(Cideciyan et al., 2012) Flicker 
perimeter is based on the use of increasing the metabolic needs of retinal 
tissue, hence, causing compensatory retinal vascularization and oxygen 
tension. In patients with outer retina pathology, the compensatory mechanisms 
may be overstretched and result in functional deficiencies.(Feigl et al., 2007, 
Formaz et al., 1997, Shakoor et al., 2006) Studies have found flicker sensitivity 
to be impaired in patients with early AMD.(Phipps et al., 2004) In particular 
Dimitrov et al have also found flicker measurements to be more sensitive than 
color threshold measurements.  Thus far, there are no repeatability studies 
published for flicker perimetry.(Dimitrov et al., 2011) 
Electrophysiological tests have been found to be able to measure the degree of 
impairment based on the integration of the BrM-RPE-PRL. These tests are 
highly specialized and expansive and limited to tertiary centers. Examples 
include dark adaptation and photostress test of cones. Recovery dynamics have 
been found to be compromised in AMD patients.(Sloane et al., 1988, Cheng 
and Vingrys, 1993, Owsley et al., 2001, Owsley et al., 2007, Bartlett et al., 2004, 
Haimovici et al., 2002) Exaggerated results were found in rods as compared to 
cones, signifying a further compromise of rods as compared to cones, 
especially in relation to age-related rod loss and marginal cone loss in healthy 
population.(Curcio et al., 1993, Jackson and Owsley, 2000) Hence, in 
monitoring purposes of early AMD post treatment in clinical trials, dynamic 
psychophysical tests may be a superior assay. 
Several of the techniques discussed have been used to monitor the progression 
of AMD in the RETILASE study. The primary outcome of the study was visual 
acuity at 12 months. There was an increase of approximately 5 letters at 6 
months in cases. According to known data from repeatability studies, this would 
not be clinically significant due to the large variability inherent in this 
measurement technique. However, the progression rate of change of VA in 
early AMD was shown to be 2 letters in the population based Beaver Dam eye 
study. This would indicate that our current results does have clinical value as a 
potential therapeutic intervention, but would require larger scale studies with 
longer term follow up.  In the RETILASE study, there are 2 components to 
consider in analyzing the results, first, the change in AMD pathophysiology post 
laser treatment, second the structural change from laser. The use of the 
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Spectralis SD OCT allowed a gross evaluation of the structural damage from 
laser in time, but was not able to analyze the intricate changes in BrM as 
expected based on the earlier laboratory results.   
Functional analysis used in the RETILASE included static threshold studies 
such as microperimetry and flicker perimetry. It was difficult in this instance to 
ascertain whether the current changes were secondary to progression of AMD 
or laser changes. It would have been useful to include dynamic studies in 
subsequent studies to evaluate ability to monitor the photoreceptor status over 
time to give an objective interpretation of photoreceptor function post treatment. 
An ideal device would be the Optos designed fundus reflectometer, which 
allows measurements of rhodopsin, and the density of rhodopsin, and its rate of 
regeneration as well as its distribution. Unfortunately, this device is currently 
only available for research.  In the design of RETILASE, there was limitation in 
funding and electrophysiological analysis were not included.  
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9.5 Conclusions and future direction 
In concluson, there were several salient findings from this thesis, 
1. The 2RT laser in the current prototype did not have a viable speckled beam 
configuration. In theory, this may lead in secondary laser damage. However, the 
clinical results did not show any involvement of the photoreceptor cells both 
structurally and functionally. 
2. Although the beam profile had proven disappointing, studies have found that 
the 2RT laser in its nanosecond domain does result in release of active-MMPs 
in porcine explant cultures.  Pilot studies in this thesis prove that higher volume 
of RPE injury increases quantity of active-MMPs and this increase in volume of 
RPE injury may be achieved by increasing number of laser spots. 
3. Laboratory studies in this thesis correlated the activity of MMPs with 
improvements in hydraulic conductivity across the human BrM. In particular, the 
older donor age appeared to require higher doses of MMPs for any 
improvements in hydraulic conductivity as compared to the younger donor 
subsets. Translated into clinical terms, this means that older aged population 
would require a higher volume of MMPs to clear debris in the outer retina for 
any transport improvements. MMPs are released by RPE migration and the 
2RT laser is a plausible modality to cause RPE injury. By increasing number of 
laser spots, the total volume of RPE injury or effective circumference for RPE 
migration could be increased for total increase in MMP release. 
Lastly, results from the RETILASE trial suggested possible short term benefits 
of visual improvements. However, the data also indicated the need for repeat 
treatment. The laser in its current form causes gross over-treatment in human 
subjects and would need to be adjusted in terms of 1.lowering the energy level 
threshold, 2. Increasing the speckled beam profile. This could be done by 
adding twisted optical fibers to limit transmission. Twisting the optical fibers 
creates differences in depth of radiation transmission, hence reducing the 
proportion of radiation that is able to pass through. 
A discontinuous laser beam and discontiguous RPE cell injury limits secondary 
laser damage and increases the effective circumference for RPE migration. 
With this, the quantity of active-MMP release per laser lesion would be higher, 
and less number of laser spots would be required for treatment. 
There were several limitations in the design of studies undertaken in this thesis. 
First, the definitive laser-MMP release studies were done on porcine explant 
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cultures. It would be crucial to repeat these studies in human explants and to 
increase the number of sample sizes with a broad range of donor age. Second, 
although there were a good number of sample sizes (n=44) in the hydraulic 
conductivity study in chapter 5, most of the samples were in the age group over 
60 years of age. Hence, the study was biased in the sense there was a 
disproportionate percentage of younger donor BrM.  
More importantly, results of the RETILASE trial at 24 months and beyond would 
allow determination of the longer term impact of the 2RT laser on human 
subjects. A laser dose escalation study with careful inclusion of assessments 
such as fundus densitometer and flash recovery ERG in the future will yield 
important and conclusive information on the 2RT treatment to prevent AMD. 
As established, this thesis has hopefully set the direction for future studies to be 
conducted. At this stage, it is still juvenile to conclude that laser is the ultimate 
preventative therapy for AMD. Perhaps combination therapy of multivitamins 
and laser will prove to be beneficial.  
The use of laser as a prophylactic therapy in AMD has been a ‘black hole’ in the 
ophthalmic community at large due to the results of the prior studies. It is 
necessary to re-educate ophthalmologists on the causes of failure and re-
introduce the current concept of debris clearance of the BrM and the safety of 
the current novel concept nanosecond laser with the results of this thesis.  
In conclusion, although the 2RT laser is superior to conventional lasers in terms 
of its damage profile, the laser in its current state is still considered inadequate 
because of a non-viable ‘speckled beam’ and insufficently low energy levels. 
Despite this, the concept of the 2RT laser has been proven in this thesis to play 
a potential role in rejuvenating transport in the aged outer retina. 
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Laser: light amplification by the stimulated emission of radiation, is an 
instrument that generates a beam of light of a single wavelength or color that is 
both highly coherent (in phase) and collimated (parallel).(Yadav, 2009) 
The following defines terms and units in accordance to ICNIRP guidelines 
(health physics 2013, 271). Power,  is defined as rate of emission of energy 
from laser, (W). Irradiance, E , (W m^-2) is defined as surface exposure dose 
rate or power density (power on a unit surface area), whilst and Radiant 
exposure, H,  (J m^-2), is defined as surface exposure dose from laser radiation. 
Radiance, L (W m^-2 sr^-1) is term used to describe ‘‘brightness’’ of an extended 
source that gives rise to an image on the retina and when integrated over time, 
gives the Radiance dose, D, (J m^-2 sr^-1).  
Pulse is defined as the time of interaction between laser beam and given 
biological tissue, example, millisecond, microseconds, nanoseconds.  
Q-switching is the creation of multiple very short pulses , for instance 1 to 
100ns , within a defined time width, with extreme high peak powers per pulse.  
Q stands for quality factor, the ratio of the energy stored in the optical 
resonant cavity to energy loss per cycle. The higher the quality factor, the lower 
the losses. This is used in Q-switching where energy is stored in the amplifying 
medium by optical pumping while the cavity Q is lowered to prevent the onset of 
laser emission. When a high cavity Q is restored, the stored energy is suddenly 
released in the form of a very short pulse of light. Example of this application 
include the 2RT nanosecond laser.  
Transmission is defined as the simple passage of laser energy through a 
biologic tissue, whilst Absorption is the change of radiant energy to another 
form (heat energy) upon interaction with biological tissues. 
Thermal effect is the generation of heat energy in absorped and adjacent 
tissue post irradiation. Thermal relaxation time refers to dissipation time of 
target tissue to approximately 63% of the incident thermal energy. 
Photoacoustic effect is the generation of rapidly moving waves in biological 
tissue, destroying melanin pigments post laser. Mechanical effect, used in the 
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context of this thesis, refers to the absorption of energy by melanosomes to 
cause microcavitation withinin RPE cells. 
 
Thermomodulation  refers to the ability of low-energy light to upregulate 
biological molecules without consequent injuries; whilst Selective 
photothermolysis is a novel concept defined as the localization of injury to 
specific targets. In retina research, Anderson and Parrish first defined 
localization of laser injury to the RPE, by manipulation of laser parameters such 
as wavelength, pulse duration and energy.  
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II. RETILASE protocol 
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Efficacy and safety of retinal rejuvenation using Ellex 2RT laser in age-related 
maculopathy (RETILASE trial) 
 
ISRCTN No:  
REC No: 11/EE/0171 
 
Sponsor: 
 
Name   King’s College Hospital NHS Foundation Trust 
 
Contact:   Dr Zoe Harris 
Address:   King’s College Hospital, Denmark Hill, London SE5 9RS 
Telephone:   020 3299 3841 
 
Email   z.harris@nhs.net 
 
  
 
Chief Investigator: 
 
Name:              Miss Sobha Sivaprasad 
Address:   King’s College Hospital, Denmark Hill, London SE5 9RS 
Telephone:   020 3299 1297 
Fax:    020 3299 4548 
Email:   Sobha.sivaprasad@nhs.net 
 
 
Signatures: 
 
___________________________   ________________ 
 
Chief Investigator      Date 
Ms Sobha Sivaprasad 
 
 
Principal Investigator:  
Mr Robin Hamilton 
Consultant in Ophthalmology 
Moorfields Eye Hospital 
162, City Road 
EC1V 2PD 
Robin.hamilton@moorfields.nhs.uk 
 
Scientific Advisor: 
Prof John Marshall 
Professor of Ophthalmology 
Institute of Ophthalmology 
11-43 Bath Street 
EC 1V 9EL 
Eye.marshall@googlemail.com 
 
Sub Investigator: 
Dr Ling Zhi Heng 
Clinical Research Fellow 
King’s College Hospital & 
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1. Summary of protocol 
Title Efficacy and safety of retinal rejuvenation with Ellex 2RT 
laser in age related maculopathy (RETILASE trial).  
Objectives To determine the efficacy and safety of Ellex 2RT laser 
in improving visual function and retinal morphology 
amongst patients with age related maculopathy. 
 
Study Design A randomized controlled trial to evaluate the efficacy 
and safety of Ellex 2RT compared to standard care in 
patients with age-related maculopathy.  
After informed consent, patients will undergo baseline 
examinations of best corrected visual acuity, contrast 
sensitivity, microperimetry and flicker sensitivity. 
Structural changes will be assessed by OCT, 2- field 
retina colour photographs, autofluorosence and fundus 
fluorescein angiography. Follow up visits will be at 6, 12, 
18 and 24 months.  
Planned Sample Size 80 patients – randomized 1:1 to treatment versus no 
treatment group. 
Patient selection Patients of either gender aged 55 or above with large 
drusen (≥125µ) in at least one eye (AREDS simple 
severity grade 2 to 3). Best corrected visual acuity in the 
study eye must be between 50 to 90 ETDRS letters. 
Treatment protocols 3) Treatment one: Ellex 2RT, 400µm diameter spot, 
2 rings of concentric subthreshold laser spots 
applied  at 2000µm (5 ½ spots sizes out from the 
fovea) and 2800µm (7 ½ spot sizes out from the 
fovea).  So a total of at least 25 spots will be 
applied.    
OR  
4) Standard care (No treatment but observed 
regularly). 
Clinical Outcome Comparison of the outcomes of Ellex 2RT compared to 
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Measures 
 
observation (standard care) will be done on the following 
parameters at 12 and 24 months: 
Efficacy analyses: 
3. Primary outcome: Mean change in visual acuity 
at 12 months. 
4. Secondary outcomes:  
d. Mean change in visual acuity at 24 months.  
e. Mean change in contrast sensitivity, 
microperimetry and flicker sensitivity at 12 
and 24 months.  
f. Changes in fundus morphology as measured 
by optical coherence tomography, colour 
fundus photographs at 12 and 24 months. 
Safety analyses by comparing the following between the 
two arms: 
11. Proportion of patients developing CNV confirmed 
by fluorescein angiography at 12 and 24 months 
12. Proportion of patients developing retinal atrophy 
as measured by fluorescein angiography, 
autofluorescence and OCT at 12 and 24 months 
13. Proportion of patients who lost more than 15 
ETDRS letters at 12 and 24 months. 
14. Proportion of patients who lost more than 30 
ETDRS letters at 12 and 24 months. 
15. Any other complications observed at 12 and 24 
months. 
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2. Background 
2.1	   Introduction	  
Age Related Macular Degeneration (AMD) is the leading cause of blindness in 
the elderly in the western society.(Leibowitz et al., 1980, Klein et al., 1992) In the 
United Kingdom, an estimated 608, 213 people have been diagnosed with AMD.  
This number is expected to increase to 755, 867 by the end of the next decade.  
This attributes to 22.5% of the ageing population.(Reidy, 2010) Clinically, “dry” or 
early AMD is characterised by large drusen and RPE pigmentary changes that 
can progress to an advanced stage, geographic atrophy. “Wet” or neovascular 
AMD, another manifestation of advanced disease, is characterised by choroidal 
neovascularisation (CNV). Clinical classification of early AMD is based on 
AREDS simplified severity scale (see below) based on photographic assessment 
of drusen size and pigment changes in the macula [4]. 
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Progression of AMD 
Dry/Early AMD à Intermediate AMD  à Advanced 
AMD 
(multiple small or  (extensive drusen or  (GA involving fovea 
intermediate drusen) non central GA)   or CNV) 
   
 
 
2.2	   The	  International	  grading	  of	  age	  related	  maculopathy	  
The progression of the disease is monitored by classifying the morphological 
changes in the fundus as per International Classification (IC) grading system: 
Standard circles for grading ARM related fundus changes.  Circles should be 
reduced on a transparent sheet according to the fundus camera used so that 
they are 1/24, 1/12, 1/8.6, 1/6 and 1/3 disk diameter.  This results in an 
approximate diameter of the fundus of 63,125,175, 250 and 500 um. 
C0: differentiates small from large drusen 
C1 and C2: measuring area of hyper or hypopigmentation of RPE 
C2: minimum area of geographic atrophy 
C3 and C4: geographic atrophy and neovascularization 
Spokes: locating centre point and estimating size of lesion. 
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Grading of Drusen 
Drusen morphology. Grade highest # present within outer circle. 
0) absent  
1) questionable  
2) hard drusen (<C1, 125um)  
3) intermediate, soft drusen (>C0_<C1; >63um<125gm)  
4) large, soft distinct drusen (>C1, 125um) 
5) large, soft indistinct drusen (>C1, 125gin) 
5a) crystalline/calcified/glistening 5b) semisolid 5c) serogranular 
7) cannot grade, obscuring lesions 
8) cannot grade, photo quality 
Number of drusen 
0) absent  
1) questionable  
2) 1-9 
3) 10-19  
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4) >20  
7) cannot grade, obscuring lesions  
8) cannot grade, photo quality 
Drusen size 
1) <Co (<63um)  
2) >C0<C1 (>63um,<125um) 
3) >CI<C2 (>125um, <175um) 
4) >C2<C3 (>175um,<250um)  
5) >C3(>250um) 
7) cannot grade, obscuring lesions 
8) cannot grade, photo quality 
Main location of drusen 
Drusen may not be central to indicated subfield, but may be more to periphery.  
1) outside outer circle (mid-peripheral subfield)  
2) in outer subfield  
3) in middle subfield  
4) in central subfield 
4a) outside fovea (center point) 
4b) in fovea  
7) cannot grade, obscuring lesions 
8) cannot grade, photo quality 
Area covered by drusen in subfield  
1) <10% 2)<25% 3)<50% 4) >50%  
7) cannot grade, obscuring lesions  8)cannot grade, photo quality 
Hyper and Hypopigmentation of the Retina 
Hyperpigmentation 
0) absent 
1) questionable 
2) present <Co (<63um) 
3) present >Co(>63um) 
7) cannot grade, obscuring lesions 
8) cannot grade, photo quality 
Hypopigmentation 
0) absent 
1) questionable 
2) present <Co (<63 um)  
3) present >Co(>63um) 
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7) cannot grade, obscuring lesions 
8) cannot grade, photo quality 
Main location hyper / hypopigmentation. 
This may not be central to indicated subfield, but may be more to periphery. 
Choose most central location.  
1) outside outer circle (mid-peripheral subfield) 
2) in outer subfield 
3) in middle subfield 4) in central subfield 
4a) outside fovea (center point) 
4b) in fovea  
7) cannot grade, obscuring lesions  
8) cannot grade, photo quality 
Neovascular AMD 
Presence 
0) absent 1) questionable 2) present  
7) cannot grade, obscuring lesions 8) cannot grade, photo quality 
Typifying features 
1) hard exudates 2) serous neuroretinal detachment 3) serous RPE detachment 
4) hemorrhagic RPE detachment 5) retinal hemorrhage 
5a) subretinal 5b) in plane of retina 5c) subhyaloid 5d) intravitreal 
6) scar/glial/fibrous tissue  
6a) subretinal 6b) preretinal  
7) cannot grade, obscuring lesions 8) cannot grade, photo quality 
Location. Choose most central location. 
1) outside outer circle (mid-peripheral subfield) 2) in outer subfield  
3) in middle subfield 4) in central subfield 
4a) not underlying (in) fovea (center point) 
4b) underlying (in) fovea  
7) cannot grade, obscuring lesions 8) cannot grade, photo quality 
Area covered 
1) >C2<C3(>175um<250um) 2) >C3<C4(->250um<500utm)  
3) >C4and < 1000um (-central circle of grid) 
4) >1000um <3000um (-middle circle) 5) ->3000um <6000um (-outer circle) 
6) >6000um 
7) cannot grade, obscuring lesions 8) cannot grade, photo quality 
Geographic Atrophy 
Presence 
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0) absent 1) questionable 2) present: ->C2 7) cannot grade, 8) cannot grade, 
Location. Choose most central location.  
1) outside outer circle (mid-peripheral subfield) 2) in outer subfield  
3) in middle subfield 4) in central subfield 
4a) not underlying (in) fovea (center point) 4b) underlying (in) fovea  
7) cannot grade, obscuring lesions 8) cannot grade, photo quality 
Area covered 
1) >C1<C3(>175um<250um) 
2) ->C3<C4(->250um<500um)  
3) >C4 and < 1000um (central circle of grid)  
4) >1000um and <3000um (-middle circle) 5)>3000um and <6000um (outer 
circle)  
6) >6000um  
7) cannot grade, obscuring lesions 
8) cannot grade, photo quality 
 
2.3	   Pathology	  of	  AMD	  
AMD is a degenerative disease that affects the outer neural retina, retinal 
pigment epithelium (RPE), Bruch's membrane (BM), and the choroid. The clinical 
hallmark of the disease are the accumulation of yellow deposits called drusen in 
the fundus and this may be associated with hypo- and hyper-pigmented areas of 
RPE, the former signifying areas of RPE cell loss.(Sarks, 1976a) Since 
photoreceptors depend on the RPE and the choroidal circulation for nutrients as 
well as for the clearance of metabolic end-products, impairment of transport 
across BM could contribute to abnormalities associated with late AMD. These 
may include photoreceptor dysfunction, atrophy, RPE detachment and sub-RPE 
neovascularisation (NV) (Sarks, 1976a, Killingsworth, 1987, Moore et al., 1995b, 
Starita et al., 1996b, Holz et al., 2004). 
 
2.4	   Bruch’s	  membrane	  (BM)	  
BM is an important pentalaminar layer, located between the choriocapillaries and 
the RPE, contributing to the transport of nutrients and waste products into and 
out of the photoreceptor layer. BM thickness has been found to increase with 
age.(Ramrattan et al., 1994a) This increases the diffusion path length, coinciding 
with an inverse relationship with hydraulic conductivity across BM as well as 
macromolecules.(Moore and Clover, 2001b) 
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Prior histological studies of aged BM have demonstrated the following: 
4. Increases in collagen content and cross-linking (Newsome et al., 1987a, 
Karwatowski et al., 1995a)  
5. Increased content and altered composition of proteoglycans has also 
been noted.(Kliffen et al., 1996b) 
6. A higher total lipid content in BM.(Moore and Clover, 2001b, Fisher, 
1987a) Lipid- and protein-rich debris has been found accumulating under 
the RPE and within BM. This contributes to the formation of focal (drusen) 
and diffuse (basal laminar and linear) deposits found in AMD. (Pauleikhoff 
et al., 1990, Green and Enger, 1993, Green, 1999b)  
Taken in totality, this results in a structural disorganization of the collagen 
fibres (Hogan and Alvarado, 1967b) and thinning as well as fragmentation of 
the elastic layer.(Spraul et al., 1999b, Chong et al., 2005)  
 
There are several pieces of evidence for the contribution of metalloproteinases 
(MMPs) to the thickening of BM, and hence, AMD. MMPs are a family of 
enzymes called zinc- required endopeptidases which are associated with 
remodeling of the ECM.  
First, both genetic and serum studies of inhibitors of MMPs (e.g. TIMP3) which is 
produced by the RPE, has been studied and found to have an increased in AMD 
patients compared to age matched controls.(Apte et al., 1994, Fariss et al., 
1997b, Kamei and Hollyfield, 1999a) Higher levels of TIMP-3 may contribute to 
the thickening of BM observed in AMD. 
Also, whilst there is a known increase in inactive forms MMP 2 and 9 levels in the 
subretinal space as well as BM of AMD (Plantner et al., 1998a, Guo et al., 
1999a), the accumulation of inactive forms of MMPs are hypothesized to be a 
consequence of remodeling of BM in aged eyes. Increased deposition of collagen 
and other ECM components induces synthesis of MMPs; however, increased 
concentration of TIMPs or decreased porosity of BM prevents its activation. 
Hence, from the gathered evidence, we postulate that BM thickening is correlated 
to AMD and an inactivation of MMPs result in increased BM thickening. 
 
2.5	   Ellex	  2RT	  laser	  	  
The retinal rejuvenation therapy (Ellex 2RT) uses nanosecond duration pulses, 
which do not harm the photoreceptors (unlike previous conventional thermal 
lasers).  It uses energy levels 500 times lower than current standard laser 
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treatment.  It was previously shown to be effective as an alternative to 
conventional laser in treatment of other retinal diseases such as diabetic macular 
edema (DMO).[27]  
 
2.6	   Prior	  Research	  Work	  
Preliminary laboratory work 
Light sensitive cells of the human retina (photoreceptors) require high level of 
energy support and waste removal for optimal functioning.  RPE is a single layer 
of epithelial cells which separates the photoreceptor layer to the choroids and 
controls many bi-directional support functions.  RPE is attached to a basement 
membrane which is a matrix of collagen otherwise known as the Bruch’s 
membrane (BM).  This acts as a semi permeable barrier between the RPE cells 
and the choroids. Prior work by Professor John Marshall and Dr Ali Hussain and 
team has shown that thickening of the BM is a precursor of AMD with a resultant 
age related decreased hydraulic conductivity.(Hussain et al., 2010a, Hussain et 
al., 2010b) Further work was done which explored treatment possibilities with 
migration of RPE cells across BM with an associated improvement in hydraulic 
conductivity.  Ellex 2RT was shown to be able to induce a wound healing 
response in the RPE which induces migration and release of metalloproteinases ( 
MMPs).(Guo et al., 1999a) This had a subsequent effect on improvement of 
transport across the Bruch’s membrane, with a postulated delay in onset of age 
related macular degeneration 
 
Preliminary clinical work done with Ellex 2RT system.  
Clinical results from a pilot study on Ellex 2RT for DME were presented at ARVO 
2008 [30] The results should be treated with caution as only 18 of the 29 patients 
completed the 6 months study. But the results showed that 43% of patients 
showed 2 or more lines gain in visual acuity and the central macular thickness 
decreased by more than 5% from baseline in 46% of patients. The laser lesions 
from the pilot study were shown to be completely subthreshold with no laser 
scars or any other complications 
A second randomized controlled study was conducted on Ellex 2RT for DME was 
presented at ARVO 2010.  The study was conducted in Adelaide, Australia 
comparing treatment of 22 eyes using 2RT with 18 eyes treated with 
conventional photocoagulation.  This study demonstrated that 2RT was safe and 
at clinically as efficient as conventional photocoagulation. 
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This laser is currently undergoing clinical trials at CERA, Centre of Eye Research 
Australia.  A 12 month report which includes 50 patients at 12 month follow up 
showed that the patients experienced improvements in visual acuity and 
reduction in drusen.  Drusen decreased in 70% of treated eyes, demonstrating a 
partial reversal of the degenerative process which causes AMD.  Using flicker 
and color thresholds, the trial showed that central visual function improved in 
38% of treated eyes [31]. 
3. Scientific Hypothesis 
In aging and AMD, the accumulation of lipid- and protein-rich deposits in BM 
results in an overall thickening and a structural re-organisation of BM.(Ramrattan 
et al., 1994a) A consequent decrease in hydraulic conductivity and impairment of 
transport through BM may play a central role in the pathogenesis of AMD. So 
improvement of the hydraulic conductivity across the BM should improve the 
transport to and from the choroid to the outer retina.  
2RT is a nanosecond pulsed laser, which uses very low energy levels to produce 
limited effects that selectively target melanosomes within the RPE cells. This 
laser energy absorption by melanosomes within RPE cells causes microbubbles 
and cavitations to form, damaging a percentage of RPE cells within the laser 
spots without rupture of the cell membranes.  The resultant effects are an 
upregulation of MMPs and cytokines and RPE cell migration. This should 
improve the hydraulic conductivity across BM to and from photoreceptors and 
delay the progression of AMD in terms of reduction of clinical markers(dursen, 
pigment abnormality), improvement in visual function (visual acuity, color and 
contrast sensitivity and rod and cone recovery dynamics). 
 
Days 4 to 7    Days 7 to 14 
     
<-- RPE cell loss  <--RPE cell migration rim of bruch’s thinning. 
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àMMP 2 and 9 upregulation àcytokines release Overall improved 
hydraulic conductivity 
4. Objectives 
To assess the efficacy and safety of retina rejuvenantion therapy (Ellex 2RT) in 
patients with large drusen (≥125 µ) in at least one eye compared to standard care 
(no treatment).  
 
Comparison of the outcomes of Ellex 2RT compared to observation (standard 
care) will be done on the following parameters at 12 and 24 months: 
Efficacy analyses: 
3. Primary outcome: Mean change in visual acuity at 12 months. 
4. Secondary outcomes:  
d. Mean change in visual acuity at 24 months.  
e. Mean change in contrast sensitivity, microperimetry and flicker 
sensitivity at 12 and 24 months.  
f. Changes in fundus morphology as measured by optical coherence 
tomography, colour fundus photographs at 12 and 24 months. 
Safety analyses will be done by comparing the following between the two arms: 
16. Proportion of patients developing CNV confirmed by fluorescein 
angiography at 12 and 24 months 
17. Proportion of patients developing retinal atrophy as measured by 
fluorescein angiography, autofluorescence and OCT at 12 and 24 months 
18. Proportion of patients who lost more than 15 ETDRS letters at 12 and 24 
months. 
19. Proportion of patients who lost more than 30 ETDRS letters at 12 and 24 
months. 
20. Any other complications observed at 12 and 24 months.  
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5. Study Purpose and Design 
5.1	   Study	  Rationale	  
We hypothesize that Ellex 2RT would improve retinal function and morphology of 
the retina in patients with age related maculopathy.  
We hypothesize that 2RT treatment will produce significantly better outcomes 
with respect to visual function improvements than the current standard of care 
(no treatment).  
5.2	   Study	  Design	  
Plan of investigation and statistical power of the trial 
This is a prospective randomized controlled trial that will compare the mean 
change in visual acuity at 12 months between the treatment group treated with 
Ellex 2RT and the observation group (standard care) in patients with age related 
maculopathy  
Sample size (Statistical Power of the study of 80%)  
A control sample of size 33, with a baseline ETDRS letters in the range 70-95, 
and 12 months ETDRS letters was used to provide estimates for the sample size 
calculation.  
The mean score at baseline was 79.7, and the SD of the one year change from 
baseline EDTRS was 7.59. To be able to detect a difference of 5 EDTRS 
between arms, in the mean change from baseline to 12 months, based on t-test, 
at the 5% level of significance, and with an 80% power, would need 76 patients 
to be recruited. Allowing for 5% dropout the required sample size would be 80 
patients, 40 in each arm using a 1:1 ratio. The data will be analysed using 
analysis of covariance which involves adjusting for baseline in order to increase 
the power and to provide narrower confidence intervals. 
 
Patient Enrolment 
We expect that we will recruit 90% of the patients from Medical Retina Clinics in 
King’s College Hospital and Moorfields Eye Hospital. The rest of the patients will 
be obtained from referrals from local optometrists and other ophthalmologists. 
The local optometrists will be made aware of this study and patients with age 
related maculopathy will be informed about the study and referred to the 
screening clinics in the research department of both institutions. Suitable patients 
will be informed of the study verbally and by means of a Patient Information 
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Sheet at the research clinics. Patients will be invited to attend a clinic dedicated 
to the study at both institutions after at least 24 hours. At this baseline visits 
written informed consent will be obtained from patients wishing to enter the study, 
prior to enrolment. 
Withdrawal from Study 
Patients have the right to withdraw from the study for any reason. The 
investigator also has the right to withdraw a patient at anytime due to failure to 
follow protocol, administrative or other reason. 
Randomisation 
Patients are randomised into 2 groups by means of an on-line computerised 
randomisation programme (randomization.com).  The follow-up investigators will 
be masked of the randomization. 
 
Patient Numbering 
Each patient is uniquely identified by a unique study number.  Once assigned to 
a patient, a number will not be reused. 
 
6. Population 
6.1	   Inclusion	  Criteria	  
1. Patients of either sex aged 55 years or over 
2. Diagnosis of age related maculopathy that meet the criteria of large drusen 
(≥125 µ) in at least 1 eye. 
3. Best corrected visual acuity in the study eye between 50 to 90 ETDRS letters 
at baseline visit.  
4. Media clarity, pupillary dilation, and subject cooperation sufficient for adequate 
fundus photographs.  
5. No previous macular laser therapy to study eye. 
6. Written informed consent and willingness and ability to be followed up for 24 
months. 
6.2	   Exclusion	  Criteria	  	  	  
1. Drusenoid PED, Choroidal neovascularisation and geographic atrophy in the 
study eye. 
2.. Macular ischaemia (FAZ > 1000µm in diameter or moderate perifoveal 
capillary loss in fluorescein angiogram). 
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3. Macular oedema of any cause such as wet AMD, diabetic macular oedema, 
pseudophakic macular oedema or taut posterior hyaloid.   
4. Co-existent ocular disease that in the investigator’s discretion would lead to 
decrease visual acuity by 3 lines or more by end of 12 months.   
5. No coexistent choroidal neovascularization or geographic atrophy in either 
eye. 
6. History of thermal lasers or treatment with intravitreal antiVEGF agents or 
steroids for any retinal conditions in the study eye. 
7. Participation in an investigational trial within 30 days of randomisation that 
involved treatment with any drug including those that has not received regulatory 
approval at the time of study entry.  
8. Anticipated major ocular surgery (including cataract extraction) for the period 
of the trial.  
9. Amblyopia in study eye. 
10. Known allergy to fluorescein dye or to any component of the study drug 
11. Pregnancy at baseline and the patient will be withdrawn from the study if she 
becomes pregnant during the course of the study. 
7. Summary of study assessments 
Time Screening #6 months 
post entry 
#12 
months 
post entry  
#18 
months 
post entry 
#24 
months 
post entry 
Informed consent x     
Ophthalmic history  x x x x x 
Medical history x x x x x 
Visual acuity x x x x x 
Contrast sensitivity x x x x x 
Microperimetry x x x x x 
Flicker sensitivity x x x x x 
Ophthalmic 
examination 
x x x x x 
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2 field photographs x x x x x 
Autofluorescence x x x x x 
Fluorescein 
angiography$ 
x    x 
OCT  x x x x x 
Randomisation x     
Treatment 
x     
$ at physician’s discretion in all other visits- if choroidal neovascularisation is 
suspected 
 
The following data will be recorded 
DEMOGRAPHIC DATA 
Date of Birth    Gender   
 Ethnicity  
Smoking history (never/previous/current) 
Family history of AMD: Members blind with AMD or having treatment for AMD 
Past Ophthalmic history 
Duration of visual loss (>6/12 or worse) if present   
Right eye 
Left eye 
AMD HISTORY 
International classification of AMD  right  
left 
Cataract history LOC classification  right 
Left 
8. Detailed assessment protocols. 
8.1 Visual function tests 
REFRACTION PROTOCOL 
The subjective refraction is to be performed at 6m using a Snellen chart with the 
room lights on. Following refraction the best VAs are to be measured at 4m using 
ETDRS Chart I for the right eye and Chart 2 for the left eye. During the VA 
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measurements the room lights need to be switched off. Both eyes are refracted 
at the baseline visit and at 12 months and 24 months (final visit). 
The VA in the non-study eye is measured as outlined above and the score 
recorded on the score sheet. If, at one of the follow-up visits, the VA in the non-
study eye differs by two lines or more from the VA found at the initial visit, the eye 
needs to be refracted as well, and the VA measurement repeated. 
1. INITIAL VA MEASUREMENT 
At the baseline visit, measure initial VA, whilst the patient is wearing his/her own 
distance glasses or unaided (if patient doesn’t have distance glasses), using 
ETDRS Chart RJChart3. At all follow-up visits use the previous study refraction, 
the fellow eye is lightly patched with a tissue. 
 
ALWAYS measure VA in the study eye first, then the fellow eye. 
• Instruct the patient that the chart contains letters only and no numbers. If the 
patient forgets this during the course of the examination, they should be 
reminded that the chart contains no numbers and asked for a letter instead of the 
number. 
• Advise the patient that there are 5 letters on each line, and that they should 
attempt to read the line from left to right. 
• The examiner must not point at any letters or read any letters out loud during 
the test. It is acceptable to briefly point at a line, should the patient have difficulty 
finding the next line. 
• The patient should be instructed to read the letters slowly, about one letter per 
second. 
• The patient should be encouraged to guess any letters that are difficult to read, 
and be instructed to make a definite decision. If the patient is unable to identify a 
certain letter they should tell the examiner that they are moving on to the next 
letter along the line. 
• If the patient incorrectly identifies a letter and then proceeds to read the next 
letter, s/he cannot go back and correct the mistake later. It is permissible to allow 
correction as long as the patient has not started to read the next letter aloud. 
• The patient should be asked (and encouraged) to move on to the next line, as 
long as they manage to correctly identify it. 
2. RETINOSCOPY 
• Retinoscopy should be performed using a light / duochrorne chart at 6m. 
3. SUBJECTIVE REFRACTION 
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• Subjective refraction should be carried out according to the methods routinely 
employed by the Visual Assessment Department at the respective departments 
using a standard Snellen chart at 6m 
4. FINAL VA MEASUREMENT 
Follow the protocol for measuring the VA’s outlined in section 1, except use Chart 
I for the right eye and Chart 2 for the left, and follow the instructions for recording 
the final ETDRS-score and VA outlined below. 
5. ETDRS-SCORE 
• Each letter correctly identified is circled on the visual acuity form. Any letters 
read incorrectly are deleted, and letters, for which no guess has been made, are 
left unmarked. Each correct letter scores one point. The total for each line is 
recorded in the right-hand column (max.5), and the scores for each line added at 
the bottom. 
• If the score is 20 or more, then 30 points are added automatically and the final 
VA score is recorded. 
• If the total score is less then 20, then the acuity should be tested at 1m. It is 
then added  to 4m score. 
 
TESTING FOR “COUNT FINGERS”, HAND MOVEMENTS, AND LIGHT 
PERCEPTION 
If the patient’s VA is so poor that he/she cannot correctly identify any letters on 
the chart when tested at one meter, then test for Count Fingers. 
I. TESTING FOR COUNT FINGERS 
The eye not being tested should be completely occluded with a patch. A light 
must be shone from behind the patients head at the examiner’s hand. The 
examiner holds the hand two feet in front of the patient’s face and presents an 
arbitrary number of fingers in random order and repeated 5 times. Eccentric 
fixation, if present, should be encouraged. 
If the patient correctly identifies 3 of the 5 presentations, then count fingers vision 
is noted, If not, then the patient must be tested for hand movements. 
2. TESTING FOR HAND MOVEMENTS 
The eye not being tested should be occluded with a patch. A light must be shone 
from behind the patient’s head at the examiner’s hand. The examiner’s hand 
	  	   330	  
should be moved two feet in front of the patient with all fingers spread out. The 
hand should be moved either horizontally or vertically at a constant speed of 
approx. one back and forth movement per second. The patient is asked to watch 
the examiner’s hand and respond to the question “in which direction is my hand 
moving?” The examiner should not explain that it will be moving either from side 
to side or up and down. Correct answers at three out of five presentations 
suggest that hand movement vision is present. If not, then you must test for light 
perception. 
3. TESTING FOR LIGHT PERCEPTION 
Light perception should be tested with an indirect ophthalmoscope in a darkened 
room. The nd ophthalmoscope should be focused at l meter with the rheostat set 
at maximum voltage. From that distance the beam should be directed in and out 
of the eye at least four times, and the patient should be asked to respond when 
they see the light. If the examiner is convinced that the patient perceives light 
should be recorded as “Light Perception”. If not, vision should be recorded as “No 
Light Perception”. 
8.2 Contrast sensitivity 
After refraction, contrast sensitivity measurement will be done using the Pelli-
Robson chart (Clement Clarke Inc., Columbus, OH) at a distance of 1 m and 
chart luminance of 80 to 120 cd/m2. The right eye will be tested followed by the 
left eye on charts 1 and 2, respectively, with +0.75 D added to the patient’s 
refraction. The patient will be asked to name each letter on the chart, starting with 
the high-contrast letters on the upper left-hand corner and reading horizontally 
across the entire line. As low-contrast letters can take some time to appear, the 
patient was given instructions to keep looking and not give up too soon. The 
optometrist will circle each letter read correctly and cross out each letter read 
incorrectly, with letters not attempted left unmarked. The test will be stopped 
when the patient failed to correctly identify two or more letters in a triplet. The 
letter-by-letter scoring will be used.  
 
8.3 Microperimetry 
Microperimetry will be performed using the Nidek MP 1 (Nidek Technologies, 
Padova, Italy) or equivalent device. This instrument allows the examiner to view 
the fundus on the computer monitor while it is imaged in real time by an infrared 
(IR) fundus camera (768 x 576 pixels resolution; 45° field of view). Fixation target 
and stimuli are projected on to the liquid crystal display (LCD) within the MP1 for 
	  	   331	  
the subject to view. The examiner can also view the stimulus and fixation target 
as part of the IR image on the computer monitor.  
The study eye will be tested and the contralateral eye will be patched during the 
test. Pupils will be dilated with one drop each of tropicamide 1% and 
phenylephrine 2.5% at least 15 minutes prior to microperimetry. Microperimetry 
will be performed by an experienced examiner. The examination will be 
conducted in a darkened room. The following parameters will be  used: a fixation 
target consisting of red ring, 1° in diameter; white, monochromatic background at 
4 apostilb (asb), stimulus size Goldman III, with 200 milliseconds projection time; 
and a customized radial grid of 30 stimuli covering the central 10° (centred on the 
fovea), 2° apart (outer stimuli). The starting stimulus light attenuation will be set 
at 10 dB. A 4-2-1 double-staircase strategy will be used with an automatic eye 
tracker that compensates for eye movements. Pretest training was performed, 
and a 5-minute mesopic visual adaptation will be allowed before starting the test. 
The mean retinal sensitivity will be evaluated within central 10°, covering 
approximately 3 mm of central retinal area on the OCT map. The “9 in 1 layout” 
printout page (or equivalent) produced by the Nidek MP1 software provides 
indices related to microperimetry performance, retinal sensitivity and fixation 
characteristics will be printed out and recorded. The duration of each 
microperimetry examination and the average eye motion speed (º/sec) will also 
be recorded as indicators of test performance. The change in fixation stability and 
retinal sensitivity. 
 
8.4 Flicker sensitivity 
The Medmont  perimeter will be used to perform static and flicker visual field 
evaluation of the central 10°. The Macula pattern will be used.  Targets will be 
0.5° in diameter, with a maximum spot brightness of 320 cd/m2 and will be shown 
on a 3.2 cd/m2 background. Spot presentation will occur for 200 ms in static 
perimetry and for 800 ms in flicker perimetry. Thresholding will be achieved with 
a 6/3 dB staircase.  
 
8.5 Autofluorescence 
The degree of RPE atrophy caused by the laser will be assessed using this 
technique. Images of fundus autofluorescence will be recorded after pupillary 
dilation using a retinal angiograph (Heidelberg Engineering, Heidelberg, 
Germany) scanning laser ophthalmoscope with a 40° field-of-view mode. The 
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ametropic corrector will be employed to correct for refractive error (up to ±12 
diopters) and to focus on the structure of interest. At least 24 single 
autofluorescence images of 512×512 pixels will be acquired in series mode with 
a frequency of 12 images per second. The best 10 images will be selected for 
automatic alignment, and a mean image will be obtained. As a result, a single 
image will be obtained for each eye. The areas of low autofluorescence will be 
measured and compared at baseline and final visit.  
8.6  2-Field Colour  and Macular Stereo Fundus Photography 
AIM: 
To grade the macula with 30 degrees magnification 
METHOD: 
2 field and macular stereo photographs must be obtained as follows:  
2- field retinal photography 
1. Centred on the disc with the temporal border on the macula 
2. Centred on the macula with the temporal border over the centre of the disc. 
 
SAMPLING TIME: 
Macular stereo photos will be taken at baseline and at 12 and 24 months 
 
8.7  Fundus Fluorescein Angiography (FFA) 
FFA will be performed in all subjects at baseline to exclude CNV and therefore 
study suitability. FFA will be repeated in all subjects at 12 and 24 months.    
FFA will be performed to assess presence of CNV at physician’s discretion. FFAs 
done up to 2 weeks prior to the baseline visit may be used instead of baseline 
FFA.  
 
Field 1 - Macula: Centre the macula at the intersection of the cross hairs in the 
ocular. It is important that good even illumination is used at all times and that the 
flash settings are kept at the correct levels to ensure this. 
The timing for the procedure is as follows: - 
1. Before the injection of the fluorescein dye, 
2. Position camera on F1 of eye to be treated (index eye) prior to injection. 
3. 5ml of fluorescein is injected rapidly (in less than 5secs if possible). 
 
Early or Transit Phase: 
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1. The 1st photograph of F1 of the index eye is taken at the start of the injection 
and the 2nd at the end of the injection. The purpose of this is to document the 
time taken to inject the dye. 
2. 15-30 sec (F1 index eye): - Take a rapid series of about 10-16 exposures at 
intervals of about 1 to 2 seconds. 
Mid Phase: 
1. 30 - 45 seconds: F1 of the index eye 
2. 50 seconds - 1 min: F1 of the fellow eye 
3. 2 min: F1 of the index and fellow eye 
4. 2½-3 min: F1 of index eye 
Late Phase: 
1. 5 min: F1 of index eye and fellow eye 
Digital files must include the following information about each patient:  
1. Study ID number  
2. Date of birth  
3. Date of angiogram. The information can then be stored in the research 
department until masked analysis by graders. 
 
8.8  Spectral Domain Optical Coherence Tomography 
Optical Coherence Tomography (OCT) will be assessed on both eyes. These 
assessments will be performed by an OCT certified photographer. OCT imaging 
will be performed using the Spectralis and OTI OCT. Scanning protocols will 
include raster and line scans. The analysis of the OCT images will be performed 
by two independent retinal specialists for features of macular drusen and 
presence, disruption or absence of the high reflectance bands corresponding to 
the external limiting membrane and inner-segment / outer-segment photoreceptor 
junction, RPE-Bruch’s membrane  and choroid. 
 
9.Treatment Regime 
Treatment spot size:     400 micron spot 
Total number of laser spots per eye:             A total of at least 25 laser spots  
Energy range:     70 – 120mJ/cm2  
Energy setting:  Energy increased while applying test 
nasal mid-peripheral area until a 
faintly visible spot is observed.  
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 Reduce the energy to 70% of 
this setting then apply the 
grid pattern 
Contact lens: Area Centralis 1:1 laser 
contact lens (or equivalent) 
 
Treatment Protocol:  
3.   Treatment one: Ellex 2RT, 400µm diameter spot, 2 rings of 
concentric subthreshold laser spots applied, at 2000µm (5 ½ spots 
sizes out from the fovea) and 2800µm (7 ½ spot sizes out from the 
fovea).  So a total of at least 25 spots will be applied.    
OR  
4. No treatment or observation (standard care) 
10. Adverse Events 
10.1	   Adverse	  Events	  
Safety evaluations will be performed by recording clinical adverse events at each 
visit.  
1. Foveal burn 
2. Conversion to wet AMD 
3. Break in Bruch Membrane, evidenced by blood or pigment released at time of 
treatment as reported by ophthalmologist. 
4. RPE atrophy increase as measured by autoflorescence. 
 
10.2	   Procedures	  for	  Recording	  and	  Reporting	  Adverse	  Events	  
A “serious adverse incident” is one which: 
• led to a death 
• led to a serious deterioration in the health of the patient, user or others and 
includes: 
• a life threatening illness or injury 
• a permanent impairment to a body structure or function 
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• a condition requiring hospitalisation or increased length of existing 
hospitalisation 
• a condition requiring otherwise unnecessary medical or surgical intervention 
and which might have led to death or serious deterioration in health had 
suitable action or intervention not taken place. This includes a malfunction of 
the device such that it has to be monitored more closely or temporarily or 
permanently taken out of service 
• led to foetal distress, foetal death or a congenital abnormality or birth defect 
• might have led to any of the above 
.Reporting Responsibilities 
All SAEs, will be reported immediately to the Chief Investigator.All serious 
adverse incidents, whether initially considered to be device related or not, will be 
reported to the UK Competent Authority  - the MHRA Devices Group.  These 
reports should initially be made as soon as possible once the Chief Investigator 
has been made aware of the incident. Copies of all Serious Incident forms will be 
sent by the Chief Investigator to the Sponsor and the REC. 
 
Reporting timelines are as follows: 
SUSARs which are fatal or life-threatening must be reported not later than 7 days 
after the sponsor is first aware of the reaction. Any additional relevant information 
must be reported within a further 8 days. 
SUSARs that are not fatal or life-threatening must be reported within 15 days of 
the sponsor first becoming aware of the reaction.  
The reporting of 2 SUSAR will lead to termination of the trial.  
The Chief Investigator will provide an annual report of all SARs (expected and 
unexpected), and SAEs which will be distributed to the Sponsor, MHRA and the 
REC. 
All other AEs are to be collected and reported from baseline to end of study (24 
months). 
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11.Data Monitoring 
11.1	   Data	  collection	  
Data will be collected on clinical report forms and entered into the study 
database.  
 
11.2	   Data	  analysis	  of	  efficacy	  
The analysis will be conducted at 12 and 24 months.   
 
11.3	   Planned	  analysis	  
Baseline characteristics of patients in each treatment arm will be summarized. 
Analysis of covariance will be used to assess whether any observed difference in 
mean visual acuity at 12 and 24 months (after adjusting for baseline difference in 
visual acuity) is statistically significant.  If any imbalance in other important 
prognostic factors is evident regression analysis will be conducted adjusting for 
those factors to assess the impact.  Data will be analysed according to the group 
to which patients were originally assigned (i.e. intention to treat).  
 
We will provide the 12 and 24 months analyses of: 
 
Efficacy analyses: 
1. Primary outcome: Mean change in visual acuity at 12 months. 
2. Secondary outcomes:  
a. Mean change in visual acuity at 24 months.  
b. Mean change in contrast sensitivity, microperimetry and flicker 
sensitivity at 12 and 24 months.  
c. Changes in fundus morphology as measured by optical coherence 
tomography, colour fundus photographs at 12 and 24 months. 
Safety analyses will be done by comparing the following between the two arms: 
1. Proportion of patients developing CNV confirmed by fluorescein 
angiography at 12 and 24 months 
2. Proportion of patients developing retinal atrophy as measured by 
fluorescein angiography, autofluorescence and OCT at 12 and 24 months 
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3. Proportion of patients who lost more than 15 ETDRS letters at 12 and 24 
months. 
4. Proportion of patients who lost more than 30 ETDRS letters at 12 and 24 
months. 
5. Any other complications observed at 12 and 24 months.  
12. Ethics and Regulatory Approvals 
The trial will be submitted through IRAS for ethics approval and MHRA for 
approval of clinical investigation for non CE-marked medical device. 
 
13. Milestones and targets for the work  
Ethical Approval to be obtained by 1st Aug 2011.   
Recruitment and randomisation of first patient by 15th Aug.  
30 eyes to be recruited by December 2011. 
Complete 80 eyes by end of March 2012  
6-monthly follow up for 2 years.   
Publication of results by June 2014. 
 
14. Quality Assurance 
The Generic model name for the 2RT system is: Product Name – Regeneris  and 
the Product Code – LR1532. 
The Quality assurance certificate is provided by the manufactuer, Ellex, along the 
investigators brochure. 
 
15. Publication policy 
All results pertaining to the trial will be released within 1 year post completion of 
trial. 
 
16. Finance 
JP Moulton Charitable Trust will be providing funding for staffing and running of 
the trial. 
Ellex will be providing the laser Ellex 2RT for the trial. 
The trial will be sponsored by King’s College Hospital NHS Foundation trust. 
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17. Signature of Chief Investigator 
 
 
 
 
 
Miss Sobha Sivaprasad   
Consultant Ophthalmologist 
King‘s College Hospital 
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III. Consent form, Patient information sheet 	  
 
 
King’s College Hospital NHS Foundation Trust 
King’s College Hospital 
Denmark Hill 
London SE5 9RS 
 
www.kch.nhs.uk 
Direct tel: 020 3299 1722 
Direct fax: 020 3299 3738 	  	  
CONSENT	  FORM	  
Efficacy and safety of retinal rejuvenation using Ellex 2RT laser in age-related 
maculopathy (RETILASE trial) 	  Name	  of	  Principal	  Researcher:	  Miss	  Sobha	  Sivaprasad	  Patient	  Identification	  Number	  for	  this	  trial:	   	   	   	   	   	  	   	   	  Please	  initial	  box	  1	  I	  confirm	  that	  I	  have	  read	  and	  understood	  the	  information	  sheet	  dated	  	  	  ____________for	  the	  above	  study	  and	  have	  had	  the	  opportunity	  to	  ask	  	  questions.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2.	  I	  understand	  that	  my	  participation	  is	  voluntary	  and	  that	  I	  am	  free	  	  to	  withdraw	  at	  any	  time,	  without	  giving	  any	  reason,	  without	  my	  medical	  care	  	  or	  legal	  rights	  being	  affected.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.	  I	  understand	  that	  sections	  of	  any	  of	  my	  medical	  notes	  may	  be	  looked	  at	  by	  responsible	  individuals	  from	  King’s	  College	  Hospital	  or	  from	  regulatory	  authorities	  where	  it	  is	  relevant	  to	  my	  taking	  part	  in	  research.	  I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  my	  records.	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4.	  I	  agree	  to	  take	  part	  in	  the	  above	  study.	  	  Name	  of	  Patient	   	   	   Date	   	   	   Signature	   	  	   	  	  Name	  of	  Person	  taking	  consent	   Date	   	   	   Signature	  (if	  different	  from	  researcher).	  	  	  Name	  of	  researcher	   	   	   Date	   	   	   	  	  	  Signature	  Name	  of	  witness	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Date	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Signature3copies:	  1	  for	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King’s College Hospital NHS Foundation Trust 
King’s College Hospital 
Denmark Hill 
London SE5 9RS 
 
www.kch.nhs.uk 
Direct tel: 020 3299 1722 
Direct fax: 020 3299 3738 
 
 
PATIENT INFORMATION SHEET 
1. Study title: Efficacy and safety of retinal rejuvenation using Ellex 2RT 
laser in age-related maculopathy (RETILASE trial) 
 
2. Invitation paragraph 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with friends, relatives and your GP if you wish. Ask us if there is anything that is 
not clear or if you would like more information. Take time to decide whether or 
not you wish to take part. 
Thank you for reading this. 
3. What is the purpose of the study? 
Age related macular degeneration is the leading cause of blindness amongst 
people above age of 55 years.  90% of AMD are dry, manifesting as yellowish 
deposits (drusen) in the retina.  Most of these patients would have no loss in 
visual acuities, but frequently complain of changes in contrast as well as 
increased need of brighter lights for reading.  Overtime, these patients may 
progress into wet AMD, with new vessel formation and bleeding in the macula.  
This is an average of 10% per annum. 
Currently, wet AMD requires multiple treatments and are selectively beneficial.  
There is to date, no method that has proven to be of benefit in the prevention of 
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advanced AMD except high doses of vitamins in a select group.  Prior work has 
shown that laser reduces the drusen in the retina and improves vision.   
Ellex 2RT is a newly developed nanosecond, non thermal laser which has 500 
times lower energy level than conventional laser.  Hence, it is painless and does 
not penetrate and cause destruction to the neural layers(photoreceptor layer).  
Preliminary lab and clinical work has also shown that 2RT rejuvenates the retina, 
causing resorption of drusen and improvements in central visual acuity. 
The purpose of this study is to prove that 2RT improves visual function and 
improves the features of the retina. Only one of your eyes will be subjected to 
2RT. 
You will have a 50% chance of being randomized into one of the 2RT treatment 
protocol.   
The trial takes 24 months. 
4. Has the study been approved by an Ethics Committee? 
Yes the study has been given a favourable opinion by the Research Ethics 
Committee. It has also been approved by King’s College Hospital Research 
Governance committee and the Medicines and Healthcare Products Regulatory 
Agency (MHRA). 
 
5. Why have I been chosen? 
You have been asked to be part of the study as you meet the inclusion criteria for 
the study, that is to say that you have early or intermediate AMD in at least one 
eye and the level of your vision meets the entry standard, you have no other eye 
disease and you are not pregnant. 69 other patients will be needed for the study. 
If you decide to take part in the study, this agreement will be irrespective of which 
of the 2 groups you are randomized to. 
6. Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent 
form. If you decide to take part you are still free to withdraw at any time and 
without giving a reason. This will not affect the standard of care you receive. If 
you do not wish to take part in this study you will not be at a disadvantage and 
will continue to receive normal clinical management. 
7. What will happen to me if I take part? 
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If you agree to take part, you will be asked, to undergo a series of baseline 
investigations to determine whether you meet the entry criteria. In addition to 
your normal investigations you will have. Some of the investigations will be done 
in City University. 
1.a Detailed refraction (measurement for glasses), vision, contrast, colour and 
flicker tests. 
2. Fundus fluorescein angiography (FFA), (a special dye will be injected through 
your arm veins and photographs taken by a computer) 
3.Optical Coherence Tomography(OCT) and autoflorescence,(a painless and 
noninvasive procedure whereby you will have to follow a blue light on a screen 
and a computer will analyse the details of the back of your eye. 
4. After receiving the laser treatment in the study eye, you will be followed up 
every 6 months for 2 years.  
8. What do I have to do?  
There are no lifestyle restrictions. You may eat and drink as normal and take your 
normal medication. You will be able to give blood. If you become pregnant no 
harm will occur to the unborn child as a result of the trial but you will be 
withdrawn from the study. 
9. What is the drug or procedure that is being tested? 
The therapy being tested is the retinal rejuvenation therapy, a new technique to 
deliver laser into the eye. 
10. What are the alternatives for diagnosis or treatment? 
The alternative to this novel therapy is observation (no treatment given) 
11. What are the side effects of taking part? 
Patients in both Groups will not be exposed to side effects over and above those 
of routine clinical care.  
12. What are the possible disadvantages or risks of taking part? 
If you have private medical insurance you should check with the company before 
agreeing to take part in the trial. You will need to do this to ensure that your 
participation will not affect your medical insurance. 
13. What are the possible benefits of taking part? 
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We hope that the treatment will help you. However, this cannot be guaranteed. 
The information we get from this study is intended to help us design and perform 
further similar large studies in the future with the intention of prevention of 
advanced AMD 
14. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the treatment/drug that is being studied. If this happens, your 
research doctor will tell you about it and discuss with you whether you want to 
continue in the study. If you decide to withdraw your research doctor will make 
arrangements for your care to continue. If you decide to continue in the study you 
will be asked to sign an updated consent form. 
Also, on receiving new information your research doctor might consider it to be in 
your best interests to withdraw you from the study. He/she will explain the 
reasons and arrange for your care to continue. 
15. What happens when the research study stops? 
After the trial has ended, your follow up will continue in the normal clinical 
settings with regular follow up in your clinic. 
16. What if something goes wrong? 
If you are harmed due to someone’s negligence, then you may have grounds for 
a legal action but you may have to pay for it. Regardless of this, if you wish to 
complain about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints 
mechanisms may be available to you. 
17. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will 
be kept strictly confidential. Any information about you which leaves the hospital I 
surgery will have your name and address removed so that you cannot be 
recognised from it. With your consent, we would like to inform your GP and your 
diabetic consultant of your participation in the trial. 
18. What will happen to the results of the research study? 
At the end of the trial we expect to publish the results in ophthalmic journals. 
These results will be available shortly after the close of the trial in Jan 2014. You 
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will not be identified in any report or publication. You can obtain a copy of the 
published results by contacting your research doctor. 
19. Who is organizing and funding the research? 
The research is being funded by a charity, JP Moulton Charitable Turst. The 
money is used to fund the tests needed for the research. 
20. Contact for Further Information 
Your contact research doctor is  
Miss. Sobha Sivaprasad (chief Investigator). 
Address: King’s College Hospital, Denmark Hill, London SE5 9RS 
Telephone: 020 3299 1722 
 
Fax: 020 3299 3738 
 
Thank you for your time reading this form and for considering taking part in this 
study. 
This Patient Information Sheet is for you to keep. 	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